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Abstract

The effects of membrane physicochemical properties on
huntingtin membrane association and downstream aggregation

Maryssa Beasley

Huntington’s Disease (HD) is a fatal neurodegenerative disorder caused by an expanded
glutamine repeat region (polyQ) within the huntingtin protein (htt). As a result of the expanded
polyQ domain, htt associates into a variety of toxic aggregate species. The polyQ domain of htt
is flanked at the N-terminal end by 17 amino acids (Nt17) that adopt an amphipathic α-helical
structure in the presence of binding partners such as lipid membranes. In addition to comprising
a lipid binding domain, the Nt17 amphipathic α-helix has been directly implicated in htt
aggregation initiation via self-association with other Nt17 α-helices. Due to this, htt/lipid
interaction likely has a large impact on the rate and extent of htt aggregate formation, with
potential implications for HD pathogenesis. The studies presented here focus on elucidating the
effect of membrane physicochemical properties on htt membrane association and downstream htt
aggregation. In order to measure membrane association, a method of normalizing
polydiacetylene (PDA) lipid binding assays was developed to enable the direct comparison of
various molecules’ binding affinity for different lipid systems. Then, the normalized PDA assay
was utilized to determine if small molecule aggregation inhibitors influence the interaction of htt
with pure and physiologically relevant lipid systems, and thioflavin-T (ThT) assays and atomic
force microscopy (AFM) were used to monitor if the interaction altered the ability of the small
molecules to inhibit htt aggregation. While both small molecules altered htt-membrane

association, EGCG remained an effective aggregation inhibitor while curcumin no longer
inhibited htt fibrillization in the presence of either lipid system. These results highlight the
complex relationship between htt-membrane association, downstream aggregation, and the
ability of small molecules to inhibit htt aggregation in a cellular environment. Subsequent studies
utilized ThT, AFM, polydiacetylene (PDA) assays, and native MS to determine how altering
membrane physicochemical properties by changing the headgroup or the tail of lipids influences
htt aggregation and membrane affinity. Our results indicate that increasing the negative charge of
lipid headgroups disrupts the insertion of Nt17 into the bilayer, which in turn decreases
membrane disruption and results in a localization effect that increases htt fibrillization. Also,
when varying the degree of unsaturation in the lipid tail, the trend of htt aggregation in the
presence of each lipid system is different than the trend of association between htt and the
vesicles, indicating that membrane properties alter the mechanism of downstream htt
aggregation. Further investigation of the interaction between Nt17 and lipid membranes with
molecular dynamics (MD) simulations reveal that a combination of the hydrophobic amino acid
and available membrane defect sizes influence the orientation of Nt17 on bilayers during the
initial stages of interaction. Collectively, these results highlight how the properties of lipid
membranes modulate htt-membrane interactions and htt aggregation mechanisms.
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1. Introduction: Structure and Functions of Huntingtin, the Protein
Associated with Huntington’s Disease

1.1 Protein misfolding disorders
A defining characteristic of numerous neurodegenerative disorders, including
Alzheimer’s Disease (AD), Parkinson’s Disease (PD), and Huntington’s Disease (HD), is the
ordered accumulation of proteinaceous material in cellular compartments and tissues. In each of
these diseases, a specific protein misfolds and associates into toxic aggregate species that result
in pathogenesis. As a result, these diseases present clinically with impaired motor and cognitive
function,1–3 while they present pathologically with neuronal cell loss and synaptic abnormalities.4
The hallmark feature of each of these neurodegenerative diseases is the conformational
rearrangement of a protein that results in the aggregation and accumulation of amyloids in the
brain.5,6 Amyloids are organized in a cross-β structure, fibrillar in morphology, resistant to
proteolytic degradation, and SDS insoluble.7
These amyloid disorders, classified also as protein misfolding disorders, are associated
with the misfolding of a normally functional protein. The typical progressive folding of proteins
is illustrated in the concept of a folding energy landscape (Fig. 1.1).8,9 Generally, newly
synthesized proteins progress along an energy landscape and fold into a minimal-energy
conformation, or native conformation, dictated by their amino acid sequence. In this
conformation, the hydrophobic amino acids are shielded from water molecules while the
hydrophilic residues are exposed at the surface, minimizing the overall free energy of the
protein.10,11 The energy landscape leading to the native conformation generally gets rougher
based on the size of the protein in question, as longer amino acid sequences can fall into
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partially-folded intermediate species that represent a local minima in the energy landscape.12 In
the case of protein misfolding disorders, the protein follows the wrong folding pathway or
energy-minimizing funnel and gets trapped in a local minima, resulting in a misfolded
conformation that is different than the native structure.

Figure 1.1 Schematic of a combined energy landscape for protein folding and
aggregation. Unfolded proteins follow a protein-folding funnel to a minimized native-state
folded structure (blue). Occasionally, a monomer does not follow the native folding pathway
and instead results in a misfolded intermediate structure. With amyloid proteins, these
misfolded states expose residues that encourage intermolecular interactions and result in
aggregation into a variety of species (red).

In protein misfolding disorders, the misfolded conformations are often partially folded
and expose aggregation-prone regions of the protein, increasing the occurrence of intermolecular
Chapter 1

|2

interactions.13 Intermolecular interactions encourage the transition from the folding energy
landscape to the aggregation energy landscape, where aggregate species such as annular
aggregates, oligomers, and fibrils are formed. Due to the combination of intramolecular and
intermolecular interactions in the aggregation landscape, a large variety of conformations and
aggregate species form that have broad ensembles of sizes and states as well as poorly defined
energy minima.13 With amyloidogenic proteins, a combination of misfolding and increased
intermolecular interactions often results in monomeric or multimeric structures rich in β-sheets,
which expose hydrophobic amino acid residues in the protein and promotes the formation of
amyloid-like fibrils.14 While the depth of the fibril well in the aggregation energy landscape
varies greatly based on the protein and the fibril structure, the energy minima is often deeper and
sharper than the native monomeric protein, making it exceptionally thermodynamically stable.15
At this point, the balance of the protein synthesis, folding, and degradation is disturbed, resulting
in the accumulation of the protein aggregates in tissues.16
1.2 Huntington’s Disease and the huntingtin protein
HD is a fatal neurodegenerative disorder that presents with symptoms of chorea,
dystonia, and cognitive deficiencies.17 This autosomal dominant genetic disease is caused by a
mutation in the IT15 gene found on the short arm of chromosome 14 that codes for the
huntingtin protein (htt) (Fig. 1.2). The mutation is an expanded region of CAG trinucleotide
repeats, which codes for an expanded polyglutamine (polyQ) domain near the N-terminus of htt.
While the normal length of the htt polyQ domain is in the range of 17-20 repeats, expansion of
this domain beyond 35 repeats is associated with disease.18,19 This is largely due to the
association of longer polyQ chains with lower free energy penalties for β-rich structure
formation.20,21 As a result, longer polyQ chains are more likely to undergo misfolding and are
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associated with increased aggregate formation and lower ages of HD onset.18,19,22 Late onset (>50
years old) occurs in individuals with a median repeat length of 42, typical onset (21-50 years old)
occurs with median repeat lengths of 45, and juvenile onset (2-20 years old) occurs in individuals
with median repeat length of 60 glutamines.22 This polyQ-dependent age of onset is a result of
toxic htt aggregate formation, as pathogenic htt misfolds in a polyQ-dependent manner23 into a
variety of aggregate species that result in the onset of Huntington’s Disease.18,19

Figure 1.2 The mutation that results in mutant, pathogenic htt protein.157 The IT15 gene
that codes for the huntingtin protein is found on the short arm of chromosome 14. An
expanded CAG triplet repeat domain in the IT15 gene codes is responsible for the mutation in
htt that results in pathogenicity. The mutation is in an N-terminal domain of htt called htt
exon1. Exon is comprised of three domains: the 17 N-terminal amino acids (Nt17), the
glutamine repeat domain (polyQ), and a proline-rich domain. The length of the polyQ domain
determines the pathogenicity of the protein, with lengths of < 35 being non-pathogenic and
lengths of 35 + being pathogenic.

Although the exact size depends on the length of the polyQ domain, full-length htt
consists of ~3142 amino acids and has a molecular weight of approximately 348 kDa.24 Until
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recently, it was not possible to express and purify the full-length protein,25 and as a result many
studies were performed with biologically relevant N-terminal htt fragments. Here, the N-terminal
fragment htt-exon1 was extensively used. Htt-exon1 has been identified in HD postmortem
brains26 and is a stable fragment that is constantly generated in the brain through proteolysis of
full-length htt.27 Htt-exon1 is responsible for the accumulation and aggregation of htt in the
striatum in HD28 and recently was identified as the most pathogenic naturally-occurring htt
fragment.29 In addition, truncation of htt to htt-exon1 in HD140Q knock-in mice results in HDlike phenotypes and age-dependent accumulation similar to that observed with the full-length
protein.28 While htt-exon1 is an important fragment in both mouse models and HD patients, it is
also an ideal system for physiologically relevant in vitro biophysical studies as oligomers and
fibrils formed by purified htt-exon1 are similar morphologically to oligomers isolated from R6/2
and HD150Q knock-in mice.30 Htt-exon1 is comprised of three domains, one of which is the
polyQ tract that begins at residue 18. The polyQ domain is flanked on the N-terminal side by 17
amino acids (Nt17) that play a role in initiating aggregation31–33 and lipid binding,34–36 and on the
C-terminal side by a proline-rich domain containing two polyproline (polyP) stretches that slows
htt nucleation37 and modulates htt-lipid interaction.34
1.3 Huntingtin aggregation mechanisms and toxicity
Once the polyQ domain of htt surpasses a threshold of 35 repeats, the free energy penalty
of β-rich structure formation decreases, encouraging the formation of aggregate species.38 Pure
polyQ peptides can misfold to form oligomers39 and amyloid-like fibrils40,41 on their own, and
the incorporation of polyQ domains into a protein is enough to trigger polyQ-mediated
aggregation.42 In fact, a number of diseases are caused by expanded polyQ domains in proteins,
including Spinobulbar muscular atrophy, Machado-Joseph disease, and Huntington’s Disease.43
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The misfolding of polyQ-containing proteins, including mutant htt, into aggregate species is a
complex process that occurs via multiple different pathways that are not mutually exclusive.
Therefore, numerous mechanisms occur simultaneously, resulting in heterogeneous mixtures of
aggregate species such as oligomers, fibrils, and inclusion bodies.31,44,45 While the specific
aggregation details can vary by protein, proteins containing expanded polyQ tracts tend to follow
the generic polyQ-mediated aggregation schemes.43 Several general mechanisms have been
proposed for polyQ-containing protein aggregation, and polyQ-containing peptides sample
multiple conformers that promote the progression through different aggregation pathways. Many
of these mechanisms are referred to as “on-pathway”, as they result in the formation of fibrils
(Fig. 1.3). The process of polyQ amyloid fibril formation is initiated via a thermodynamically
unfavorable rearrangement of a monomer into one of many non-native conformations.20 In nonnative conformations associated with aggregation, the polyQ region of the protein forms a
monomeric or multimeric β-sheet through a combination of intramolecular and intermolecular
interactions. The formation of this β-rich nucleus is referred to as the nucleation step and is the
rate-limiting step in htt aggregation.46–48 In one widely accepted aggregation pathway for pure
polyQ peptides, a monomer undergoes a conformational rearrangement to a structure that
directly nucleates fibril formation.40,41,48 The nucleus formation sets off a nucleation-dependent
polymerization49 that results in the rapid expansion of fibrillar aggregates during what is referred
to as the elongation phase.46,48 In another prominent on-pathway aggregation scheme, fibril
formation occurs via oligomeric intermediate structures that undergo a slow structural
rearrangement into a β-rich structure.50,51 While this aggregation scheme can occur with pure
polyQ peptides, it occurs more prominently when the polyQ sequence is in the context of a larger
protein like htt.52 The increased elongation of fibrils is also encouraged through the dissociation
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of oligomers into monomer species that can add to the exposed β-strands at the fibril ends.50,53
PolyQ-containing peptides can also sample conformations that promote the progression of offpathway aggregation pathways.54 Off-pathway aggregation mechanisms lead to the formation of
a number of aggregates that do not go on to form fibrils, such as small annular aggregates,
amorphous aggregates, and off-pathway oligomers.44 Monomers and higher order aggregate
species can then accumulate into large aggregate species called inclusions that are a hallmark of
HD.23

Figure 1.3 Htt aggregation pathways. Htt aggregates via three generally accepted
aggregation mechanisms that all begin with the misfolding of a monomer into a non-native
conformation. On-pathway aggregation, which results in β-rich fibrillar structures, can occur
through (a) the direct misfolding of monomeric htt or through (b) oligomeric intermediate
species. (c) Off-pathway aggregation results in the formation of oligomers, annular
aggregates, and large amorphous aggregates. (d) Together, fibrils and amorphous aggregates
can accumulate to form large inclusions that are observed in the brains of HD patients.
Reprinted with permission from Adegbuyiro, A. et al. Proteins Containing Expanded
Polyglutamine Tracts and Neurodegenerative Disease. Copyright 2017 American Chemical
Society.
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The complexity of huntingtin aggregation can result in structural variation within subsets
of aggregate species.33,55 Early monomeric conformational and structural variability results in the
formation of oligomers with large degrees of structural variance, with some oligomers exhibiting
β-cross interactions between monomers while others are non-amyloid α-helix rich structures.50,56
In addition to varying in structure, the oligomers can also differ greatly in size; oligomeric htt
species can range from small species like tetramers or dodecamers50,57 to large species containing
upwards of hundreds of monomers.23,57 These populations are observed with purified proteins, as
well as in the brains of R6/2 mice containing pathogenic-length htt-exon1.30 With htt fibrils,
despite a consistent β-hairpin-based polyglutamine core,53,58 structural characterization has
revealed the potential for variation in structure and neurotoxicity as a result of the placement of
the flanking domains.59,60 Variation in htt aggregate structure can result from numerous factors
such as temperature,61 polyglutamine length,23 and cellular environment.62–64
Due to the heterogeneous nature of htt aggregation, it can be difficult to distinguish
which aggregate species are most involved in toxicity. There is much debate concerning the most
toxic aggregate forms, as many distinct aggregate species have been linked to various toxic
mechanisms.55,65,66 The diffusely distributed population of htt aggregates in cells has been
identified as significantly toxic through cell survival analysis67,68 and is comprised of a variety of
aggregate species ranging from small oligomers69–71 to amorphous aggregates and fibrils.72,73
Oligomers have been identified as a complex toxic population74 that induces ER stress in striatal
neurons75 and can initiate htt aggregation in vitro.30 However, oligomers are not the only toxic
species in the diffuse population, as there is also evidence that htt fibrils exhibit toxic properties.
Htt-exon1 analogs that are mutationally constrained to favor the formation of fibrils over other
aggregate species decrease the rate of survival in both cells and flies,73 and homogenous
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populations of htt-exon1 fibrils can induce apoptotic cell death by binding to and permeabilizing
lipid membranes.72 While some toxic mechanisms have been linked to specific aggregate
species, the complexity of the diffuse population aggregate composition makes it challenging to
identify the species responsible for much of htt cytotoxicity. Despite the involvement of many
aggregate species in various toxic mechanisms, other aggregates may exhibit a protective effect.
The formation of inclusion bodies reduces neuronal death in a potential neuroprotective
mechanism,68,76 and exposure to conditions that allow aggregation but suppress inclusion
formation results in increased huntingtin-induced cell death.74 The combination of htt aggregate
cytotoxic and protective mechanisms highlights the complexity of mutant htt toxicity and HD
pathogenesis.
1.4 Nt17 structure and function
The Nt17 domain is important in HD pathogenesis as it has been implicated as a
promoter of htt aggregation.32,50,77 Nt17 is intrinsically disordered, or virtually unstructured, in
bulk solution, but undergoes a conformational shift to an amphipathic α-helix in the presence of
binding partners (Fig. 1.4).78,79 Briefly, an amphipathic α-helix consists of separate
predominately hydrophobic and predominately hydrophilic sides. This conformational shift has
been implicated as an important driver of htt aggregation, as Nt17 α-helices can associate with
each other to form varying multimeric species ranging from compact globular structures to
elongated helical bundles.31 The variation in multimer structures exposes different residues of
Nt17 to the solvent, resulting in changes to downstream aggregation and potentially Nt17-driven
htt oligomerization.31 One of these experimentally observed multimeric structures is an α-helical
tetramer structure31,50 that builds up into higher order, α-helix rich oligomers, making these
tetrameric Nt17 species crucial in the early stages of aggregation.32,33 Oligomers are a potent
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toxic aggregate species of htt and Nt17 is crucial for the formation of oligomers, as removing
Nt17 from htt-exon1 completely eliminates the formation of nonamyloid oligomers.77,80 In
addition to encouraging oligomer formation, Nt17 plays a role in fibrillar aggregate formation;
the α-helical oligomers formed as a direct result of Nt17 association can undergo a slow
structural transition to β-sheet aggregates, eventually resulting in fibril formation.50

Figure 1.4 The structure and function of the Nt17 domain.157 Nt17 is unstructured in bulk
solution but undergoes a conformational shift to an amphipathic α-helix with one hydrophobic and
one hydrophilic face in the presence of binding partners. The α-helix can be involved in lipid
binding through the insertion of the helix into the membrane or in the early stages of aggregation
through self-association. Adapted (in part) with permission from Arndt, J. R. et al. Nucleation
Inhibition of Huntingtin Protein (htt) by Polyproline PPII Helices: A Potential Interaction with the
N-Terminal α-Helical Region of Htt. Copyright 2019 American Chemical Society.

In addition to spearheading htt aggregation, the Nt17 amphipathic α-helical structure
acts as a lipid binding domain (Fig. 1.4). Nt17 exhibits many properties associated with the
amphipathic α-helical motif, such as an association with lipid binding81,82 and the preferential
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binding of defects induced by curvature.83 As a lipid binding domain, Nt17 is crucial for the
interaction of htt with lipid membranes; polyQ peptides alone do not appreciably insert into lipid
membranes, but polyQ peptides flanked by Nt17 directly interact with and disrupt lipid
vesicles.34 In addition, Nt17 preferentially facilitates the interaction of htt-exon1 peptides with
supported lipid bilayers with higher degrees of curvature.84 The interaction of Nt17 with lipid
bilayers involves the insertion of nonpolar residues into the membrane through four general
steps: approach, reorganization, anchoring, and insertion.35 The approach is driven by long-range
electrostatic interactions between the peptide and the lipid headgroups, followed by the
reorganization where the peptide undergoes conformational rearrangements to bring the nonpolar
peptide residues closer to the hydrophobic membrane core. The anchor step is initialized when
one of those nonpolar restudies positions inside the membrane core, and then additional nonpolar
residues partition into the membrane during the insertion step as the peptide undergoes further
structural rearrangement. The end result is a stable α-helical structure that is close to parallel
with the membrane surface and buries the nonpolar residues of Nt17 in the hydrophobic
membrane core.35,36,78
Nt17 has numerous sites that can undergo post-translational modifications (PTM) like
acetylation,85 SUMOylation,86,87 phosphorylation,88,89 and oxidation.90 Modification of Nt17
directly influences htt function and HD progression by impacting htt membrane
association,64,88,91 translocation,92,93 aggregation,64,88,91,94 and toxicity.86,94,95 The impact of Nt17
PTM on htt aggregation and lipid binding have revealed the crucial role specific amino acids
play in these processes. The acetylation of the three lysine residues (K6, K9, K15) using a
selective covalent label decreases the extent of htt lipid binding and membrane disruption, while
also decreasing fibril formation in favor of large, globular aggregate species.64 These lysine
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residues can also be SUMOylated; SUMOylation of K6, K9, and K15 prevent htt accumulation
on lipid bilayers and promote the formation of large, amorphous aggregate species while
reducing the overall extent of aggregation.86,91 The lysine residues that lie at the edge of the
hydrophilic region of the amphipathic α-helix (K6 and K15) are protected in early htt aggregate
species, indicating a potential role of the residues in the early stages of Nt17 self-association.96
Nt17 can also undergo phosphorylation at three residues (T3, S13, S16), resulting in changes to
htt aggregation and lipid binding. Phosphorylation at residue S13 or S16 results in significant
decrease in Nt17 helical content, resulting in decreased membrane binding and lowered rate and
extent of aggregate formation.88,97 On the other hand, T3 phosphorylation modulates mutant htt
conformation by stabilizing the Nt17 amphipathic α-helix, but still results in a significant
inhibition of htt aggregation.98,99 Similarly, oxidation of M7 increases the stability of the α-helix,
expanding it by 2 residues, but reduces the binding affinity of htt for micelles ~3-4 fold.90
Together, the results obtained from PTM studies on htt reveal the specific amino acids that may
play a critical role in lipid binding and the early stages of aggregation.
1.5 Functions and toxic events associated with htt-lipid interaction
Interaction between htt and lipid membranes has been associated with a wide range of
normal htt functions. Vesicular and mitochondrial trafficking are impaired in htt knock-out mice,
implicating htt as an important contributor in axonal transport.100,101 Htt is also involved in
trafficking between the nucleus and cytoplasm through Nt17-mediated reversible association
with the endoplasmic reticulum (ER), endosomes, and autophagic vesicles.102 Membrane
association is also crucial for htt localization to subcellular components like the nucleus and
plasma membrane.103,104 Htt is detected in synaptosomal membrane fractions and has been
observed by immunoelectron microscopy to localize to vesicle membranes and microtubules.105–
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There is increasing evidence that a component of HD pathology is the result of toxic loss-of-

function, potentially due to the disruption of interaction between htt and membranes. Htt
knockout mice exhibit increased apoptosis and early embryonic lethality,108,109 and even mice
that are heterozygous for htt knockout exhibit significant neuronal degeneration,108,110 indicating
that htt is an essential protein. Direct disruption of htt functions related to membrane association
have detrimental effects such as organelle dysfunction,111,112 cell death,113 and brain
degeneration. 100,101
While the interaction between htt and lipid membranes is important for proper function,
these interacts change when htt has an expanded, pathogenic-length polyQ domain.114,115 There
is a polyQ length dependence on the formation and stability of the Nt17 amphipathic α-helix,50
and htt-exon1 disrupts the structural integrity of lipid bilayers in a polyQ-dependent
manner.114,116 As longer polyQ domains also result in quicker aggregation,20,48,117 it has been
hypothesized that the polyQ-length dependence on htt-lipid interaction is in part a result of this
fast aggregate formation.116 In fact, numerous aggregate species have been implicated in htt
membrane interaction and disruption.54,118–122 Oligomeric htt-exon1 binds to and disrupts
membranes consisting of brain lipids, resulting in membrane leakiness and toxicity in neurons.118
Fibrillar aggregates interact with ER membranes to distort morphology and dynamics,119 while
membranous structures are incorporated into htt inclusions.121,122 With many of htt normal
functions involving direct interaction with lipid membranes, the increased association and
detrimental effects of htt aggregates on lipid membranes may play a critical role in HD
pathology.
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Figure 1.5 Factors that influence lipid membrane properties.157 (a) Lipids consist of a
hydrophilic head and hydrophilic tail. (b) The size of the lipid head and saturation of the tail
alter the shape of a lipid monomer. (c) Lipid tail saturation alters how tightly lipid monomers
can pack together in a membrane. (d) Additional membrane components, such as sterols, can
influence the packing and properties of lipid membranes. (e) Membrane curvature increases
the propensity and size of available membrane effects.
In addition to being influenced by properties of the protein – such as aggregation state –
the interaction between htt and lipids is also influenced by lipid properties. Lipids are
comprised of a hydrophilic head and hydrophobic tail (Fig. 1.5a), so they spontaneously form
bilayers in aqueous environments to shield the tails from water. The size and charge of the
headgroup, as well as the length and saturation of the lipid tail, play a role in determining the
lipid shape, how the lipid monomers assemble, and the properties of the lipid bilayer (Fig.
1.5b). For example, the size of the lipid headgroup plays a role in the preferred curvature of a
bilayer system,123 and the size and saturation of the tail influence properties such as packing and
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fluidity.124 Double bonds in the lipid tail provide “kinks” that make it more difficult for the lipids
to pack together, resulting in increased fluidity with increased degrees of tail unsaturation (Fig.
1.5c). Increased membrane fluidity results in a higher propensity for the occurrence of
membrane defects,125 which is important for the Nt17 defect-detecting amphipathic α-helix.126
The physicochemical properties of a membrane system are largely determined by the membrane
composition (Fig. 1.5d),127 which is likely why alterations to membrane composition influence
the interaction between htt and lipid bilayers. The addition of cholesterol to total brain lipid
extract (TBLE) decreases htt insertion and htt-induced permeabilization of vesicles.62 Increased
concentrations of sphingomyelin (SM) or ganglioside (GM1) in TBLE also decreases htt-lipid
interaction, but increased SM content results in a higher susceptibility to htt-induced
permeability while GM1 has no effect.128 In addition to lipid shape and composition, the
propensity and size of bilayer defects are largely influenced by membrane curvature (Fig.
1.5e).123,129 Nt17 preferentially associates with curved membranes over flatter membranes,84
likely due to the increased likelihood of membrane defects when curvature is induced.123,129 The
interaction of htt with lipid membranes is a complex mechanism that is influenced by a wide
array of lipid properties, and understanding the effect of these properties on htt membrane
selectivity is important in understanding the normal function and cytotoxic effects of mutant htt.
1.6 The influence of membranes on huntingtin aggregation
Because of the dual roles of the Nt17 amphipathic α-helix in lipid binding and the early
stages of aggregation, the presence of membranes as a potential binding partner could influence
htt aggregation. In computational studies, htt monomers are capable of perturbing the physical
properties of POPC bilayers in a manner that favors dimerization and the early stages of
aggregation.36 This may explain why surfaces, such as membranes, promote specific aggregation
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pathways.130 Biophysically, POPC/PS lipid vesicles have been found to catalyze the aggregation
of htt-exon1(46Q) by anchoring to the membrane and increasing the local protein
concentration,131 but this effect is dependent on peptide:lipid ratios and the polyQ length.132 On
the other hand, the presence of vesicles comprised of total brain lipid extract (TBLE) decreases
the fibrillization of the same htt fragment.63,128 This indicates that composition is likely a factor
in the effect of a membrane on htt aggregation, a notion that is supported by the fact that DOPCSM-Chol vesicles have no effect on aggregation118 but spikes of SM in TBLE systems decreases
oligomer formation128 and cholesterol decreases htt fibrillization as a function of concentration.62
In addition, the presence of lipid membranes can have a stabilizing effect on certain aggregate
species like oligomers.34 Lipids are also incorporated into or associated with a large variety of htt
aggregates. Htt co-aggregates with neuronal lipids in transgenic mouse models,120 and htt
inclusion bodies incorporate multi-vesicular membranes and mitochondria into their surfaces.122
The association of htt with brain lipid LUVs alters the nucleation phase of aggregation,118
potentially enhancing the formation, stabilization, and morphology of toxic aggregate species
that can incorporate lipids and may represent an important factor in HD progression.
1.7 Combination of experimental approaches to study huntingtin at different scales
Huntingtin aggregation is a complex process that begins with the rearrangement of
mutant htt into a non-native conformation20 and results in the formation of large aggregate
species.23,43,66 Alterations to monomeric htt, like through a PTM, influence the aggregation and
lipid binding of htt likely by influencing the early stages of interaction.64,91 A particularly
challenging component of studying htt interaction with binding partners is finding techniques
that have the resolution to study the early mechanisms and structures as well as the resulting
down-stream aggregate morphologies and populations. To overcome this issue, studies presented
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in Chapter 4 and Chapter 5 will combine native mass spectrometry and atomic force microscopy
to study how early Nt17-lipid interactions effect downstream aggregation.

Figure 1.6 Electrospray ionization produces gas-phase ions from solution.157 For
electrospray ionization, charge is applied to a solution of analyte in the capillary tip, forming
charged droplets. The droplets undergo solvent evaporation, decreasing the size of the droplet
until the repulsion of the charges in the droplet results in Coulomb fission. The processes of
desolvation and Coulomb fission are repeated until a single charge analyte ion transitions to
the gas phase.
Mass spectrometry has recently been established as a useful technique to study the early
phases of htt interactions, from Nt17 monomeric and multimeric structures31,96 to the beginning
stages of htt lipid binding.133 Many of these studies utilize electrospray ionization (ESI), a
technique that converts solution-phase analytes into gas-phase ions (Fig. 1.6) .134,135 In order to
accomplish this, charged droplets are produced in the electrospray capillary tip, and then the
charged particles are shrunken via solvent evaporation. Eventually, the electrostatic repulsion of
the charges in the shrinking droplet overcome the surface tension holding the droplet together
and the droplet undergoes Coulomb fission.136 The droplets undergo desolvation and Coulomb
fission until the droplets contain approximately one analyte ion.137 This is considered a “soft”

Chapter 1

| 17

ionization technique because non-covalent interactions, native state, and complexes are largely
preserved without fragmentation.138–140 When the biological analytes are prepared in a
nondenaturing solvent and sprayed with ESI, the technique is called native mass spectrometry
(Native MS). Because samples can be prepped in physiologically relevant solvents and undergo
ionization without fragmentation or disruption, native MS is perfect to study the early stages of
htt fragments with binding partners such as other htt fragments, small molecules, or lipid
membranes.
To determine the effects that these early stage interactions have on htt aggregation, atomic
force microscopy (AFM) can be used to study the later stage aggregates (Fig. 1.7). AFM was
developed as a method to perform three-dimensional imaging of surfaces,141 making it perfect for
measuring the structural and morphological features of protein aggregates. While electron
microscopy (EM) is often used to study amyloid aggregates due to higher scan speeds,142 it also
requires extensive sample preparation that can distort aggregate morphology. 143–145 Also, EM
images are 2D, while AFM provides the additional advantage of a z-dimensional measurement to
provide 3D surface images. 146 Due to its nanoscale resolution and ability to be operated in both
air and solution, AFM has emerged as a tool to study nanostructure formation,130,147
morphological characteristics of protein aggregates,64,91,148,149 and the mechanical changes in
lipid bilayers as a result of interaction with amyloid proteins.150–152 In general, an AFM images a
surface by measuring the vertical displacement of a probe upon interaction with the sample
surface. The probe – an ultrasharp tip, in this case – is attached to the end of a cantilever and
experiences forces from the sample as it is brought close to the surface. The cantilever acts as a
harmonic oscillator as the tip approaches the surface and experiences a measurable deflection
according to Hooke’s Law as a result of forces between the tip and sample. A laser aligned
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to reflect off the back of the cantilever deflects as a result of the vertical displacement, which
changes the reflected laser position on a photodiode detector. The displacement measured by the
photodiode detector is corrected via the feedback loop, where the piezo adjusts the vertical
position of the sample stage as necessary to maintain a constant cantilever deflection or
amplitude. This process occurs for each pixel of the desired surface area, and the piezo scanner
moves the cantilever back and forth across the surface sample to create a complete 3D image.

Figure 1.7 Schematic representation of an AFM.157 An ultra-sharp tip is brought in close
contact with the sample surface, resulting in a measurable deflection of the cantilever. The
deflection is determined by a laser reflected off the back of the cantilever onto a photodiode
detector. The photodiode provides information about the deflection to the feedback loop that
results in the production of a three-dimensional image of the artifact measured on the surface.

While many modes of AFM have been developed for special purposes, the most
commonly utilized AFM techniques are contact mode, non-contact mode, and tapping mode. In
contact mode, the probe is brought in direct contact with the surface and the deflection of the
Chapter 1

| 19

cantilever is measured. A voltage is applied to the piezo to raise or lower the sample and restore
the desired deflection. The voltage required for the correction provides a measure of the height of
the surface feature. Contact mode has many advantages, but it is not ideal for imaging soft
biological samples because the intense frictional and adhesive forces can result in damage of
samples and distorted image data even at the lowest tracking forces available.153,154 In noncontact
AFM, the probe never contacts the surface; instead, the forces applied on the probe from the
sample as the tip approaches the surface result in a change in the amplitude of the cantilever’s
resonant vibration. Here, the force interactions are measured by the change in amplitude at a
constant frequency or by measuring the change in resonant frequency.141,155 However, noncontact mode presents limitations such as slower scan speeds and high potential for unstable
feedback.156 Because of the disadvantages of contact and non-contact modes, the studies
presented here will utilize tapping mode AFM. In tapping mode, the cantilever is oscillated near
its resonance frequency and placed close enough to the surface that during each oscillation it
briefly makes contact with the surface. When the tip intermittently contacts the surface, the
amplitude of the cantilever oscillation changes as a result of surface characteristics. For example,
the cantilever has less room to oscillate when going over a bump, thus resulting in a decrease in
oscillation amplitude. Through the feedback loop, the piezo scanner raises or lowers the sample
stage to maintain a constant cantilever amplitude and the amount the sample stage must move
determines the height of the surface features. Tapping mode is ideal for studying amyloid
aggregate species because it results in lower forces and less damage to soft biological samples
while maintaining a high lateral resolution.156

Chapter 1

| 20

1.8 Dissertation Rationale
The association of htt with lipid membranes is crucial for normal htt function but can also
induce toxic effects when the htt has a pathogenic length polyQ domain. The toxic effects of
mutant htt on lipid membranes result in organelle dysfunction and neuronal degeneration as HD
progresses, and yet the properties of the lipid membrane that influence mutant htt membrane
selectivity are widely unknown. In addition, despite the established fact that lipid membranes
alter htt aggregation, whether this effect is consistent with membranes of different compositions
has not been studied. Here, we explore the effect that membrane physicochemical properties
have on htt aggregation, lipid binding, and its interaction with potential therapeutic agents.
In Chapter 2, we present a method of normalizing polydiacetylene (PDA) lipid binding
assays to allow for the direct comparison of interaction with different lipid systems. The
sensitivity of PDA/lipid vesicles comprised of DOPC, POPC, POPE, or POPG were examined,
allowing us to compare systems with different fluidity, headgroup size, charge, and tail
saturation. The normalization protocol reduced batch-to-batch and lipid-to-lipid PDA variability
to establish a cost-effective, quick, and reproducible method of measuring membrane affinity.
Finally, the results of the PDA assays after normalization were verified with small molecule and
peptide applications through comparison to previous studies. By utilizing this normalization
method, we can further study the interaction between mutant htt and different lipid membranes,
In Chapter 3, we determined how lipid membranes of different composition influenced
the effectiveness of two known amyloid aggregation inhibitors, epigallocatechin 3-gallate
(EGCG) and curcumin, in inhibiting htt fibrillization. Htt aggregation in the presence and
absence of the small molecules and lipid (POPC or TBLE) were monitored over time using
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thioflavin T aggregation assays (ThT), revealing that the effectiveness of curcumin in particular
is largely decreased by the presence and composition of the lipid membranes. Finally, PDA
assays were utilized to determine how the interaction of htt with pure or physiological lipid
systems was influenced by the presence of each small molecule. This chapter reveals that htt
aggregation is a complex mechanism that is significantly altered by cellular components such as
lipid membranes, and that the effect is dependent on the composition of the membrane.
Once Chapter 3 results indicated that htt association with the lipid systems varied with
composition, we examined the role that lipid physicochemical properties have in these
interactions. In order to do this, pure lipid systems were selected that have the same tail group
and different head (Chapter 4) or same head group and different tail (Chapter 5). The extent and
rate of htt formation in the presence of each lipid system was monitored with ThT assays, and the
aggregate morphologies were observed using atomic force microscopy (AFM). In order to
determine why the lipids have different effects on htt aggregation, PDA assays were performed
with each lipid system and Nt17-lipid complexes were studied with native mass spectrometry.
For additional mechanistic analysis in Chapter 5, the early stages of Nt17-lipid association were
examined with weighted ensemble molecular dynamics simulations. Chapters 4 and 5 sought to
determine lipid properties – such as fluidity, packing, and charge – that influence htt-lipid
interaction with the hopes of explaining the selective association of htt to specific membranes.
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2. Normalizing Polydiacetylene Colorimetric Assays of Vesicle Binding
Across Lipid Systems1
Numerous life processes occur at cellular and subcellular membranes, predominately
comprised of lipids. Determining the binding affinity of proteins and other molecules to lipid
membranes provides insight into cell signaling, transport, energy metabolism, disease
progression, and drug discovery. Mixed polydiacetylene (PDA) lipid vesicles mimic cell
membranes and exhibit a colorimetric response induced by mechanical stress, which can be
associated with the binding of proteins or molecules. Due to its simple spectroscopic readout,
PDA assays are amenable to high-throughput screens. However, PDA assays exhibit batch to
batch variability and the sensitivity of the assay is influenced by the physicochemical properties
of lipid vesicles. Here, a method of normalizing PDA lipid binding assays to reduce variability
and enable direct comparison of different lipid systems is described. Normalization of PDA
sensitivity reduced variability between batches of PDA/lipid systems of DOPC, POPC, POPE,
and POPG by upwards of 78%, providing a cost-effective, simple, and reproducible method of
determining relative membrane binding affinity for various molecules with the potential for highthroughput screening.
2.1 Introduction
Lipids are the dominant component of cellular membranes and have numerous critical
biological functions as signaling molecules,1 transporters,2 protein recruiters,3 energy sources,4
and initiators of cell-to-cell interaction.5 Eukaryotic organisms contain a dozen major lipid

This article/chapter was published in Analytical Biochemistry, 609, Beasley, M., Stonebraker A., Legleiter, J.,
Normalizing polydiacetylene colorimetric assays of vesicle binding across lipid systems, Copyright Elsevier (2020)
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classes that are comprised of hundreds of individual species6,7 and the lipid composition of
membranes directly impact their function. Varying lipid composition alters physicochemical
properties of membranes,8 changing membrane structure, fluidity, charge density, and
interactions with various molecules.5 These variations significantly impact membrane
function.9,10 Many proteins directly interact with membranes as part of performing various
cellular processes, such as vesicular trafficking, and undergo structural transitions associated
with regulating biological activity of peptides such as peptide hormones, antimicrobial peptide
functions, and amyloid formation.11 In addition, membrane binding is an important step for
many drugs to reach their biological target, so the affinity of pharmaceuticals to membranes
impacts drug delivery and uptake.2 As membrane affinity of proteins and small molecules varies
with lipid composition, there is a need to efficiently measure and directly compare interactions
between molecules and different lipid systems.
Several techniques measure the binding affinity of molecules to different membranes,
but many are costly, inaccurate, or lack the ability for high throughput. The n-octanol/buffer
partition system is commonly used to determine the membrane affinity of drugs; however, it
does not accurately model electrostatic interactions associated with the negative charge of
membranes.12 While implementation of a liposome/buffer system via equilibrium dialysis can
overcome this issue, this method is not amenable for high-throughput experimentation as
equilibrium dialysis chambers contain few reaction wells and experiments require long periods
of incubation.13 Chromatographic techniques, such as immobilized artificial membrane
chromatography, are capable of measuring lipid binding affinities, but these methods often suffer
from low cross-column reproducibility.14 Surface plasmon resonance (SPR) techniques are
highly accurate and allow for real-time monitoring of the binding of peptides to an immobilized
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lipid bilayer with high throughput experiments; however, the method is expensive.15 An SPR
instrument capable of probing 36 reactions at once costs over an order of magnitude more than a
multimode microplate reader capable of analyzing 384 samples at once, and a single biosensor
chip for SPR experiments can cost around $250 (approximately $7 per data point).16,17
Polydiacetylene/lipid systems have the potential to qualitatively measure membrane
affinity in a simple, cost effective, and high-throughput manner. Polydiacetylene (PDA) is a
polymer that displays a colorimetric shift (from blue to red) when the conjugated backbone
experiences a stress or structural perturbation. This colorimetric response can be quantitatively
measured via absorption or fluorescence spectroscopy. Stress applied to the system by stimuli
such as temperature,18 pH,19 proteins or peptides,20,21 small molecules,22 and metal ions23 can
invoke the colorimetric response. With regards to the interaction of molecules to lipid
membranes, the colorimetric response is quantitatively correlated to membrane affinity in a
reproducible manner.24 As diacetylene monomers are inexpensive, PDA/lipid vesicles very
closely mimic bilayer environments within cellular membranes,25 and the colorimetric response
is easily measured in a multi-well plate format, PDA assays are an ideal option for cost effective,
accurate, high-throughput measurement of the interactions of molecules and peptides with lipid
membranes.26–28
While PDA assays are often used to compare the binding of different molecules to a lipid
system,29,30 it has not been used to compare how molecules bind multiple different lipid systems.
Lipid composition influences the colorimetric response for a set amount of stress as a factor of
fluidity, making direct comparison of different PDA/lipid systems challenging.25 This paper
presents a method of data analysis and normalization of the sensitivity of PDA assays for four
lipid systems of different fluidity and charge: 1,2-dioleoyl-sn-glycero-3-phosphocholine
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(DOPC), 1-palmitoyl-2-oleoyl-glycero-3-phosphocholine (POPC), 1-palmitoyl-2-oleoyl-snglycero-3-phosphoethanolamine (POPE), and 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1'rac-glycerol) (POPG). The presented method enables PDA/lipid binding assays to be used as a
reliable technique to directly compare the membrane interaction and binding of molecules, drugs,
and peptides to various lipid systems.
2.2 Materials and Methods
2.2.1 Materials
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1-palmitoyl-2-oleoyl-glycero-3phosphocholine (POPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE), and
1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (POPG) were purchased from
Avanti Polar Lipids. Diacetylene monomers of 10,12-tricosadiynoic acid for the PDA assays
were purchased from GFS Chemicals (Columbus, OH). Small molecules (−)–epigallocatechin-3gallate (EGCG) and riluzole were purchased from Acros Organics. Synthetic β-amyloid 1−40
was purchased from AnaSpec Inc. (San Jose, CA) and Alfa Aesar (Tewksbury, MA). All data
was collected on a SpectraMax M2 microplate reader.
2.2.2 Preparation of lipid/PDA vesicles
Lipid and 10,12-tricosadiynoic acid were mixed at a 2:3 molar ratio in a
chloroform/ethanol (5:1) solution and dried with a gentle stream of nitrogen until a film was
formed. Once fully dried, the film was reconstituted in 70 °C buffer (150 mM NaCl, Tris-HCl,
pH 7.4) and probe-sonicated at 125 W for 10 min. The opaque solution was then protected from
light and stored overnight at 4 °C to allow the lipids to self-associate into vesicles. The following
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day, the solution was gradually brought to room temperature and irradiated with 254 nm light for
10 min with constant stirring. The resulting royal blue solution was stored at 4 °C before use.
2.2.3 Preparation of EGCG
Powdered EGCG (4.5 mg) was dissolved in 1 mL DMSO to create a 10 mM stock
solution. Stock solutions of 7.5, 5, 2.5, and 1 mM EGCG were formed from the stock solution
through serial dilution. For each experiment, 1 µL was added to each 100 µL well to result in
final EGCG concentrations of 100, 75, 50, 25, and 10 µM EGCG.
2.2.4 Preparation of β-amyloid peptide
Synthetic β-amyloid 1-40 (Aβ40) peptide was equilibrated to room temperature and then
dissolved in HFIP for aliquoting. Aliquots were left in a fume hood for 1 h to allow the
evaporation of the HFIP, and then the samples were dried in vacuum overnight to remove
residual HFIP. Dried films were stored at -20 °C until needed. On the day of the experiment, the
Aβ40 films were equilibrated to room temperature and then dissolved in DMSO. Stocks were
prepared to 2 mM, and 1 µL of the stock solution was added to each 100 µL well for a final Aβ
concentration of 20 µM.
2.2.5 Determination of colorimetric response
PDA/lipid assays were performed in a 96-well plate format (100 µL total volume per
well) with a PDA/lipid vesicle concentration of 400 µM using a SpectraMax M2 microplate
reader at 30 °C. The absorbance at blue (640 nm) and red (550 nm) wavelengths were recorded
and used to calculate the percent colorimetric response (% CR):
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% 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟 = (

where 𝑃𝑃𝑃𝑃 =

𝑃𝑃𝑃𝑃0 − 𝑃𝑃𝑃𝑃1
�𝑃𝑃𝑃𝑃 ) × 100
0

(1)

𝐴𝐴640
�𝐴𝐴 + 𝐴𝐴 for the negative (blank) control (PB0) or the sample (PB1). Each
640
550

condition was performed in triplicate, and reported values are averages of these replicates. For

each experiment, a negative control was included that consisted of 50:50 PDA/lipid vesicles and
neat buffer. Each experiment was completed a minimum of three times with unique batches of
lipid/PDA vesicles.
2.2.6 Assay normalization and analysis
Lipid/PDA vesicles were exposed to 100 mM NaOH for 3 h to obtain the maximum %
CR for each batch of lipid/PDA vesicles. The maximum potential % CR for each system was
defined as the maximum value of the steady state of the kinetic curve. The steady state was
determined to begin at the measurement where the signal did not change beyond ± 5% of the
colorimetric response for at least one hour. The 5% change was selected as the determining

factor because it demonstrates little to no further increase in colorimetric response, while still
allowing for the potential of noise in the assay. For normalization, the CR for each assay was
normalized to the maximum % CR to determine the relative % CR for each system:
𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟 % 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑠𝑠𝑒𝑒 = (

% 𝐶𝐶𝐶𝐶𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠
�% 𝐶𝐶𝐶𝐶
× 100
𝑚𝑚𝑚𝑚𝑚𝑚 )

(2)

where % CRmax is the steady state maximum CR associated with the NaOH standard. The
between-batch relative standard deviation (RSD) was calculated to determine the reproducibility
for the same lipid system, and between-system RSD was calculated to determine the variability
between lipid systems.
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2.3. Results and Discussion
2.3.1 Colorimetric response is linearly correlated to applied stress
To establish a relationship between mechanical stress and % CR, a series of PDA assays
were performed with DOPC, POPC, POPE, and POPG vesicles exposed to various doses of
NaOH (up to 200 mM; Fig. 2.1a). NaOH stresses the systems by increasing repulsion among
lipid head groups within the vesicles, invoking a colorimetric response.19,31 For each lipid
system, % CR increased in a dose dependent manner with NaOH until the 45 mM exposure,
saturating the response and resulting in a working range up to 35 mM NaOH. The magnitude of
the % CR varied from batch-to-batch and across lipid systems (Fig. 2.2). With 45 µM doses of
NaOH, a steady state CR was reached within an hour, and increasing NaOH concentration
beyond 45 µM reduced the time to reach a steady state response. The background noise in the %
CR ranged from 0.3 to 1.2 % across all lipid systems and the maximum signal to noise ratio
(based on saturated % CR) varied from batch-to-batch and across lipid systems (Table 2.1).
Within the working range, the maximum % CR responded linearly with increasing NaOH dose
across all lipid systems; however, batch-to-batch variability within single lipid systems was
observed (Fig. 2.1b). For example, batch 1 of PDA/DOPC vesicles were significantly less
sensitive to NaOH compared to batches 2 and 3. In addition, the doses of NaOH used here result
in a relatively large mechanical stress on the vesicles compared to many systems of interests, i.e.
proteins and small molecules. This suggests that, beyond application as a simple positive control,
NaOH exposure can be used as a method to calibrate the response of PDA/lipid vesicles. Such a
method would facilitate comparison between unique preparations of PDA/lipid vesicles of the
same lipid and potentially allow for relative comparisons between PDA/lipid vesicles comprised
of different lipids.
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Figure 2.1 PDA normalization reduces assay variability. (a) Kinetic curves of the % CR
of PDA/lipid systems of DOPC, POPC, POPE, and POPG exposed to NaOH. Comparison
of the maximum % CR for different PDA/lipid systems as a function of NaOH dose (b)
before and (c) after normalization. Data points are the average of independent triplicates of
each condition, and error bars represent standard error.

Figure 2.2 The response of PDA/lipid vesicles to NaOH varies batch to batch. % CR
kinetic curves for different batches of PDA/lipid vesicles consisting of (a) DOPC, (b) POPC,
(c) POPE, and (d) POPG exposed to various doses of NaOH.
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Table 2.1 Maximum S/N for three batches of each PDA/lipid system.
DOPC
POPC
POPE
POPG

Background noise
Maximum S/N
Background noise
Maximum S/N
Background noise
Maximum S/N
Background noise
Maximum S/N

Batch 1
1.1
62.0
1.2
60.2
0.6
35.3
0.6
101.2

Batch 2
0.5
48.9
1.8
44.8
0.4
52.0
0.8
107.5

Batch 3
1.0
59.2
0.6
46.6
0.3
76.6
0.6
116.0

Mean
56.7 ± 7.0
50.5 ± 8.4
54.6 ± 20.8
108.3 ± 7.4

2.3.2 Calibration and normalization of colorimetric response enhances cross-batch and
lipid-to-lipid reproducibility
To facilitate the direct comparison of different PDA/lipid preparations, calibration curves
from individual batches of PDA/lipid vesicles were normalized, using Eq. 2, to the maximum %
CR associated with a saturating dose of NaOH (100 mM; Fig. 2.1c). This normalization
significantly reduced batch-to-batch variability (Table 2.2). The between-batch relative standard
deviation (RSD) for DOPC/PDA vesicle response ranged from 39.5-48.5% for each data point
prior to normalization, and this was reduced to 2.3-9.3% (an average reduction in RSD of
89.4%). The POPC/PDA systems demonstrated a between-batch RSD of 43.8-71.8% before
normalization. Upon normalization, the RSD dropped to 1.2-8.5% (an average reduction in RSD
of 91.1%). Even for systems that did not display large batch-to-batch heterogeneity (POPE and
POPG), normalization reduced variability across batches. For the POPE/PDA system, the RSD
values ranged from 2.13 to 11.09% before normalization, and from 1.53 to 10.97% after
normalization. Despite the reproducibility between the three trials before the correction, the RSD
still decreased by an average of 19.50% after the correction. The POPG/PDA systems also
demonstrated strong reproducibility before correction, with RSD values of 7.64-15.49%. After
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correction, the RSD values decreased by an average of 47.84% to give values between 1.01 and
8.68%. Thus, a standard dose of NaOH can be used to normalize PDA assays, allowing for direct
comparison between batches.
Table 2.2 Batch to batch relative standard deviation (RSD) values for
each PDA/lipid system before and after normalization as a function of
NaOH added.
NaOH treatment (mM):
10
20
25
30
RSD of DOPC
Raw data
39.5
46.9
46.6
48.5
Normalized
9.3
2.9
2.3
6.3
RSD of POPC
RSD of POPE
RSD of POPG

Raw data
Normalized
Raw data
Normalized
Raw data
Normalized

43.8
8.5
8.3
5.4
7.6
7.2

51.0
4.7
10.1
11.0
10.8
6.9

61.9
1.2
10.7
7.3
15.3
8.7

68.6
8.4
11.1
9.8
15.5
6.0

35
44.3
2.3
71.8
1.3
2.1
1.5
14.4
1.0

When comparing different lipid systems, variability in PDA/lipid colorimetric response
can be due to differences in prep methods or the physicochemical properties of the vesicles.
However, this variation can be accounted for, resulting in similar sensitivity for all systems in
response to an external stress. The % CR changed linearly as a function of NaOH concentration
for all four lipid systems, with R2 values ranging from 0.9565 to 0.9957. However, the slopes of
the linear fits – indicative of the sensitivity of the PDA/lipid system - varied greatly between
different lipid systems. When RSD values were calculated for all the trials of the four lipid
systems before normalization, the values ranged from 42.49 to 46.24% (Table 2.3). Thus, each
system demonstrated a linear relationship between colorimetric response and stress on their own,
but the results were not directly comparable or consistent between the different lipid systems.
After normalization of each lipid system, the between-system RSD decreased to 1.75-14.45%,
resulting in a percent reduction of 65.99 to 96.18% (Table 2.2). Despite varying fluidity, bilayer
Chapter 2

| 43

thickness, area per lipid, and charge density between the DOPC, POPC, POPE, and POPG
vesicles, all four lipid systems demonstrated similar sensitivity after normalization to a
determined stimulus, suggesting that the normalization procedure can facilitate comparisons
across lipid systems.
Table 2.3 Between-system relative standard deviation (RSD) values for all PDA/
lipid systems before and after normalization as a function of NaOH added.
NaOH treatment
10
20
25
30
35
(mM):
Raw data
41.8
42.5
46.2
44.5
45.7
Normalized
13.6
14.5
8.2
8.7
1.8
% improvement
67.4
66.0
82.4
80.4
96.2

2.3.3 Normalized PDA assays can determine relative binding affinities of small molecules and
peptides to lipid membranes

Despite varying physicochemical properties across DOPC, POPC, POPE, and POPG
vesicles, all four lipid systems demonstrated similar sensitivity after normalization (Fig. 2.1C,
Table 2.3), suggesting that NaOH normalization can facilitate comparisons across lipid systems.
As a result, the normalization procedure was next applied to measuring relative membrane
affinities of small molecules and peptides to vesicles comprised of different lipids (Fig. 2.3). A
100 mM dose of NaOH was utilized as a standard in separate wells which were monitored
simultaneously with kinetic experiments with small molecules or peptides to obtain the
maximum % CR of each PDA/lipid vesicle system. All subsequent measurements using a
specific PDA system and batch were made relative to the maximum % CR determined by the
standard.
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Figure 2.3 PDA/lipid vesicles exhibit a
colorimetric response upon exposure to
EGCG and Aβ peptide. The left column
presents data before normalization, and the
right column presents data after
normalization with a 100 µM NaOH
standard. (a) % CR kinetic curves for
different PDA/lipid systems (DOPC, POPC,
POPE, and POPG) exposed to EGCG. (b-c)
EGCG dose dependency %CR kinetic curves
for two distinct batches of DOPC/PDA
vesicles. (d) Maximum relative %CR
induced in two distinct batches of
DOPC/PDA vesicles as a function of EGCG
dose. (e) %CR kinetic curves for different
PDA/lipid systems exposed to Aβ before and
after normalization with a 100 µM NaOH
standard. Data points are the average of
independent triplicates of each condition, and
error bars represent standard error.

Interaction with lipid membranes has a large impact on the pharmacokinetic properties of
different molecules, such as the transport, distribution, and accumulation. To determine the
accuracy of PDA assays in measuring relative membrane affinity of molecules, the four
PDA/lipid vesicle systems (DOPC, POPC, POPE, and POPG) were exposed to (−)–
epigallocatechin-3-gallate (EGCG) (Fig. 2.3a). EGCG is an abundant catechin in green tea,
Chapter 2

| 45

and its bioactivity has been extensively studied for potential therapeutic applications, ranging
from being an effective cancer chemopreventative32 to an amyloid formation inhibitor.22,33–35
EGCG stocks were prepped in DMSO at a high enough concentration so that DMSO comprised
1% of the final volume within a well, which does not elicit a CR (Fig. 2.4a). Exposure to EGCG
(100 µM) elicited a CR in all four lipid systems to varying degrees (Fig. 2.3a). Before
normalization, the CR elicited by EGCG was similar for POPC and DOPC (maximum % CR
~38%). EGCG interacted with POPE vesicles (maximum % CR ~9%) and POPG vesicles
(maximum % CR ~4%) to a lesser extent. Upon normalization, it is apparent that EGCG has a
higher affinity for POPC compared with DOPC (71.91% versus 56.93%). The trend with POPE
and POPG vesicles was unchanged. As an additional control, PDA vesicles of all four lipid
systems were exposed to a small molecule, riluzole, that does not interact with lipid membranes,
and no CR was elicited (Fig. 2.4b). The relative lipid binding affinity for EGCG for the different
lipid systems after normalization is consistent with literature reports using other methods. EGCG
readily interacts with lipid membranes containing PC lipids.36–38 Specifically, EGCG damages
PC liposomes, resulting in membrane leakage.39 This damage of PC lipids membranes would
invoke a mechanical stress that would elicit the CR in PDA vesicles observed with the two PC
lipid systems. Furthermore, X-ray lamellar diffraction patterns of POPC and DOPC bilayers
indicate that EGCG more strongly disrupts POPC bilayers.40 This difference was only apparent
here after normalization of the PDA assays. The decreased % CR associated with exposure of
POPE to EGCG in comparison to PC lipids is consistent with molecular dynamic simulations
demonstrating a decreased likelihood of EGCG forming bonds with POPE.41 Finally, anionic
lipids further reduce the affinity of EGCG for lipids as determined by a reduced ability of EGCG
to quench NPN-fluorescence,39 which correlates with POPG inducing the smallest relative %
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CR. In addition, two different batches of DOPC/PDA vesicles with varying sensitivities were
exposed to EGCG to determine reproducibility of a dose response (10-100 µM, Fig. 2.3b-c).
With larger EGCG dose, % CR increased. The maximum relative % CR linearly correlated with
EGCG dose; however, the relationship varied between batches (Fig. 2.3d). This batch-to-batch
variability was significantly reduced by normalization.
Figure 2.4 DMSO and riluzole do
not elicit a colorimetric response.
PDA/lipid vesicle response to the (a)
DMSO or (b) riluzole. The top row
presents data before normalization, and
the bottom row presents data after
normalization with a 100 µM NaOH
standard. Data points are the average of
independent triplicates of each
condition, and error bars represent
standard error.

Next, the β-amyloid peptide (Aβ) peptide was used as a model system to investigate the
applicability of normalized PDA assays to probe peptide/membrane interactions (Fig. 2.3e). Aβ
aggregation is a hallmark of Alzheimer’s Disease (AD). Numerous toxic mechanisms involve
Aβ’s ability to bind cellular membranes, and these interactions are heavily influenced by
membrane composition.42,43 As a result, understanding the relative affinity of Aβ for different
lipid components can provided insight into a variety of toxic mechanisms associated with Aβ.
For this study, only POPC and POPE PDA/lipid vesicles were used as comparable, unambiguous
experiments in the literature were available. Each of these lipids are electrostatically neutral but
have different physicochemical properties that are largely influenced by the size of the lipid
headgroups, such as fluidity and area per lipid. PDA/POPC or PDA/POPE vesicles systems were
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exposed to Aβ40 (20 µM), and % CR was measured every 30 min for 48 h. Parallel NaOH (100
mM) standard experiments were performed simultaneously and used for normalization. Aβ did
not induce a CR with either POPC or POPE for ~12 h, then the % CR steadily increased for
several hours in both systems, reaching a steady-state response at ~18 h and 21 h for POPC and
POPE respectively. Prior to normalization, the steady-state % CR was larger for POPE; however,
this was not statistically significant. After normalization, Aβ had a larger and statistically
significant (p < 0.01) interaction with POPE in comparison with POPC, consistent with previous
observations of Aβ interactions with POPC or POPE.44,45 Aβ protofibrils exhibit stronger
electrostatic interactions with POPE than POPC due to the larger POPC headgroup restricting the
interaction between Aβ and the phosphate of the lipid head group, 44 and an overall decreased
affinity of Aβ for POPC compared to POPE has been observed with MD simulations.45 The
consistency with literature reports suggest that the normalized PDA assays accurately reflect the
relative interaction of Aβ40 with these different lipid systems.
2.4 Conclusion
PDA lipid binding assays are a simple, cheap, and accurate method of determining
relative membrane binding affinity that can be used in high-throughput experimentation.
However, there are complications associated with batch-to-batch reproducibility and in
comparing across different lipid systems. Here, a simple normalization procedure was
demonstrated that addresses both issues. A CR was induced in PDA/lipid vesicles in a dose
dependent manner upon exposure to NaOH, and the magnitude of the % CR was linear within a
working range across four different lipid systems (DOPC, POPC, POPE, and POPG).
Normalization of the PDA assays by making signals relative to the maximum achievable CR for
a lipid system through the use of an NaOH standard resulted in significantly lowered batch-toChapter 2
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batch and between-lipid RSD values. Standardization of PDA assays with NaOH was then used
to determine the relative affinity of a model small molecule (EGCG) and peptide (Aβ) with
different lipids. In all cases, results of the normalized PDA assay aligned with previous literature
on the relative membrane affinity of EGCG39–41 and Aβ.44,45 With this normalization of PDA
lipid binding assays, meaningful comparisons can be made between batches and lipid systems,
enabling a variety of experiments to determine relative membrane affinities of different
molecules, pharmaceuticals, and peptides.
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3. Lipid membranes influence the ability of small molecules to inhibit
huntingtin fibrillization1
Several diseases, including Alzheimer’s disease, Parkinson’s disease, and Huntington’s
disease (HD), are associated with specific proteins aggregating and depositing within tissues
and/or cellular compartments. The aggregation of these proteins is characterized by the formation
of extended, β-sheet rich fibrils, termed amyloid. In addition, a variety of other aggregate species
also form, including oligomers and protofibrils. Specifically, HD is caused by the aggregation of
the huntingtin (htt) protein that contains an expanded polyglutamine domain. Due to the link
between protein aggregation and disease, small molecule aggregation inhibitors have been pursued
as potential therapeutic agents. Two such small molecules are epigallocatechin 3-gallate (EGCG)
and curcumin, both of which inhibit the fibril formation of several amyloid-forming proteins.
However, amyloid formation is a complex process that is strongly influenced by the protein’s
environment, leading to distinct aggregation pathways. Thus, changes in the protein’s environment
may alter the effectiveness of aggregation inhibitors. A well-known modulator of amyloid
formation is lipid membranes. Here, we investigated if the presence of lipid vesicles altered the
ability of EGCG or curcumin to modulate htt aggregation and influence the interaction of htt with
lipid membranes. The presence of 1-palmitoyl-2-oleoyl-glycero-3-phosphocholine or total brain
lipid extract vesicles prevented the curcumin from inhibiting htt fibril formation. In contrast,
EGCG’s inhibition of htt fibril formation persisted in the presence of lipids. Collectively, these

1Reprinted

with permission from Beasley, M. et al. Lipid membranes influence the ability of small
molecules to inhibit huntingtin fibrillization. Biochemistry 58, 4361–4373. Copyright 2019
American Chemical Society
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results highlight the complexity of htt aggregation and demonstrate that the presence of lipid
membranes is a key modifier of the ability of small molecules to inhibit htt fibril formation.
3.1 Introduction
The polymerization of specific proteins into fibril aggregates with an underlying cross-β
structure, generically referred to as amyloid, is associated with a broad range of diseases. For
example, aggregation of the amyloid-β peptide (Aβ) and tau are associated with Alzheimer's
disease; α-synuclein (α-syn, UniProtKB P37840) is implicated in Parkinson's disease; aggregates
of islet amyloid polypeptide (IAPP, UniProtKB P10997) form in diabetes mellitus type 2; and
mutated forms of the huntingtin protein (htt, UniProtKB P42858) with an expanded
polyglutamine (polyQ) stretch underlie Huntington's disease (HD). Amyloid formation is a
complex, heterogeneous process that involves a number of intermediate aggregate species,
including a variety of oligomers, protofibrils, and amorphous aggregates.1–3 In particular,
oligomers have been implicated as prominent toxic species.4–6 The aggregation process for any
given amyloid-forming protein is highly dependent on its environment. For example, changes in
pH,7,8 metal ions,9 and preparatory protocols10 influence aggregate structure and morphology. In
particular, HD is caused by an expanded polyglutamine (polyQ) domain that must surpass a
critical threshold of ~ 35 repeat units,11–13 and the extent of htt fibrillization correlates directly
with increasing polyQ length.14–16 Htt can form a heterogeneous mixture of oligomers15,17–19 that
have been observed in a variety of HD models.20–24
Due to the apparent role of protein aggregation in amyloid diseases, a number of small
molecules that inhibit or modify amyloid formation have been identified.25,26 Two specific
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polyphenols, (−)–epigallocatechin-3-gallate (EGCG) and curcumin, have been extensively
studied due to their ability to generically inhibit amyloid formation. EGCG, a compound
commonly found in green tea, reduces aggregation and cytotoxicity of Aβ27–30, α-syn,27,31,32 and
tau.33 For htt, EGCG decreases the formation of toxic htt aggregates in both yeast and
Drosophila models.34 Curcumin, an abundant molecule in the spice turmeric, inhibits fibril
formation of Aβ and α-Syn.35–37 With regards to htt, the ability of curcumin to inhibit fibril
formation is less clear, as it has been reported to both promote38 and inhibit htt fibril formation.39
This apparent contradiction may lie in the ability of other cellular factors to influence htt
aggregation and the interaction between htt and curcumin.
With the notion that the cellular environment may influence the efficacy of small
molecule inhibitors of amyloid formation, it becomes important to understand how specific
cellular components influence the ability of small molecules to modify aggregation. Lipid
membranes are known modulators of aggregation as altered aggregation in the presence of
membranes, compared to bulk solution, has been observed for multiple amyloids, including
htt,40–43 Aβ,44–47 and α-syn.48,49 The presence of cellular membranes comprised of lipid bilayers
also alters amyloid aggregation by nucleating aggregation or stabilizing certain aggregate species
and morphologies.50 Specifically with regards to HD, mutant htt shows increased binding affinity
for phospholipids over non-mutated htt and can also disrupt the structural integrity of
phospholipid bilayers.51–53 EGCG has been shown to inhibit permeabilization of model
membranes and mitochondrial membranes by Aβ and α-syn aggregates.54–56 EGCG also interacts
with and binds to membranes themselves, but significantly decreases membrane disruption
capabilities of Aβ when pre-incubated with the peptide.57
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To determine the effect these small molecules have on htt aggregation in membranous
environments, we investigated if the presence of lipid altered the ability of either EGCG or
curcumin to modulate aggregation and influence htt lipid binding. We found that the presence of
either pure or physiological membrane systems interfered with the ability of curcumin to
decrease htt fibril formation, while EGCG’s inhibition of fibril formation persisted in the
presence of lipids. Our studies suggest that the interaction between htt and curcumin is largely
altered by cellular environment, while EGCG led to a propensity for the formation of amorphous
aggregates regardless of the interaction with membrane systems.
3.2 Materials and Methods
3.2.1 Purification of GST-htt-exon1 fusion protein
Glutathione S-transferase (GST)-htt-exon1(46Q) fusion proteins were expressed and
purified as previously described.58 In short, the GST-htt fusion proteins were expressed by
induction in Escherichia coli with isopropyl-thio-galactopyranoside (IPTG) for four hours at 30
°C. The cells were lysed using both lysozyme (0.5 mg/mL) and sonication, and the fusion
proteins were purified by liquid chromatography (BioRad LPLC) using a 5 mL GST affinity
column. Fractions were analyzed using gel electrophoresis to verify the presence and purity of
htt. Protein concentration was determined using Coomassie Bradford reagent. Prior to any assay,
fusion proteins were subjected to high speed centrifugation at 20,000g for 45 minutes at 4 °C to
remove pre-existing aggregates. To initiate aggregation for experimentation, the fusion proteins
were incubated with Factor Xa (Promega, Madison, WI) to cleave the GST tag. All experiments
were performed in buffer A (50mM Tris-HCl, pH 7, 150mM NaCl).
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3.2.2 Preparation of lipid vesicles
Lipid vesicles of 1-palmitoyl-2-oleoyl-glycero-3-phosphocholine (POPC) or total brain
lipid extract (TBLE) were prepared by rehydrating the lipid film in buffer A. Lipid solutions
were then subjected to 10 freeze/thaw cycles using liquid nitrogen followed by bath sonication
for 30 minutes. The size and polydispersity of lipid vesicles were measured with dynamic light
scattering (NanoBrook 90plus Particle Size Analyzer, Brookhaven Instruments) to verify the
formation of large unilamellar vesicles (LUVs). The mean and standard deviation of vesicle sizes
were determined by assuming a lognormal distribution of the DLS data.
3.2.3 Thioflavin T aggregation assays
Purified htt-exon1(46Q) was diluted to a final concentration of 20 µM in the presence of
125 µM Thioflavin T (ThT, Sigma-Aldrich, St. Louis, MO) and the desired small molecule (20
µM or 100 µM). In experiments when lipid was used, the lipid concentration was 400 µM,
resulting in a 20:1 lipid:protein ratio. Reactions were run in black Costar 96-well plates with
clear flat bottom and the ThT fluorescence was monitored using a SpectraMax M2 microplate
reader. Experiments were run at 37 °C with 440 nm excitation and 484 nm emission, with
readings every 5 minutes for 18 hours. The initial rate of each ThT plot was calculated over a
period of three hours, starting at the point where the fluorescence signal was larger than the set
threshold. The threshold was set at 10% of the maximum signal obtained for each condition; this
ensures that the data has made a significant increase from the baseline and avoids rate
calculations starting in the noise of the lag phase. These initial aggregation rates were normalized
to the htt control (100%) for ease of comparison. The relative maximum fluorescence was
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determined by finding the maximum fluorescence intensity for each condition and normalizing
them to the maximum fluorescence intensity of the htt control (100%).
3.2.4 Atomic force microscopy (AFM)
Incubations of htt-exon1(46Q) (20µM) in the presence and absence of small molecule
aggregation inhibitors (100µM) were maintained at 37 °C and 1400 rpm using an orbital mixer.
Control incubations of small molecule aggregation inhibitors (100 µM) alone were also used. In
addition, incubations performed with lipid vesicles were done at a lipid to peptide ratio of 20:1.
At various time points, 2 µL aliquots of each condition were deposited onto freshly cleaved mica
(Ted Pella Inc., Redding, CA) for 1 minute, washed with 200 µL of ultra-pure water, and dried
using a gentle stream of clean air. Images were collected using a Nanoscope V Multi-Mode
scanning probe microscope (VEECO) equipped with a closed loop vertical engage J-scanner.
Silicon-oxide cantilevers with a nominal spring constant of 40 N/m and a resonance frequency of
300 kHz were used. Scan rates were set between 1 and 2 Hz with cantilever drive frequencies at
10% of resonance. All images were then analyzed using the MATLAB image processing toolbox
(MathWorks) as previously described.59,60
3.2.5 Vesicle-binding assay
To measure the interaction between the htt and lipid vesicles, a polydiacetylene (PDA)
lipid binding assay was performed using previously reported protocols.61,62 In short, diacetylene
monomers of 10,12-tricosadiynoic acid (GFS Chemicals, Columbus, OH) and the lipid system of
choice were mixed at a 2:3 molar ratio in a 4:1 chloroform/ethanol solution. The solution was
evaporated off under a gentle stream of nitrogen, and then the resulting dry films were
reconstituted in buffer A at 70 °C. Lipid solutions were then sonicated at 100 W for 10 minutes
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using a sonic dismembrator (FisherSci) before being stored overnight at 4 °C to allow the selfassembly of vesicles. The next day, lipid mixtures were irradiated at 254 nm for 15 minutes with
constant stirring to polymerize the 10,12-tricosadiynoic acid and result in a dark, royal blue
solution. Experiments were performed in triplicate in a 96-well format, with the colorimetric
response being recorded every 5 minutes for 18 hours using a SpectraMax M2 microplate reader.
The negative control included equal ratios of PDA/lipid solution and buffer, while the positive
control included saturated NaOH (pH=12) to create a range of colorimetric response for each
lipid system. Polymerized vesicles were exposed to htt at a final concentration of 20 µM and
small molecule concentrations of 100 µM. The PB, defined by Ablue/(Ablue + Ared) was calculated
for the control (PB0) and each sample condition (PB). The percent colorimetric response (% CR)
indicates the extent of insertion or disruption of the lipid membrane by htt and was calculated
using the following equation:
𝑃𝑃𝑃𝑃0 −𝑃𝑃𝑃𝑃

% 𝐶𝐶𝐶𝐶 = �

𝑃𝑃𝑃𝑃0

� × 100

(1)

Data was normalized to the maximum colorimetric response for each system, which was found
by incubating the PDA/lipid solutions with 1:1 1M NaOH.
3.3 Results
3.3.1 Curcumin and EGCG inhibit htt fibrillization
All experiments in this study were performed with a mutant htt fragment that expresses
exon 1 with 46Q (htt-exon1(46Q)), which was purified from Escherichia coli as a soluble fusion
with glutathione S-transferase (GST). Cleavage of the GST moiety with factor Xa released the
htt-exon1(46Q) fragment, initiating aggregation. To determine the relative ability of curcumin
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and EGCG to inhibit htt fibril formation, ThT aggregation assays were performed with httexon1(46Q) and varying ratios of the small molecules (1:1 and 5:1 small molecule to htt; Fig.
3.1a-b). All relevant controls were measured and subtracted from the curves to show only the
fluorescence signal from the htt aggregation (Fig. 3.2), and multiple independent experiments
were performed (Fig. 3.3). For the initial relative aggregation rate, curcumin slowed aggregation
to 50% and 35% of the control rate for 1:1 and 5:1 treatments respectively (Fig. 3.1c). At a 1:1
ratio, curcumin reduced the overall ThT signal to 62% of the control signal, and increasing the
dose of curcumin to 5:1 resulted in an additional reduction to 48% of the control signal (Fig.
3.1d). EGCG was more effective in reducing apparent fibril formation, as the relative initial
aggregation rate was reduced to a larger extent (31% and 10% of the control rate for 1:1 and 5:1
treatments respectively; Fig. 3.1c). EGCG reduced the maximum ThT fluorescence signal to
32% and 24% of the control signal for the 1:1 and 5:1 doses respectively (Fig. 3.1d). While ThT
fluorescence is traditionally considered to track fibril formation, ThT signals are not always
indicative of fibril formation and does not provide information about the formation of other
aggregate species. As a result, further experimentation is required to verify aggregate inhibition.
Figure 3.1 Curcumin and EGCG
decrease htt fibrillization. ThT aggregation
assays for htt-exon1(46Q) in the
presence of (a) curcumin or (b)
EGCG. Htt-exon1(46Q) concentrationwas
20 µM. (c) The initial rate of aggregation and
(d) the relative maximum fluorescence were
determined with respect to the htt control.
Normalization was performed with respect
to the htt control. Analysis shown in (c)
and (d) were determined as averages over
all trials (shown in Fig. 3.3). Error bars are
provided for every 6th datapoint (30 min) and
represent the standard error of the mean. *
represents a p value < 0.05 and **
represents a p value < 0.01.
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Figure 3.2 Small molecules alone or with lipid
do not result in a ThT signal. ThT fluorescence
assay controls of (a) curcumin and (b) EGCG
alone, as well as controls of the small molecules in
the presence of (c) POPC or (d) TBLE vesicles.

Figure 3.3 The effect of small molecules on htt fibrillization is consistent across
all experiments. Individual trials of ThT assays for 20 µM htt (blue) in the presence of
1:1 curcumin (yellow), 5:1 curcumin (orange), 1:1 EGCG (green), or 5:1 EGCG (gray). All
ratios are provided as small molecule to htt protein. ThT curves were performed without
lipids or in the presence of either POPC or TBLE vesicles. Three independent plates were
run for each condition.
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To further establish the inhibition of htt-exon1(46Q) fibrillization by curcumin and
EGCG and to determine the impact of these small molecules on aggregate morphology, AFM
analysis was performed. This is particularly important to do with regard to EGCG, as it can
compete with ThT binding to fibrils for some amyloid-forming proteins.29 Co-incubation
experiments were performed with fresh preparations of htt-exon1(46Q) and with either curcumin
or EGCG at a molar ratio of 5:1 (small molecule to protein). Control incubations of httexon1(46Q) without the small molecules were also analyzed. Htt-exon1(46Q) concentration was
20 µM. Representative AFM images of aliquots removed from solutions of htt-exon1(46Q) in
the presence and absence of curcumin or EGCG after 1, 3, 5, and 8 h of incubation are shown in
Fig 3.4. To quantify the effect of the small molecules on aggregation, AFM images from all
incubations were analyzed by counting the number of fibrils and oligomers per µm2 (Fig. 3.4b)
using automated scripts written in Matlab. For this analysis, oligomers were defined as any
feature taller than 0.8 nm in height with an aspect ratio (longest distance across to shortest
distance across) less than 3.0, indicating a globular structure. Fibrils were defined as aggregates
taller than 0.8 nm in height with an aspect ratio greater than 3.0. These criteria were based on
hand measured characteristics of representative examples of each aggregate type. The height
threshold of 0.8 nm was chosen based on the background RMS roughness of mica that had been
exposed to either curcumin or EGCG in the absence of htt (Fig. 3.5).
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Figure 3.4 AFM analysis of the impact of curcumin or EGCG on htt-exon1(46Q)
aggregation (ratio of 5:1 small molecule to htt). (a) Representative AFM images of 20 µM
htt-exon1(46Q) incubated alone, with curcumin, or with EGCG as a function of time.
Colormap is the same for all images (see top color bar). The insets in the AFM images of htt
incubated with EGCG uses a reduced color map (see bottom, labeled color bar) to make the
shorter fibrils in these samples easier to see. (b) Image analysis of the number of oligomers
per unit area as a function of time. (c) Height histograms of oligomers observed in AFM
images as a as a function of time. (d) Image analysis of the number of fibrils per unit area as a
function of time. (e) Height histograms of fibrils observed in AFM images as a function of
time. For (b) and (d), error bars represent the standard deviation, and * represents a p value <
0.05, and ** represents a p value < 0.01 using a student’s T test.
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Figure 3.5 Small molecules and lipids result in AFM backgrounds with low
RMS roughness. Representative AFM images of the backgrounds associated with (a) near
buffer, (b) curcumin, (c) EGCG, (d) POPC lipid vesicles, and (e) TBLE vesicles. The line
in each image corresponds to the height profile provided below each image.

Htt-exon1(46Q) incubated in the absence of small molecules exhibited extensive
oligomer formation after 1 h of incubation with a steady increase in the number of oligomers
with longer incubation times. After 1 and 3 h of incubation, oligomers were predominately 3-3.5
nm in height (Fig. 3.4a and b). Oligomers became slightly larger with time (a mode of 4-4.5 nm
and 4.5-5 nm for 5 and 8 h time points respectively, Fig. 3.4c)). Fibrils appeared after 3 h of
incubation in the htt-exon1(46Q) alone incubation, and the number of fibrils steadily increased
with time (Fig 3.4a and d). While the number of fibrils increased, the average height along the
fibril contours did not change with time (mode of 6.5-7.5 nm, Fig. 3.4e).
When curcumin was co-incubated with htt-exon1(46Q), the formation of aggregates was
inhibited. Oligomers appeared in similar numbers as the control after 1 h of co-incubation with
curcumin; however, the number of oligomers per unit area was significantly reduced from the 3 h
time point for the duration of the experiment (Fig 3.4a and b). Fibrils were not detected until
after 3 h, and they were significantly reduced in number compared to control (p < 0.05,
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Fig. 3.4a and d). The fibril population continued to be significantly smaller in comparison to the
control for the duration of the experiment (p < 0.05 and p < 0.01 after 5 and 8 h respectively).
While the number of oligomers and fibrils was reduced in the presence of curcumin, the size of
the htt oligomers observed with curcumin was different compared to control experiments (Fig.
3.4c). At 1 h, the mode height of oligomers formed in the presence of curcumin was 2.5 nm.
With longer incubation times, the oligomers became progressively larger with a mode height of
4.0-4.5 nm after 3 h and 6.5-7.0 nm after 5 and 8 h of co-incubation with curcumin. This was
consistent with a previously reported tendency of conditions that slow htt fibrillization promoting
larger oligomeric aggregates.15,63 Fibrils formed in the presence of curcumin were similar in
morphology to control. The average height along the contour of the fibril did not change with
time with an overall mode of 6.5-7.0 nm (Fig. 3.4e).
Figure 3.6 EGCG alters htt
oligomer morphology. Histograms of
the surface occupied by individual
oligomers observed for htt-exon1(46Q)
incubated alone, with curcumin, or
EGCG.

When EGCG was co-incubated with htt-exon1(46Q), the formation of aggregates was
robustly inhibited. Both oligomer and fibril formation were significantly decreased (p < 0.01) at
all time points (Fig. 3.4a, b, and d). While the number of aggregates was reduced, the
morphologies of the observed aggregates formed in the presence of EGCG were very different
compared with those observed in control and + curcumin experiments (Fig. 3.4c and e).
Aggregates distinguished as oligomers from our automated scripts were often large and
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conglomerate-looking in morphology. That is, these aggregates were granular in appearance,
adopted a variety of shapes, and often had a flat (~ 2-2.5 nm thick) region around its periphery.
These aggregates were larger than the typical oligomers formed by htt, occupying a much larger
area of the surface, and more heterogeneous in morphology (Fig. 3.6).The propensity to form
these large aggregates of htt in the presence of EGCG has previously been reported.34 While a
small population of fibrils were detected, the morphological characteristics of these fibrils were
very different compared to control as they had a much smaller average height along their
contours (mode of 1-1.5 nm) compared to fibrils formed by htt alone or with curcumin (Fig. 3.4e
and 3.7). These thin, fibrillar species often (although not always) appeared to be growing from a
larger, conglomerate aggregate (Fig. 3.7). This unique structure could represent a single
protofilament that are incorporated into larger amyloid fibrils.

Figure 3.7 Htt aggregate morphology is altered by curcumin and EGCG. AFM
images comparing the morphology of htt-exon1(46Q) fibrils formed in the (a) absence
of small molecules, (b) with curcumin, or (c) with EGCG. In (c), the boxed insets
correspond to the second color bar to better visualize the fibril structures associated with
htt incubated with EGCG. The color lines in each image corresponds to the height profiles
directly below each image.
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3.3.2 Lipid membranes alter the ability of curcumin and EGCG to inhibit fibrillization
Figure 3.8 POPC and TBLE alter
the ability of small molecules to inhibit
htt-exon1(46Q)
fibrillization.
ThT
aggregation assays for htt-exon1(46Q)
aggregated in the presence of (a) POPC
or (b) TBLE lipid vesicles. Httexon1(46Q) concentration was 20 µM.
Curcumin and EGCG were added at a 5:1
molar ratio of small molecule to htt. The
initial rate of aggregation in the presence of
(c) POPC or (d) TBLE vesicles was made
relative to the aggregation rate of htt with
the lipid vesicles in the absence of the
small molecules. Finally, the relative
maximum
fluorescence
of
each
condition in the presence of (e)
POPC or (f) TBLE lipid vesicles at the
end of the 18 h kinetic run was compared.
Analysis shown in (a) and (d) were
determined as averages over all trials
(shown in Fig. 3.3). Error bars are provided
for every 6th datapoint (30 min) and represent
the standard error of the mean. * represents a
p value < 0.05 and ** represents a p value
< 0.01.
To determine if the presence of lipid membranes impacts the ability of curcumin or
EGCG to alter htt aggregation, we used two lipid systems. POPC was selected as it was
previously shown to promote a distinct htt aggregation process.43 The other system was total
brain lipid extract (TBLE) as it also alters htt aggregation40,64,65 and represents a more
physiologically relevant mixture of lipids. Both lipid systems were introduced as vesicles, and
the lipid to protein ratio was 20:1. Initially, the relative ability of curcumin and EGCG to inhibit
htt fibril formation in the presence of POPC or TBLE vesicles was assessed by ThT aggregation
assays (Fig. 3.8; all independent trials are shown in Fig. 3.3). As determined by DLS, the
protocol used produced POPC vesicles with an average diameter ~130-145 nm with a
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polydispersity index (PDI) of ~0.34-0.4 and TBLE vesicles with average diameter of ~180-195
nm with a PDI of ~0.25-0.3 (representative DLS distributions are presented in Fig. 3.9). The
concentration of htt-exon1(46Q) was 20 µM, and the small molecule to protein ratio was 5:1.
Figure 3.9 POPC and TBLE vesicles
were comparable in size. Representative
DLS analyses of (a) POPC and (b) TBLE
vesicle size. Vesicle size
distributions were calculated by
assuming a lognormal distribution.
Each plot is a combination of three runs.

The impact of exposing htt-exon1(46Q) to these two lipid systems (in the absence of
small molecules) was varied. The addition of POPC accelerated htt aggregation compared to the
absence of lipids; whereas, TBLE slowed htt aggregation (compare the fluorescence intensity of
the htt alone experiments in Figs. 3.1 and 3.8). In the presence of POPC, curcumin was able to
delay the onset of fibrillization, as a lag phase was clearly observed (Fig. 3.8a). However, fibril
growth occurred rapidly once initiated, as the initial aggregation rate exceeded that of htt alone
in the presence of POPC (35% larger, Fig. 3.8c). The overall ability of curcumin to inhibit
fibrillization was reduced in the presence of POPC, with the maximum ThT signal being 68%
larger than control (Fig. 3.8e). In the presence of TBLE vesicles, htt aggregation proceeded
faster without a discernable lag phase in the presence of curcumin compared to control (35%
increase in the initial aggregation rate, Fig. 3.8d), and the relative maximum ThT signal was
increased by 40% compared to control (Fig. 3.8f). Htt-exon1(46Q) aggregation in the presence
of POPC and TBLE vesicles was inhibited by EGCG (relative maximum ThT signals that
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were reduced to 41% and 22% compared to the control signal for incubations with POPC or
TBLE respectively, Fig. 3.8a-f).
To further establish that POPC or TBLE vesicles altered the ability of curcumin and
EGCG to inhibit htt-exon1(46Q) fibrillization, AFM analysis was performed. As before, coincubation experiments were performed with fresh preparations of htt-exon1(46Q) (20 µM) and
with either curcumin or EGCG at a molecular ratio of 5:1 (small molecule to protein), however,
lipid vesicles of either POPC or TBLE were also added to the co-incubations at a 20:1 lipid to
protein ratio. Control incubations of htt-exon1(46Q) with POPC and TBLE vesicles but without
the small molecules were also performed (Figs. 3.10 and 3.11). Representative AFM images of
aliquots removed from solutions of htt-exon1(46Q) in the presence and absence of curcumin or
EGCG after 1, 3, 5, and 8 h of incubation in the presence of POPC or TBLE vesicles are shown
in Fig. 3.10 and Fig. 3.11 respectively. To quantify the effect of the small molecules on
aggregation in the presence of lipids, AFM images from all incubations were analyzed by
counting the number of fibrils and oligomers per µm2 (Fig. 3.10 and 3.11) using automated
scripts written in Matlab. As the addition of lipids to these incubations resulted in taller
backgrounds once deposited on mica (Fig. 3.10), the height threshold used for image analysis
was increased to 1.5 nm. As a result, oligomers were defined as any feature taller than 1.5 nm in
height with an aspect less than 3.0, indicating a globular structure. Fibrils were defined as
aggregates taller than 1.5 nm in height with an aspect ratio greater than 3.0.
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Figure 3.10 AFM analysis of the impact of curcumin or EGCG on htt-exon1(46Q)
aggregation in the presence of POPC lipid vesicles. (a) Representative AFM images of 20 µM
htt-exon1(46Q) incubated with POPC (20:1 lipid to protein) with no small molecules, with
curcumin, or with EGCG (ratio of 5:1 small molecule to htt) as a function of time. Color map is
the same for all images. (b) Image analysis of the number of oligomers per unit area as a function
of time. (c) Height histograms of oligomers observed in AFM images as a as a function of time. (d)
Image analysis of the number of fibrils per unit area as a function of time. Arrows indicate that no
fibrils were observed. (e) Height histograms of fibrils observed in AFM images as a function of
time. For (b) and (d), error bars represent the standard deviation, and * represents a p value < 0.05,
and ** represents a p value < 0.01 using a student’s T test.
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Figure 3.11 AFM analysis of the impact of curcumin or EGCG on htt-exon1(46Q)
aggregation in the presence of TBLE vesicles. (A) Representative AFM images of 20 µM
htt-exon1(46Q) incubated with TBLE (20:1 lipid to protein) with no small molecules, with
curcumin, or with EGCG (ratio of 5:1 small molecule to htt) as a function of time. Color map is
the same for all images (B) Image analysis of the number of oligomers per unit area as a function
of time. (C) Height histograms of oligomers observed in AFM images as a as a function of time.
(D) Image analysis of the number of fibrils per unit area as a function of time. Arrows indicate
that no fibrils were observed. (E) Height histograms of fibrils observed in AFM images as a
function of time. As fibrils were not observed for htt-exon1(46Q) incubations with TBLE and
EGCG, this condition is not presented in the fibril histograms. For (B) and (D), error bars
represent the standard deviation, and * represents a p value < 0.05, and ** represents a p value <
0.01 using a student’s T test.
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Htt-exon1(46Q) incubated in the presence of POPC exhibited extensive oligomer
formation after 1 h of incubation (Fig. 3.10). While the number of detectible oligomers increased
after 3 h, the oligomer population remained relatively stable during the time course of the
experiment (Fig. 3.10b). After 1 h of incubation the mode height of oligomers was 4-5.5 nm (Fig.
3.10c). Oligomers were slightly larger at 3 and 5 h of incubation as the mode height was 5-6 nm
at these time points. At 8 h of incubation, oligomers decreased in size with a mode height of
~2.5-3.5 nm. These oligomer species may contain lipid components; however, it is unlikely that
they are comprised of lipids alone, as features observed from pure lipid incubations were all
smaller than 1.5 nm in height and were not globular in appearance (Fig. 3.5). Fibrils appeared
after 1 h of incubation in the htt-exon1(46Q) with POPC incubations, which was earlier than
without any lipids (Fig 3.10a and d). The number of fibrils steadily increased with time, reaching
a larger population compared with htt incubations without lipids, which is consistent with results
from the ThT assays. While the number of fibrils increased, the average height along the fibril
contours (mode of 6-7 nm) did not change with time and was comparable to fibrils formed in the
absence of lipids (Fig. 3.4e and 3.10e).
When co-incubated with htt-exon1(46Q) in the presence of POPC, curcumin’s ability to
reduce aggregation was dampened (Fig. 3.10). While there was initially a significant reduction in
oligomers, the number of oligomers formed at 5 and 8 h of co-incubation was not significantly
different compared to incubations of htt-exon1(46Q) in the presence of POPC (Fig. 3.10b).
There was, however, a larger distribution of oligomer sizes, yet the mode size of oligomers was
comparable to those formed in the presence of POPC but the absence of curcumin at 1, 3, and 5 h
(Fig. 3.10c). At 8 h, the oligomer height distribution was shifted toward larger sizes. The
promotion of larger oligomers by curcumin that was observed in the absence of lipid was much
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more subtle in the presence of POPC due to the larger distribution of oligomer sizes. Similar
populations of fibrils were detected after 1 and 3 h from co-incubations with curcumin to control
in the presence of POPC, and a small (but significant, p < 0.05) reduction in the fibril population
was observed at 5 and 8 h (Fig. 3.10d). Fibrils formed in the presence of curcumin were similar
in morphology to control (Figs. 3.10e and 3.12a). The average height along the contour of the
fibril was larger compared with control fibrils, with a mode average height along the fibril
contour of 8.5-9 nm; however, the distribution of these heights was also much broader,
suggesting that lipids may be incorporated into the fibril structure.

Figure 3 . 12 Curcumin and EGCG alter htt-exon1(46Q) aggregate morphology in
the presence of lipid vesicles. AFM images comparing the morphology of htt-exon1(46Q)
fibrils formed in the absence of small molecules, with curcumin, or with EGCG for
incubations performed in the presence of (a) POPC or (b) TBLE vesicles. The color lines in
each image corresponds to the height profiles directly below each image.
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When EGCG was co-incubated with htt-exon1(46Q) in the presence of POPC vesicles,
EGCG was still an effective inhibitor of fibril formation (Fig. 3.10). The number of oligomers
per unit area was significantly (p < 0.01 at all time points) reduced compared to control (Fig
3.10b), and no fibrils were observed at any time point (Fig. 3.10d). While the number of
oligomers was reduced, the morphologies of the observed oligomers formed in the presence of
POPC vesicles and EGCG were very different compared with those in the control (Fig. 3.10c).
There were a number of small oligomers (~2-3 nm in height), but there was also a large
population of larger aggregates that could be considerably larger than 10 nm in height (Fig.
3.12a) and occupy large amounts of surface area (Fig. 3.13). The size of these aggregates was
heterogeneous, and the ability of EGCG to promote large, globular htt aggregates was not
diminished by the presence of POPC. However, unlike the aggregates observed when EGCG
was incubated with htt alone, these species were more rounded and smooth in appearance.
Figure 3.13 EGCG promotes large
oligomeric aggregates of htt-exon1(46Q) in the
presence of POPC. Histograms of the surface
occupied by individual oligomers
observed for htt-exon1(46Q) incubated
alone, with curcumin, or EGCG in the presence
of POPC lipid vesicles.

Htt-exon1(46Q) incubated in the presence of TBLE exhibited oligomer formation after 1
h of incubation with the population of oligomers increasing with time (Fig 3.11a and b). Unlike
incubations in the absence of lipids or with POPC vesicles, the oligomers that formed in the
presence of TBLE increased in size with time (going from a mode height of 5-6 nm at 1 h to a
mode height of 7.5-8.5 nm after 8 h, Fig. 3.11c). This increase in height is consistent
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with the observed trend that slowing fibril formation can promote large oligomeric species of htt
to form. The number of fibrils per unit area (with TBLE) was smaller compared with incubations
performed with POPC vesicles (Fig. 3.11c); however, fibril numbers were comparable with httexon1(46Q) incubations without lipids. Closer inspection of the AFM images suggests that the
fibrils formed in the presence of TBLE were shorter than those grown in the absence of lipids,
which could result in the reduced ThT signal. That is, the longer fibrils formed in the absence of
TBLE would have more surface area (due to more monomers per fibril) to bind ThT, producing a
larger signal. Despite this apparent difference in fibril length, the average height along the fibril
contours (mode of 6.5-7 nm) of fibrils formed in the presence of TBLE did not change with time
and was comparable to fibrils formed in the absence of lipids and POPC (Fig 3.11e and 3.12b).
When co-incubated with htt-exon1(46Q) in the presence of TBLE, curcumin no longer
reduced aggregation (Fig 3.11). After 1 h, a significant increase in the htt oligomer population
was observed for co-incubations with curcumin (Fig. 3.11b). The large number of oligomers per
unit area was stable at later time-points, and the numbers were comparable to control. The height
distributions of oligomers formed from co-incubations of htt with curcumin in the presence of
TBLE was very comparable to control at all time points (Fig. 3.11c). Consistent with the ThT
analysis, the number of fibrils formed from co-incubations of curcumin in the presence of TBLE
was significantly larger compared with control at 5 and 8 h (Fig. 3.11d). The average height
along the contour of the fibril was larger for control fibrils, with a mode average height along the
fibril contour of 8.5-9 nm (Fig. 3.11e); however, the distribution of these heights was also much
broader. The mode average height along the contour was 5-6.5 nm for fibrils formed from coincubations with curcumin in the presence of TBLE. The thickness along these fibrils formed in
the presence of TBLE (in the absence and presence of curcumin) were quite varied (Fig. 3.12b).
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Figure 3.14 EGCG promotes large
oligomeric aggregates of htt-exon1(46Q) in the
presence of TBLE. Histograms of the surface
occupied by individual oligomers
observed for htt-exon1(46Q) incubated
alone, with curcumin, or EGCG in the presence
of TBLE lipid vesicles.

When EGCG was co-incubated with htt-exon1(46Q) in the presence of TBLE, the
formation of aggregates was robustly inhibited, as the number of oligomers per unit area was
significantly reduced compared to control (Fig 3.11). Oligomer and fibril formation was
significantly (p < 0.01) decreased at all time points (Fig. 3.11b and d). While the number of
aggregates was reduced, the morphologies of the observed aggregates formed in the presence of
EGCG were very different compared with those observed in control and + curcumin
experiments (Fig. 3.11c and 3.12b). Similar to incubations in the presence of POPC, aggregates
distinguished as oligomers from our automated scripts were often large, conglomerate-looking in
morphology when incubated with TBLE vesicles. These aggregates were larger than the typical
oligomers formed by htt, occupying a much larger area of the surface, and more heterogeneous
(Fig. 3.14). Again, the lipid surfaces did not impede the ability of EGCG to prevent htt fibril
formation and promote large globular aggregates. These large, non-fibrillar aggregates tended to
be smooth and rounded similar to those observed with EGCG and htt in the presence of POPC.
At the 8 h time point, some of these larger aggregates had a flat, peripheral feature. However, this
feature was distinct from the peripheral featured observed for EGCG and htt incubation in the
absence of lipids as these flat regions were between 5-10 nm in height, suggesting that these
might be lipid bilayer stacks.
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Figure 3.15 Curcumin and EGCG
alter htt lipid binding. Lipid binding
assays for (a) PDA/POPC vesicles exposed
to either curcumin or EGCG, (b)
PDA/POPC vesicles exposed to httexon1(46Q) with either curcumin or
EGCG, (c) PDA/TBLE vesicles exposed
to either curcumin or EGCG, and (d)
PDA/TBLE vesicles exposed to httexon1(46Q) with either curcumin or
EGCG. Error bars are provided for every
6th datapoint and represent the standard
error of the mean.

Figure 3.16 Individual trials of the PDA lipid binding assays are consistent.
Background plots of the lipid/PDA vesicles in the presence of 100 µM curcumin (orange) or
EGCG (gray). Assays performed with htt have subtracted out the appropriate small molecule
background, so the signal shown is that associated specifically with the htt in the presence of
curcumin (orange) or EGCG (gray).
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As the presence of lipid vesicles altered the ability of curcumin and EGCG to inhibit
fibril formation, we next performed a performed a series of colorimetric membrane binding
assays using lipid/polydiacetylene (PDA) vesicles (Fig. 3.15). These vesicles were made with
either POPC or TBLE as the lipid component. Lipid/PDA vesicles have varied colorimetric
responses (CRs) when exposed to proteins or small molecules depending on the extent of
interaction.52,53 The CR in the lipid/PDA vesicles is related to transitions of the PDA polymer
backbone structure, which is affected by changes in tension associated with exogenous
molecules interacting with and/or inserting into the vesicle.53 By measuring absorbance of both
the blue (640 nm) and red (500 nm) wavelengths of lipid/PDA vesicles upon exposure to httexon1(46Q), the % CR was obtained, which directly corresponds to the protein/lipid interaction.
Importantly, the % CR response takes into account background experiments performed with the
small molecules, so the response associated with curcumin or EGCG in the absence of htt is
easily removed to obtain the % CR associated specifically with the htt. These background
experiments with just curcumin or EGCG can be compared with neat buffer to determine the
extent to which each small molecule interacts with the lipids as well (all independent PDA
assays are shown in Fig. 3.16). With POPC/PDA vesicles, curcumin by itself invoked a minimal
% CR, demonstrating that curcumin has little interaction with POPC (Fig. 3.15a). However, the
% CR of curcumin alone was extensive with TBLE/PDA vesicles, starting as high as 45% and
reaching over 60% CR within hours, suggesting that curcumin strongly binds to TBLE (Fig.
3.15c). EGCG, which is known to bind lipids,57 interacted with both POPC and TBLE, with a
slightly larger interaction with TBLE (Fig. 3.15a and c). Htt-exon1(46Q) by itself had a stronger
(~3×) interaction with TBLE/PDA vesicles in comparison with POPC/PDA vesicles. The
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addition of curcumin or EGCG reduced the interaction of htt-exon1(46Q) with both POPC/PDA
and TBLE/PDA vesicles (Fig. 3.15b and d).
3.4 Discussion
Amyloid formation is highly dependent on environmental factors, complicating efforts to
design effective small molecules that inhibit disease-related protein aggregation. A major
environmental factor that influences the aggregation of numerous amyloid-forming proteins is
the presence of cellular and subcellular membranes comprised predominately of lipids. Here, we
investigated how the presence of lipid vesicles altered the ability of two known amyloid
inhibitors, curcumin and EGCG, to prevent htt fibrillization. First, we verified that both
curcumin and EGCG inhibited fibril formation of htt-exon1(46Q) in the absence of lipid
membranes. In particular, EGCG promoted unique htt aggregate species compared to controls,
i.e. large, globular aggregates and thin protofilaments. Next, we determined that POPC enhances
htt fibril formation; whereas, TBLE reduced htt fibril formation. In the presence of lipid vesicles
of either POPC or TBLE, curcumin became ineffective in inhibiting htt fibrillization and even
promoted fibril formation in the presence of TBLE. In contrast, EGCG remained effective in
preventing htt fibrillization in the presence of lipid vesicles; however, some small oligomers and
large conglomerate aggregates still formed. Collectively, these results underscore the complexity
of htt aggregation and targeting fibril formation with small molecules.
Surfaces, especially lipid membranes, are known to heavily influence amyloid formation,
even promoting unique aggregation pathways.50 Results presented here that the ability of
curcumin and EGCG to alter htt aggregation is modified by the presence of lipid vesicles further
support this notion. For htt, taking into account the influence of lipid membranes in the
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aggregation process of htt may play a key role in targeting the aggregation process as a
therapeutic strategy, as htt and its aggregate forms are often intimately linked to a variety of
membranes.52 For example, htt localizes to specific subcellular compartments as a result of its
normal function via lipid interactions,66 participates in the transport of lipid vesicles (endocytic,
synaptic or lysosomal),53,67–69 is associated with acidic phospholipids,51 and localizes to brain
membrane fractions.70 Htt also localizes to the ER,66,71–74 mitochondria,75–80 and plasma
membrane.51 Literature reports have suggested both enhanced43 and inhibited40,63,64,81 htt
fibrillization in the presence of membranes. This discrepancy appears to be due to properties of
the particular lipid systems used in these studies and can be modified by changes in membrane
composition.41,42
Curcumin’s inability to effectively inhibit fibril formation in the presence of lipids may
be due to a variety of reasons. In the assays performed here, it is important to note that htt
aggregation is likely occurring both on the membrane surface and in solution, creating a complex
system. Curcumin initially appeared to delay the onset of htt aggregation in the presence of
POPC vesicles, but this ability dissipated with time. Htt aggregation on POPC/POPS bilayers
proceeds via a unique mechanism compared to aggregation in solution.43 A plausible scenario is
that curcumin is more effective against the pathway associated with aggregation in solution than
that occurring on the POPC membrane. However, curcumin did reduce the overall interaction of
htt with the POPC bilayer, and curcumin itself did not significantly interact with the lipid
surface. Perhaps more interestingly, curcumin increased fibril formation in the presence of TBLE
vesicles. Unlike POPC, TBLE appears to reduce htt fibril formation.40,63,82 Based on the PDA
assay, curcumin by itself strongly interacted with the vesicle surface, suggesting that the
curcumin was sequestered within the vesicle. In addition, the interaction of htt with the TBLE
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vesicles was greatly inhibited by the presence of curcumin. Collectively, this suggests a scenario
in which curcumin is quickly taken up by the TBLE vesicles, altering the membrane. This
alteration reduces the amount of htt bound and aggregating on the TBLE vesicle surface, which
is a slower fibril-forming pathway. As a result, there is a larger amount of htt aggregating in
solution in the presence of curcumin compared with controls of htt with just the TBLE vesicles.
As the curcumin that would inhibit fibrillization in solution has been sequestered by the TBLE
vesicles, the portion of htt in solution is free to aggregate. As a result, fibrillization increased in
the presence of curcumin and TBLE vesicles. While investigated for its interaction with Aβ, it
has also been suggested that curcumin binds to later stage aggregate species like protofibrils.83,84
If curcumin also targets later stages of the aggregation process of htt, this too could contribute to
its differing abilities to modify htt fibrillization in the presence and absence of lipids, especially
if the aggregation process in the presence of lipids is altered.
EGCG remained effective in preventing htt fibril formation in the presence of lipid
vesicles. The effectiveness of EGCG as an amyloid inhibitor in the presence of lipids appears to
be protein specific, as EGCG was unable to prevent IAPP fibrillization on a lipid membrane85
but was more effective in preventing Aβ aggregation in the presence of vesicles.57 EGCG is
known to be incorporated into lipid vesicles,57 and we did observe that EGCG by itself invoked a
colorimetric response in our PDA assays, verifying that it directly interacted with both POPC
and TBLE. EGCG appears to target early events in htt aggregation,34 and this also appears to be
the case for EGCG’s interaction Aβ and α-synuclein aggregation.27 This ability to intervene in
the htt aggregation process at an early stage could be why EGCG remained an effective inhibitor
in the presence of lipids. Even though EGCG remained effective in the presence of both lipid
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systems and promoted larger, nonfibrillar aggregates, the morphology of these large aggregates
was distinct, suggesting that lipid vesicles did influence how EGCG interacts with htt.
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4. Lipid headgroups alter huntingtin aggregation on membranes
Huntington's Disease is a neurodegenerative disorder caused by an expanded
polyglutamine(polyQ) domain within the huntingtin protein (htt). As a consequence of polyQ
expansion, htt associates into a variety of aggregates that underlie cellular toxicity. Within cells,
htt associates with numerous membranous organelles that exert influence on the aggregation
process. In particular, the first 17 amino acids at the N-terminus of htt (Nt17) serve as a lipidbinding domain that is intrinsically disordered in bulk solution but adopts an amphipathic αhelical structure upon binding membranes. Beyond this, Nt17 is implicated in initiating htt
fibrillization. As the htt/membrane interaction is likely influenced by lipid properties, the impact
of lipid headgroups on htt-exon1 aggregation, membrane activity, and the ability to form
protein:lipid complexes was determined. Htt-exon1 with a disease-length polyQ domain was
exposed to lipid vesicles comprised of lipids with either zwitterionic (POPC and POPE) or
anionic (POPG and POPS) headgroups. With zwitterionic head groups, large lipid to peptide
ratios were required to have a statistically significant impact on htt aggregation. Anionic lipids
enhanced htt fibrillization, even at low lipid:protein ratios, and this altered aggregate
morphology. Despite the larger impact of anionic lipids, htt-exon1(46Q) was more membrane
active with zwitterionic lipid systems. The ability of Nt17 to form complexes with lipids was
mediated by lipid headgroups as zwitterionic ionic lipids more readily associated with
multimeric forms of Nt17 in comparison with anionic lipids. These results highlight the
complexity of htt/membrane interactions and the resulting impact on the aggregation process.
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4.1 Introduction
Amyloid diseases are defined by abnormal deposition of proteinaceous aggregates
(amyloid fibrils or plaques) in tissues and organs. Amyloid forming proteins include β-amyloid
(Aβ) and tau related with Alzheimer’s disease (AD), α-synuclein (α-syn) implicated in
Parkinson’s disease (PD), human islet amyloid polypeptide (hIAPP) linked with type II diabetes,
and the huntingtin protein (htt) associated with Huntington’s disease (HD). In general, amyloid
fibrils form via a nucleus-dependent polymerization mechanism beginning with a rate-limiting
nucleation step that leads to rapid elongation of the β-sheet rich aggregates.1–3 In HD, a genetic
neurodegenerative disorder, an aberrant expansion of a polyglutamine (polyQ) region in the first
exon of htt (>35 repeat glutamine residues) promotes toxic aggregation. Beyond the formation of
fibrils, htt aggregates via numerous mechanisms that can occur simultaneously, resulting in a
heterogeneous mixture of species, including oligomers, fibrils, annular aggregates, and inclusion
bodies.4–6
The complexity of htt aggregation makes it difficult to gain consensus on the prominent
aggregate form involved in toxicity. Several aggregate species could be involved in a variety of
potential cytotoxic mechanisms, while others may impart a protective effect. Inclusion bodies
were initially thought to be prominent toxic entities as their formation preceded behavioral
deficits in mouse models.7 While it is true that large scale cellular degeneration is observed in the
striatum coinciding with the presence of intracellular aggregates comprised of mutant htt, there is
only moderate degeneration within the cerebral cortex despite a typically larger inclusion load.8
A poor correlation between inclusion body formation and toxicity is also apparent in cellular
models of HD.9 Survival analysis suggests that particularly potent toxic species reside in
diffusely distributed htt throughout cells and that the formation of inclusion bodies may be
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protective.10 However, the diffuse htt population implicated in toxicity is a complex mixture that
includes htt species ranging from monomers and small oligomers11–13 to amorphous aggregates
and fibrils,14–16 making it difficult to pinpoint toxic species. In fact, there is evidence linking htt
oligomers,12,17,18 fibrils,19,20 and even inclusions21 to cellular dysfunction and toxicity.
While aggregation is a complex process, the direct interaction of htt with intracellular and
subcellular membranes that are predominately comprised of lipids further modifies aggregation.
For example, the first N-terminal 17 amino acids (Nt17) of htt-exon1 is implicated in promoting
the formation of α-helix rich oligomer intermediates that nucleate fibril formation; however,
Nt17 facilitates the binding of htt to lipid membranes by forming an amphipathic α-helix. A
number of model lipid membranes, ranging from total brain lipid extracts (TBLE) to pure lipid
systems, alter the rate of aggregation and the resulting aggregate species observed. For example,
POPC/POPS lipid vesicles enhanced fibril formation,22 but TBLE and other brain extracts tend to
reduce fibrillization.23 In addition, lipid components ranging from cholesterol,24 sphingomyelin,
and GM125 can further modify htt aggregation on membranes.
Beyond influencing aggregation, several toxic mechanisms involve htt/lipid interactions.
Htt aggregation on membranes can lead to membrane disruption and permeabilization that has
been associated with organelle dysfunction in HD.26–29 In addition, mutant htt demonstrates
enhanced binding to phospholipid bilayers compared to wild type30–32 and is associated with
membranous organelles such as the endoplasmic reticulum (ER),33 mitochondria,34,35 and golgi
apparatus.36 Htt aggregates accumulate brain lipids27,37 and membranous structures are
incorporated into htt inclusion bodies.38,39 The association of htt with organelles via membrane
interactions result in disrupted trafficking,34 synaptic degeneration,40 and neuronal cell death.41
While posttranslational modifications within Nt17 regulate the localization of htt to different
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organelles, the membrane composition of these organelles also plays a role, as membrane
physicochemical properties dictate protein/lipid interactions.
Here, the aim was to determine how lipid headgroups influence the membrane activity of
htt. To achieve this, the extent of aggregation and membrane activity of htt in the presence of
model lipid vesicles with identical tails but different headgroups (POPC, POPE, POPG, POPS)
was determined. To further investigate the role of surface charge, two of the selected systems are
zwitterionic (POPC and POPE), while two are anionic (POPG and POPS). First, the impact of
the different lipid systems on the rate of htt aggregation and resulting aggregate morphology was
elucidated with thioflavin-T (ThT) aggregation assays and atomic force microscopy (AFM). Htt
membrane activity and protein/lipid complex formation were resolved via polydiacetylene
(PDA) lipid binding assays and native mass spectrometry (MS). These studies suggest that htt
membrane activity increases with bilayer fluidity and that increased membrane charge density
promotes a unique lipid interaction mechanism that alters oligomer formation and enhances
fibrilization.
4.2 Materials and methods
4.2.1 Purification of glutathione S-transferase (GST)-htt exon1 fusion protein
Glutathione S-transferase (GST)-htt exon1 fusion proteins with pathogenic-length
polyglutamine repeats (46Q) were expressed and purified as previously described.42 Briefly, the
protein was expressed in Escherichia coli for 4 h at 37 °C followed by the addition of lysozyme
and probe-sonication to release the protein. Purification was accomplished using a BioRad low
pressure liquid chromatograph equipped with a GST-affinity column. Relevant fractions were
pooled into one bulk solution and placed in dialysis at 4 °C for 2 days. Prior to any experiments,
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the protein solution was subjected to a high-speed centrifugation (22,000 ×g for 30 min) to
remove any aggregate species that may have formed during dialysis. To initiate aggregation, the
desired volume of protein solution was incubated with Factor Xa (Promega, Madison, WI) for 30
min to cleave the GST tag from the htt-exon1(46Q). All experiments were carried out in a tris
buffer (150 mM NaCl, Tris-HCl, pH 7.4).
4.2.2 Formation of lipid vesicles
Lyophilized lipid was dissolved in chloroform and aliquoted into Eppendorf tubes. The
aliquots were dried under a gentle stream of nitrogen, and the resulting lipid films were stored at
-20 °C until needed. For experiments, lipid films were rehydrated in tris buffer (150 mM NaCl,
Tris-HCl, pH 7.4) for 1 h at 30 °C. Once rehydrated, the lipids were subjected to 10 freeze-thaw
cycles using liquid nitrogen and a thermomixer (55 °C). After the freeze-thaw cycles, lipid
solutions were bath-sonicated for 1 h and then stored at 4 °C.
4.2.3 Thioflavin T aggregation assay
Thioflavin T fluorescence assays (ThT, Sigma-Aldrich, St. Louis, MO) were performed
to monitor fibril formation. To ensure GST cleavage, htt-exon1(46Q) was incubated with
cleaving agent Factor Xa for 1 h on ice. Then, htt-exon1(46Q) (20 µM) was incubated with ThT
(200 µM) in the presence and absence of various pure lipid systems (POPC, POPE, POPG, or
POPS). Prior to the addition of ThT or lipid vesicles, the htt-exon1(46Q) underwent
centrifugation to remove preexisting aggregates. When lipid was present, the concentration was
either 100 µM, 200 µM, or 400 µM to result in lipid:htt ratios of 5:1, 10:1, or 20:1. Experiments
were performed in Costar clear-bottom 96-well plates at 37 °C and ThT fluorescence was
monitored with a SpetraMax M2 microplate reader (440 nm excitation, 484 nm emission) every
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5 min over an 18 h period. Each experiment was performed three separate times, and within each
experiment individual conditions were run in triplicate. Reported values are an average of the
three trials within one representative experiment used in figures. The rate was calculated as
previously described.23 Briefly, the rate was measured over a 3 h period that started when the
intensity of the fluorescence exceeded 10% of the maximum signal obtained for that condition.
This threshold was selected to ensure a significant increase in fluorescence and to avoid
calculation starting in any noise in the lag phase. Both the rate and the maximum fluorescence
for each condition were normalized to the htt control (100%).
4.2.4 Atomic force microscopy
Ex situ atomic force microscopy (AFM) was used to investigate the morphology of htt
aggregates formed in the presence or absence of lipid vesicles. Htt-exon1(46Q) (20 µM) was
incubated with and without 400 µM lipid vesicles (to result in a 20:1 lipid:protein ratio) at 37 °C
for a period of 8 h. After 1, 3, 5, and 8 h of incubation, a 2 µL aliquot of each condition was
deposited on freshly cleaved mica for 1 min. Then, the mica was rinsed with 18 MΩ water and
dried with a gentle stream of clean air. Samples were imaged using a Nanoscope V Multi-Mode
scanning probe microscope (VEECO) equipped with a closed-loop vertical engage J-scanner.
Silicon-oxide cantilevers with nominal spring constant of 40 N/m and a resonance frequency of
300 kHz were used. Scan rates were set to 1.99 Hz with cantilever drive frequencies at 10% off
resonance. All images were analyzed using the Matlab image processing toolbox (MathWorks)
as previously described.5,43
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4.2.5 Polydiacetylene lipid binding assay
A normalized polydiacetylene (PDA) lipid binding assay was utilized to measure the
interaction between htt-exon1(46Q) and different lipid systems. Briefly, diacetylene monomers
(10,12-tricosadiynoic acid) and various lipid systems were dissolved in a 4:1 chloroform:ethanol
solution and mixed at a 2:3 molar ratio. Solutions were dried under a gentle stream of nitrogen
until a fully dried lipid film was formed, and then films were reconstituted in hot tris buffer (150
mM NaCl, Tris-HCl, pH 7.4, 70 °C). Lipid solutions were sonicated at 125 W for 10 min, then
protected from light and left at 4 °C overnight to allow vesicle formation. The following day,
lipid vesicles were exposed to UV light (254 nm) to polymerize the diacetylene monomers,
resulting in a royal blue solution that can undergo a colorimetric shift to red as a result of
mechanical stress. PDA/lipid solutions (400 µM) were incubated with htt-exon1(46Q) at 30 °C,
and the blue (650 nm) and red (500 nm) absorbances were recorded every 5 min for 18 h. The
negative control consisted of equal volumes of neat buffer and PDA/lipid solution, while the
internal standard involved equal volumes of 1M NaOH and PDA/lipid. The NaOH creates
repulsion between headgroups via protonation, causing a colorimetric shift. The dose of NaOH
used saturates the system, resulting in a maximum colorimetric shift for each lipid system that
can be used to normalize results. The % CR was calculated for each condition using the
following equation:
𝑃𝑃𝑃𝑃0 −𝑃𝑃𝑃𝑃

% 𝐶𝐶𝐶𝐶 = �

𝑃𝑃𝑃𝑃0

� × 100

(1)

where PB is defined as Ablue/(Ablue + Ared) for the negative control (PB0) and sample condition
(PB).
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4.2.6 Electrospray Ionization-Mass Spectrometry (ESI-MS)
Native MS44 was used to investigate complexes formed between Nt17 peptide and
various lipid vesicles.45 Lipid vesicles were formed as previously described, but films were
reconstituted in HPLC-grade water instead of tris buffer. Nt17 peptide (20 µM) was incubated
with lipid vesicles (20:1 lipid:peptide) for 5 h at 37 °C. Samples were analyzed using a Q
Exactive Hybrid Quadrupole mass spectrometer (Thermo Fischer, San Jose, CA) equipped with a
commercial HESI source. Spectra were recorded in positive-ion mode over a mass-to-charge
(m/z) ratio range of 400 to 4,000, and samples that included anionic lipids were also recorded in
negative-ion mode. Samples were infused at a rate of 10 uL/min and the needle was biased at
3,500 V relative to the mass spectrometer inlet. The parameters for the MS instrument were: 400
°C for the capillary inlet temperature, 30 °C for the analyzer temperature, 80 V for the S-lens
assembly, 400 ms for the maximum injection time, 1 × 106 for the AGC, and 70,000 for the MS
resolution. Each spectrum was recorded in triplicate for 90 s each, and the data was analyzed
using the Xcalibur 2.2 software suite (Thermo Scientific).
4.3 Results
4.3.1 Lipids modify htt aggregation to various extents
All experiments in this study, with exception of the native MS studies described later,
were performed with a mutant htt-exon1 fragment with 46Q (htt-exon1(46Q)). Htt-exon1(46Q)
was expressed as a soluble fusion with GST, and cleavage of GST by Factor Xa initiates
aggregation. Htt-exon1(46Q) was incubated with vesicles of POPC, POPE, POPG, or POPS at
various lipid to protein molar ratios (5:1, 10:1, and 20:1), and aggregation was monitored as a
function of time using ThT, which fluoresces when bound to β-sheet structure associated with

Chapter 4

| 96

fibrils (Fig. 4.1a-d). All relevant controls were measured and subtracted from the curves to show
only the fluorescence signal from htt aggregation. Htt aggregation in the absence of lipids was
performed for comparison. Multiple independent experiments were performed. The slope of the
ThT curves were analyzed to compare the relative rates of aggregation for each condition (Fig.
4.1e), as was the maximum signal for each condition to compare the extent of fibril formation
(Fig. 4.1f).
The effect of lipid vesicles on htt-exon1(46Q) aggregation appeared to be greatly
dependent on the headgroup charge of each lipid system. The two zwitterionic lipid systems –
POPC and POPE – each had minimal impact on htt-exon1(46Q) aggregation until the 20:1
lipid:protein ratio (Fig. 4.1a-b). At 5:1 or 10:1 lipid:protein ratio, neither lipid system resulted in
a change to the maximum fluorescence of more than ± 5% when compared to the control. In the
presence of 20:1 POPC, the rate of htt-exon1(46Q) fibrilization increased by 39% and resulted in
44% increase in the average ThT signal compared to the absence of lipid (Fig. 4.1e-f). However,
the presence of 20:1 POPE reduced the aggregation rate by 18%, which resulted in a 24%
decrease in the maximum ThT signal compared to control (Fig. 4.1e-f).
While the two zwitterionic lipid systems ultimately influenced htt aggregation differently
(POPC enhanced aggregation; POPE inhibited aggregation), statistically significant changes
were not observed until the lipid to protein ratio became sufficiently large. In contrast, the two
anionic lipid systems (POPG and POPS) significantly enhanced the rate and extent of htt
aggregation at lipid to protein ratios as small as 5:1 (Fig. 4.1c-d). For both anionic lipid systems,
the largest increase in aggregate formation occurred at the 5:1 lipid:protein ratio (114% increase
with POPG and 66% increase with POPS compared to htt aggregation in the absence of lipids).
Increasing the lipid:protein ratio resulted in a decrease in the effect for lipid systems. The
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presence of POPG vesicles increased the extent of aggregation by 106% at the 10:1 ratio, but this
decreased to an 84% increase at the 20:1 ratio. The same trend appeared with POPS, where
adding more lipid decreased the impact on the extent of aggregation (62% increase at 10:1 and
38% increase at 20:1). For both systems, changes in the rate of aggregation mirrored the extent
of aggregation (Fig. 4.1e-f). POPG increased the rate of aggregation formation at all
concentrations (185% increase at 5:1 and 10:1, and 143% increase at 20:1), as did POPS (232%
increase at 5:1, 126% increase at 10:1, and 70% increase at 20:1).
Figure 4.1 Varying the lipid headgroup
alters how vesicles influence htt
fibrilization. ThT aggregation assays for
htt-exon1(46Q) in the presence of (a)
POPC, (b) POPE, (c) POPG, or (d) POPS
lipid vesicles. Htt concentration was 20
µM, and the lipid to htt molar ratio was
5:1, 10:1, or 20:1. The aggregation rate
for each condition is represented by the
(e) slope relative to the control assay with
no lipids, which is set to 100. The (f)
relative maximum fluorescence for each
condition was calculated in the same way,
setting the no lipid condition to 100. In
panels a-d, error bars are provided for
every sixth data point (30 min) and
represent the standard error of the mean
(SEM). Analyses shown in panels e and f
were determined as averages over all
trials, and values are normalized as a
percentage with respect to the htt control
in the absence of lipid. Error bars
represent SEM. * represents a p value <
0.05, and **represent a p value <0.01
using a Student’s t-test.
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To further investigate the influence that the different lipid vesicles have on httexon1(46Q) aggregation, AFM analysis was performed (Fig. 4.2). Incubation experiments were
performed with monomeric htt-exon1(46Q) (20 µM) in the presence and absence of POPC,
POPE, POPG, or POPS lipid vesicles at a molar ratio of 20:1 lipid:htt. At designated time points
(1, 3, 5, and 8 h), incubations were sampled for AFM analysis. Control incubations of the
different lipid vesicles were also imaged to determine the associated backgrounds on the mica
surface (Fig. 4.3). For all incubation conditions, a variety of oligomers and fibrils were observed
(Fig. 4.2), and further analysis of aggregate population and morphology was carried out. To
quantify the effect of the lipids on aggregation, AFM images from all incubations were analyzed
by counting the number of fibrils and oligomers per square micron using automated scripts
written in Matlab that determined morphological features of each individual aggregate present in
the image. For the analysis, oligomers were classified as any feature taller than 1.0 nm with an
area of fewer than 40 pixels and with an aspect ratio (longest distance across to shortest distance
across) of less than 3.0, indicating a globular structure. The 1.0 nm height threshold was selected
to overcome the effect of background associated with AFM images of lipid controls. Fibrils were
identified and counted by hand in each image.
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Figure 4.2 Representative AFM images showing the effect of different lipids on httexon1(46Q) aggregation. Htt-exon1(46Q) (20 µM) was incubated with (a) no lipid, (b) POPC
vesicles, (c) POPE vesicles, (d) POPG vesicles, or (e) POPS vesicles at various time points. The
ratio of lipid to htt was 20:1. The colormap and scale bar is applicable to all images.
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Figure 4.3 AFM images of lipid backgrounds. Representative AFM images of the
backgrounds associated with (a) neat buffer, (b) POPC, (c) POPE, (d) POPG, and (e) POPS
lipid vesicles deposited on mica. The line in each image corresponds to the height profile
provided below each image. These backgrounds were used to determine appropriate height
threshold values for AFM image analysis.
Consistent with the ThT assays, each lipid system (POPC, POPE, POPG, POPS)
impacted the extent of htt-exon1(46Q) fibrilization. In the absence of lipid, a small population of
fibrils were present after 1 h, and fibril content grew steadily with time (Figs. 4.2 and 4.4a).
While ThT fluorescence is traditionally interpreted to be a measure of fibril formation, raw fibril
counts aren’t necessarily directly comparable to ThT assays as the length of fibrils varies greatly
and fibril bundling can occur. Therefore, the total extent of fibril formation was also determined
at the 8 h time point by measuring the percent of the surface area covered by fibrils (Fig. 4.4b).
After 8 h of incubation, fibrils covered ~2% of the mica surface. As fibril thickness can vary
along its length, the fibril morphology was assessed by measuring the average height along the
contour, and the mode fibril height was 7.5 nm (Fig. 4.4c).
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Figure 4.4 AFM analysis of the impact
of different lipid systems on httexon1(46Q) aggregation. (a) Analysis
of the number of fibrils formed in the
presence of each lipid system as a
function of time. (b) The percent area of
each image covered by fibrils at the 8 h
time point for each condition. (c) Height
histograms of fibrils formed in the
presence of different lipid systems. (d)
Image analysis of oligomers per unit area
as a function of time for each condition.
Correlation plots of the height and
diameter of each oligomer and
histograms of these morphological
features at 1 h and 8 h in the presence of
(e) no lipid, (f) POPC, (g) POPE, (h)
POPG, and (i) POPS vesicles. For
panels a, b, and d, error bars represent
the SEM, * represents a p value <0.05,
and ** represent a p value <0.01 using a
Student’s t-test.

In the presence of POPC lipid vesicles, the number of htt-exon1(46Q) fibrils was similar
to control during the first 5 h but there was a statistically significant increase in fibril
population after 8 h (p < 0.01, Fig. 4.4a). Despite this increased number of fibrils, fibril content
formed in the presence of POPC vesicles covered only a slightly larger surface area compared
with control (2.3%, Fig. 4.4b). The mode height (8.0 nm) of fibrils formed with POPC vesicles
was similar to control (Fig. 4.4c). In the presence of POPE vesicles, htt-exon1(46Q) formed
fewer fibrils than control at all time points (Fig. 4.4a) and covered a smaller surface area (1.5%,
Fig. 4.4b). Again, fibril morphology was indistinguishable from control as the mode height was
7.5 nm (Fig. 4.4c).

Chapter 4

| 102

With both anionic lipid systems (POPG and POPS), the number of fibrils formed was
significantly larger compared with control (Fig. 4.4a), with the largest fibril population observed
with POPS. Under both POPG and POPS conditions, fibrils covered a significantly larger
surface area at 8 h (5.0% for POPG and 3.9% for POPS, Fig. 4.4b). The fibril morphology was
also altered by anionic lipids, as the distribution and mode height of these fibrils was shifted to
smaller values with heights mainly ranging from 5-7.5 nm (Fig. 4.4c). In particular, fibrils
formed with POPG developed a unique morphology with time. That is, fibrils bundled into
clumps with multiple fibrillar extensions emanating from a central core (Fig. 4.5). Fibrils formed
with POPS vesicles were shorter in length than control, as demonstrated by the number of fibrils
formed being ~4× that of control while only covering ~2× the surface area.

Figure 4.5 POPG vesicles promote a unique htt-exon1(46Q) fibril morphology.
Representative AFM images of a unique fibril morphology formed as a result of htt-exon1(46Q)
incubation with POPG lipid vesicles.
While AFM analysis of fibril formation was consistent with ThT assays, AFM also
provides information concerning oligomeric aggregates. In the absence of lipid, oligomers of httexon1(46Q) formed within 1 h, and the oligomer population peaked at the 3 h time point (Fig.
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4.4d). As the experiment progressed, the oligomer population decreased, but not to a statistically
significant extent. Morphological analysis of oligomer height and diameter demonstrated that htt
oligomers became larger with time in the absence of lipid. After 1 h of incubation, oligomers
were predominately 4-4.5 nm in height, while the mode size grew to 5.5-6.0 nm at 8 h (Fig.
4.4e). In the presence of zwitterionic lipid species (POPC or POPE), oligomer formation again
peaked after 3 h (Fig. 4.4d); however, the population of oligomers at any given time tended to be
smaller compared to incubation in the absence of lipid (Fig. 4.4f-g). With POPC lipid vesicles,
the population of htt-exon1(46Q) oligomers decreased at each time point relative to control (p <
0.05 at 3, 5, and 8 h, Fig. 4.4d). Oligomers formed in the presence of POPC after 1 h were
smaller than control (3-3.5 nm), and these smaller oligomers persisted with time (Fig. 4.4f). After
8 h, htt-exon1(46Q) incubated with POPC formed a more heterogeneous mixture of oligomers
with a broad distribution of sizes and a mode height spanning 3-6.5 nm. In the presence of POPE
lipid vesicles, the number of oligomers was similar to control through 3 h, but starting with 5 h,
the population of oligomers drastically decreased (Fig. 4.4d). Despite the change in the
population of oligomers, the morphology of oligomers formed in the presence of POPE was
similar to control (Fig. 4.4g). After 1 h, the oligomers had a mode height of 3.5-4.5 nm and they
grew to 5.5-6.5 nm after 8 h.
When incubated with anionic lipids (POPG or POPS), the extent and morphology of
oligomers formed was significantly different than in the absence of lipid. With POPG vesicles,
the most oligomers were observed at 1 h, and the oligomer population decreased with time (Fig.
4.4d). After 1 h of incubation, oligomers were slightly smaller than the control with a mode
height of 2-2.5 nm (Fig. 4.4h). While oligomers increased in size with time, they remained
significantly smaller (3.0-3.5 nm mode height) with POPG after 8 h of incubation compared to
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control (5.5-6.0 nm mode height). Similar to POPG, the peak oligomer population was observed
at 1 h for htt incubated with POPS vesicles, and the number of oligomers progressively
decreased (Fig. 4.4d). Morphological analysis of oligomers formed with POPS vesicles revealed
that they were significantly smaller than the control, with a mode height of 2.5-3 nm after 1 h of
incubation (Fig. 4.4i). At 8 h, oligomer morphology was more heterogeneous but still drastically
smaller (3-3.5 nm mode height).
4.3.2 Htt has varying affinity for different lipid systems
With the presence of the different lipid systems directly impacting htt aggregation, the
extent of htt-exon1(46Q) direct interaction with the different lipid systems was determined by a
series of colorimetric membrane binding assays using PDA/lipid vesicles. These vesicles were
formed with either POPC, POPE, POPG, or POPS as the lipid component. PDA/lipid vesicles
have colorimetric responses (CRs) when exposed to proteins that directly correlate with the
extent of interaction. The CR in the PDA/lipid vesicles is related to transitions of the PDA
polymer backbone structure, which is affected by mechanical stress associated with exogenous
molecules directly binding and/or inserting into the vesicle. By measurement of the absorbance
of both the blue (640 nm) and red (500 nm) wavelengths of PDA/lipid vesicles upon exposure to
htt-exon1(46Q), the % CR was obtained, which directly corresponds to the protein−lipid
interaction. GST alone does not bind lipids46 or result in a CR (data not shown), so here any
measured CR is a result of htt-exon1(46Q) interaction with the vesicle. In addition, not cleaving
the GST tag inhibits the ability of htt to bind lipids.47 As the sensitivity of the CR varies with
different lipid systems incorporated into PDA/lipid vesicles, all PDA/lipid vesicle systems were
exposed to a large dose of NaOH to determine the maximal % CR, and this was used to
normalize all data to allow quantitative lipid-to-lipid comparison.
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PDA vesicles formed with POPC as the lipid component exhibited a colorimetric shift
in the presence of htt-exon1(46Q) that increased with increasing htt concentration (Fig. 4.6a).
Exposure to 5 µM htt-exon1(46Q) elicited a CR that grew steadily, reaching a maximum % CR
of ~18% (Fig. 4.6e). When htt-exon1(46Q) dose was increased to 10 or 20 µM, the % CR grew
rapidly for the first 3 h, but began to level off with maximum % CR of ~35% and ~45% for the
two htt doses respectively (Fig. 4.6e). POPE/PDA vesicles exhibited a dose dependent increase
in CR with increasing dose of htt-exon1(46Q) but to a lesser extent than POPC/PDA vesicles
(Fig. 4.6b). In all three cases (5, 10, and 20 µM htt-exon1(46Q)), there was limited change in
the CR until 3 h. Then, the %CR increased for POPE/PDA vesicles exposed to 5 µM (maximum
CR ~12%), 10 µM (maximum CR ~20%), and 20 µM (maximum CR ~ 25%) htt-exon1(46Q)
(Fig. 4.6e).
Figure 4.6 Htt-exon1(46Q) membrane
association is altered by lipid
headgroup. PDA/lipid binding assays
for (a) POPC, (b) POPE, (c) POPG, or
(d) POPS exposed to 5, 10, or 20 µM httexon1(46Q). (e) The maximum % CR
for each condition after 18 h. (f) Direct
comparison of the kinetic lipid binding
assay for each lipid system when
exposed to 20 µM htt. Error bars are
provided for every sixth data point and
represent the SEM.
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A peculiar dose-dependent pattern of htt/lipid interaction was observed by the PDA
assays using anionic lipids (Fig. 4.6c-d). While the CR steadily increased when these two lipid
systems were exposed to htt, the magnitude of the CR decreased with increasing htt dose (Fig.
4.6e). In the presence of 5 µM htt-exon1(46Q), POPG/PDA vesicles exhibited a maximum %
CR of ~27%, while this dropped to ~19% upon exposure to 20 µM htt-exon1(46Q). This trend
persisted with POPS/PDA vesicles, as 5 µM htt elicited the largest % CR (~20%) for this system
and exposure to 20 µM htt only resulted in an ~13% CR. Due to the decreased interaction of htt
with anionic lipids, htt had the largest interaction with anionic lipids at the 5 µM dose; however,
at the 20 µM dose the zwitterionic lipids interacted more strongly with htt (Fig. 4.6e).
4.3.3 Vesicle charge alters the complexes formed between the lipid binding domain of htt
and lipids
As the ability of htt-exon1 to bind lipids is facilitated by Nt1726 and it has been shown to
act in modifying the aggregation process on membranes22, native MS was utilized to determine
the propensity and composition of complexes formed between Nt17 and the different lipid
systems (POPC, POPE, POPG, and POPS). The interaction mechanism between Nt17 and lipid
bilayers does not change upon the addition of glutamines;48 therefore, experiments performed
with Nt17 can provide insight into the interaction between htt-exon1(46Q) and lipid membranes.
Beyond the formation of small multimers, htt aggregation is driven by the polyQ domain,49 so
conclusions about higher-order aggregate formation cannot be drawn from the population of
detected Nt17 multimeric species. Nt17 (20 µM) was incubated with POPC, POPE, POPG, or
POPS lipid vesicles (20:1 lipid:peptide) for 5 h. The 5 h incubation time was determined from
the kinetic PDA data, as htt induces a noticeable colorimetric response in all four lipid systems
after 5 h of incubation. The relative abundance of each species was determined in relation to the
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doubly-charged monomer peptide ion ([M+2H]2+ ion at m/z ~ 988). All experiments were
performed in triplicate.

Figure 4.7 Nt17 forms complexes with lipids that are observable by native MS. Mass spectrum
showing the ions obtained after ESI of Nt17 with (a) POPC, (b) POPE, (c) POPG, or (d) POPS lipid
vesicles after 5 h of co-incubation. Insets represent expanded regions in which specific observed ions
are present.
Ions comprised of peptide-lipid complexes were observed with all four of the lipid
systems in various combinations, with the number of peptides per complex ranging from 1-4 and
ranging from 1-6 lipids (Fig. 4.7 and Fig. 4.8; Table 4.1). Notably, the composition and relative
abundance of the identified ions varied by lipid system (Fig. 4.8). POPC formed the greatest
number of distinct complexes ranging with monomeric (6% relative abundance), dimeric (1.2%),
trimeric (0.03%), and tetrameric (0.009%) Nt17 (Figure 4.8, Table 4.1). Twelve distinct ions
containing a single Nt17 monomer were observed with POPC, with up to 6 lipid molecules
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associating with Nt17. The diversity of Nt17/POPC species was maintained with dimers (7 ions,
up to 5 lipid molecules), trimers (3 ions, up to 5 lipid molecules) and tetramers (4 ions, up to 5
lipid molecules). POPE formed complexes with monomeric (4.5%), dimeric (0.13%), trimeric
(0.02%), and tetrameric (0.006%) Nt17 as well, but with fewer combinations of peptide and lipid
compared with POPC (Figure 4.8, Table 4.1). Only 6 distinct complexes were identified for
Nt17 monomers and POPE with up to 4 lipid molecules associated with the peptide. In addition,
Nt17/POPE species formed with dimers (2 ions with 3 or 5 lipid molecules), trimers (3 ions, up
to 4 lipid molecules), and tetramers (2 ions with 1 or 3 lipid molecules).

Figure 4.8 Populations of complexes formed with Nt17 and lipid are altered by the
lipid headgroup. The relative abundance of ions observed with POPC, POPE, POPG, or
POPS lipids and Nt17 (a) monomers, (b) dimers, (c) trimers, or (d) tetramers. The total
relative abundance of complexes formed with each Nt17 species is presented (top), along
with the breakdown of relative abundance as a function of lipid content (bottom) for each
system. Error bars represent the SEM.
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Table 4.1 Assigned ions for Nt17 incubated with POPC, POPE, POPG, or POPS
lipid vesicles along with their mass to charge ratios.
Iona

m/z

Charge
State

Nt17 + 1POPC

2734.63

1

Nt17 + 1POPC

1367.82

Nt17 + 1POPC

Iona

m/z

Charge
State

Nt17 + 1POPE

1346.79

2

2

Nt17 + 1POPE

898.19

912.21

3

Nt17 + 2POPE

Nt17 + 2POPC

1747.11

2

Nt17 + 2POPC

1165.41

Nt17 + 3POPC

Iona

m/z

Charge
State

Nt17 + 1POPG

2723.61

1

3

Nt17 + POPG

1362.31

2

1705.55

2

Nt17 + 1POPG

908.54

3

Nt17 + 2POPE

1137.37

3

Nt17 + 2POPG

1736.59

2

3

Nt17 + 3POPE

2064.32

2

Nt17 + 2POPG

1158.06

3

2126.91

2

Nt17 + 4POPE

2423.08

2

Nt17 + 3POPG

2110.88

2

Nt17 + 3POPC

1418.60

3

2Nt17 + 3POPE

3051.34

2

Nt17 + 3POPG

1407.58

3

Nt17 + 4POPC

2506.70

2

2Nt17 + 5POPE

3768.87

2

Nt17 + 4POPG

2485.16

2

Nt17 + 4POPC

1671.80

3

3Nt17 + POPE

3320.83

2

Nt17 + 4POPG

1657.11

3

Nt17 + 5POPC

2897.99

2

3Nt17 + 2POPE

2461.05

3

2Nt17 + 1POPG

2349.33

2

Nt17 + 5POPC

1925.00

3

3Nt17 + 4POPE

2931.75

3

2Nt17 + 1POPG

1566.55

3

Nt17 + 6POPC

2180.17

3

4Nt17 + POPE

2872.23

3

2Nt17 + 2POPG

1816.07

3

2Nt17 + 1POPC

2354.84

2

4Nt17 + 3POPE

3350.58

3

2Nt17 + 1POPC

1570.22

3

Nt17 + 1POPS

1368.27

2

2Nt17 + 2POPC
2Nt17 + 3POPC

1823.42
3113.93

3
2

Nt17 + 1POPS
Nt17 + 2POPS

912.51
1748.52

3
2

2Nt17 + 3POPC

2076.62

3

Nt17 + 2POPS

1166.01

3

2Nt17 + 4POPC

2331.13

3

Nt17 + 3POPS

2128.77

2

2Nt17 + 5POPC
3Nt17 + 1POPC

2583.01
2235.90

3
3

Nt17 + 3POPS
Nt17 + 4POPS

1419.51
1673.01

3
3

3Nt17 + 3POPC

2482.21

3

Nt17 + 5POPS

1926.51

3

3Nt17 + 5POPC

3241.02

3

Nt17 + 6POPS

2180.01

3

4Nt17 + 1POPC
4Nt17 + 2POPC

2886.25
3139.45

3
3

4Nt17 + 3POPC

3392.64

3

a The following average masses have been used to assign the peaks: 1974.04 for Nt17 peptide, 759.59 for POPC lipid, 717.51 for
POPE lipid, 758.57 for POPG lipid, and 760.50 for POPS lipid.
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With the anionic lipid systems, fewer distinct complexes were observed, and species with
larger peptide content were not detected (Fig. 4.8, Table 4.1). That is, ions containing only a
monomer of Nt17 predominated for both POPG (45%) and POPS (39%). Three distinct Nt17
dimeric complexes formed with POPG, but these represented a small fraction of Nt17 (0.34%).
No trimeric or tetrameric Nt17 ions were observed with POPG, and multimeric Nt17 ions were
completely absent with POPS (Fig. 4.8, Table 4.1). Nt17/POPG formed 9 distinct monomeric
complexes with up to 4 lipid molecules, but only 3 dimeric species with up to two lipid
molecules were detected (Fig. 4.8, Table 4.1). With POPS, 9 distinct monomeric ions were
observed, and Nt17 monomers were associated with up to 6 POPS molecules. Despite the lower
number of observed species, POPG and POPS complexes with Nt17 monomers had a
significantly larger relative abundance compared with the zwitterionic lipid systems, suggesting
that Nt17 monomers may have a higher affinity for anionic lipids.
4.4 Discussion
The aggregation process of amyloid proteins is largely dependent on the cellular
environment, with one major component being the presence of subcellular membranes comprised
of lipids. In this study, the impact of various lipid headgroups on htt-exon1(46Q) aggregation
and membrane activity was investigated. The vesicles comprised of anionic lipids significantly
enhanced htt-exon1(46Q) fibrillization, even at low lipid:protein ratios; meanwhile, larger
lipid:protein ratios were required to observe any impact on aggregation in the presence of
zwitterionic lipid vesicles. Anionic charged lipids promoted unique aggregate morphologies,
with both fibrils and oligomers exhibiting significantly lower average heights compared with
control. The membrane activity of htt-exon1(46Q) as determined by PDA assays was largest for
zwitterionic lipid systems in comparison with anionic lipid systems. In addition, complexes
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formed between the Nt17 lipid binding domain htt and anionic lipids were abundant but
predominately comprise of a single Nt17 monomer, whereas zwitterionic lipids readily formed
complexes with Nt17 multimers. Collectively, these results highlight the complexity of htt-exon1
aggregation and how it is impacted by the presence of lipid membranes.
Understanding the interplay between amyloid proteins and membranous surfaces is
critical for understanding a variety of associated toxic mechanisms. Physicochemical features of
lipids heavily influence selective interactions of amyloid proteins with membranes.50 Bilayer
fluidity, degree of hydration, 51 and membrane composition24,25 all influence lipid interactions of
amyloid proteins. Both htt52 and α-syn53 display increased affinity for highly curved lipid
membranes, as curvature impacts vesicle lateral pressure and the prevalence of transient packing
defects.54 Lipid peroxidation, which is known to decrease membrane fluidity and slow lateral
diffusion,55 decreases the membrane activity of Aβ.56 Here, the influence of lipid headgroups on
physicochemical membrane properties likely underscore the varying membrane activity of htt
observed. Nt17 interacts with lipids by forming an amphipathic α-helix.57 This is a common
structural motif found in several proteins that preferentially binds curved membranes due to the
high density of transient packing defects induced by curvature that act as putative binding
sites.58–60 With this in mind, the larger htt membrane affinity for POPE vs POPC (the
zwitterionic systems) may be associated with POPE’s smaller headgroup, which results in a
higher transition temperature and lower lateral fluidity.61 The larger lateral mobility of POPC
lipids results in a higher density of transient packing defects for Nt17 to bind, increasing the
likelihood of htt interaction with the membrane as observed in the PDA assay. When comparing
the anionic lipid systems, the higher membrane activity is again observed with the system of
higher fluidity (POPG).62 In addition, membrane thickness influences membrane affinities of
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other amyloid proteins. Aβ exhibits increased interaction with and disruption of thinner bilayers
such as DLPC when compared to thicker bilayers comprised of POPC or DOPC.63 In contrast, αsyn has a higher affinity for SUVs comprised of thicker bilayers.64 The thickness of bilayers
comprised of each lipid system used here has been determined through a combination of
experimental and computational approaches: POPC is 39.1 Å,65 POPE is 43.2 Å,66 POPG is 36.7
Å,67 and POPS is 40.8 Å thick.62 In this study, when directly comparing the two zwitterionic
lipids or the two anionic lipids, htt exhibited increased interaction with the thinner bilayer (POPC
> POPE and POPG > POPS).
Beyond the initial interaction of amyloid proteins with lipid membranes, these surfaces
can promote alternative aggregation mechanisms, resulting in unique aggregate morphologies
and stabilization of intermediates structures.50 This appears to be highly dependent on the
composition of the lipid membrane.23,24,68,69 POPC/POPS membranes promoted a distinct Nt17mediated htt aggregation mechanism that catalyzed fibrillization via membrane anchoring and
two-dimensional diffusion.22 In contrast, total brain lipid extracts stabilize oligomers of a
fragmented polyQ peptide containing Nt1726 and impede fibrillization of htt-exon1. Here, four
different lipid systems influence the rate of htt-exon1(46Q) aggregation to varying extents, with
modifying effects on aggregate morphology (both fibrils and oligomers). Zwitterionic lipid
systems required a large lipid to protein ratio to impact the rate of fibril formation with POPC
enhancing aggregation and POPE repressing it. Even so, the resulting aggregate morphologies
were similar to control. Anionic lipids induced the most significant alterations to htt-exon1(46Q)
aggregation, similar to what has been observed with other amyloid proteins. For example, hIAPP
aggregation is altered by acidic phospholipids, resulting in the formation of off-pathway
oligomers.68 Interestingly, hIAPP also interacts with lipids via an amphipathic α-helical domain.
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In the case of α-syn, acidic phospholipid membranes enhance fibrillization.53 With httexon1(46Q), fibrils and oligomers formed in the presence of anionic phospholipids displayed
unique morphological features, i.e. smaller initial oligomers and thinner fibrils, suggesting an
alternative aggregation mechanism. Fibril polymorphisms of htt-exon1 results from the
placement of flanking domains rather than changes in the polyglutamine core packing70 and in
this case may be a function of the strong association mechanism between Nt17 monomers and
anionic lipids. This would be consistent with the presence of POPS in the model membranes
used in the study by Pandey et al. that suggested a unique Nt17 mediated aggregation
mechanism.22
As alluded to above, the effect of lipids on htt-exon1(46Q) aggregation is likely mediated
through the direct interaction with Nt17. Based on computational studies, the interaction of Nt17
with phospholipid bilayers involves four basic steps: approach, reorganization, anchoring, and
insertion.48 Despite sharing the same basic steps, the precise mechanism of Nt17 binding is
influenced by membrane composition and properties.45 Here, it appears lipid headgroup charge
alters the progression through this Nt17 membrane binding process. When examining the
interaction of anionic lipid systems with htt, a high relative abundance of ions including Nt17
monomer were observed by native MS, but the colorimetric response in the PDA assay was low
for both systems. Combined, these results indicate an inefficiency in the binding process between
the anchoring and insertion step that can result in the formation of monomeric species detectable
by MS without invoking a large PDA colorimetric response. Despite inefficient insertion
indicated by the low PDA response, localization of htt monomers at the membrane surface would
be enhanced by electrostatic interaction between the net positively charged Nt17 and anionic
lipid headgroups.71 This electrostatic interaction could also lend some stability to any ions
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formed. This localization at the anionic lipid surface results in a region of high htt concentration,
enhancing aggregation as observed by ThT and AFM. Such a scenario is consistent with the
observation by ThT that increasing the lipid to protein ratio reduces the observed enhancement of
htt aggregation as the available htt would be spread across a larger total vesicle surface area,
decreasing the localized concentration.
In HD, one potential toxic mechanisms is that htt aggregation disrupts the membrane
integrity of specific organelles.29,33,35 Mutant htt demonstrates enhanced binding of lipid
membranes and disrupts phospholipid bilayer structural integrity in a polyQ-length dependent
manner.30–32 Htt aggregates accumulate brain lipids27,37 and membranous structures are
incorporated into htt inclusions.38,39 The factors determining the affinity of htt for specific
membranous organelles are not completely understood, but results presented here indicate a role
for membrane composition. Htt is associated with mitochondria29,35 and endoplasmic reticulum
(ER)33 membranes in vitro, each of which contain a large percentage of the phosphatidylcholine
(PC) lipids (46 and 54%, respectively72), for which htt-exon1(46Q) demonstrated the largest
membrane activity. Specifically, htt associates with the outer mitochondrial membrane, which
has a higher PC lipid content than the inner membrane.73 In addition, htt-exon1(46Q) monomers
had a high affinity for the anionic lipid headgroups, which correlates with the association of htt
to acidic phospholipids at the plasma membrane.30 The effect of anionic lipids on htt membrane
activity and aggregation decreased with increasing lipid:protein ratios. This is consistent with the
observation that the affinity of htt for the phosphatidylserine of plasma membranes decreases
with increasing lysate concentration.30 In addition to the studies reported here, other membrane
components such as cholesterol, sphingomyelin, and GM1 all influence the membrane activity of
htt.24,25
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In addition to potentially toxic mechanisms, localization and normal functions of htt can
be associated with its affinity for lipid membranes. Htt is directly involved in ER-to-Golgi
transport and vesicle fusion at the plasma membrane, making it a crucial player in secretory
pathways.36 Variability in membrane affinity results in selective localization of htt to specific
subcellular components, such as the nucleus,74 as well as trafficking to autophagic vacuoles,
mitochondria, ER, and Golgi.75,76 The importance of Nt17 in these functions is supported by
abundant sites of post-translational modifications, such as phosphorylation, that result in changes
to htt trafficking and nuclear export.77–79 With the importance of Nt17 affinity for specific lipids
in htt localization and trafficking, alterations to membrane composition that are associated with
HD may play a role in toxic disruption of normal htt function.28,80,81
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5. Physicochemical Properties Altered by the Tail Group of Lipid Membranes
Influence Huntingtin Aggregation and Lipid Binding
Huntington's Disease is a neurodegenerative disorder caused by an expanded
polyglutamine (polyQ) domain within the huntingtin protein (htt) that spurs the formation of
toxic protein aggregates. Htt directly interact with membranes, which influence the aggregation
process and can lead to membrane abnormalities. These interactions are facilitated by the 17 Nterminal residues (Nt17) which form an amphipathic α-helix (AH) implicated in both lipid
binding and aggregation. Here, the impact of lipid tail unsaturation (DMPC, POPC, or DOPC) on
htt/lipid interactions was investigated. The influence of the lipid vesicles on aggregation did not
correlate with the degree of htt-membrane association, indicating that membrane properties alter
htt aggregation. This can be linked to the initial lipid-binding mechanisms that influence Nt17
orientation on the membrane surface based on compatibility between specific hydrophobic
residue and membrane defects.
5.1 Introduction
Numerous neurodegenerative diseases are characterized by formation and deposition of
toxic protein aggregates in tissues. Huntington’s Disease (HD) is caused by an expanded
polyglutamine (polyQ) domain within the huntingtin protein (htt) that promotes aggregation.
PolyQ expansion beyond a threshold of ~35 residues is associated with disease and correlates
with the extent of aggregation, age of onset, and severity of symptoms.1–3 Htt aggregation is a
complex, multipathway process that results in a heterogeneous mixture of aggregates ranging
from oligomers and annular aggregates4,5 to β-sheet-rich fibrils and inclusion bodies.6–11 The
heterogeneity of htt aggregation complicates assigning specific modes of toxicity to discreet
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aggregate species. While aggregation leads to the formation of toxic aggregates, other species
may prove benign or even protective. The diffuse fraction of htt within cells appears particularly
toxic;11,12 however, this fraction is populated by a complex mixture of monomers, oligomers,
amorphous aggregates, and fibrils.13–17 Despite this complexity, some aggregate species are
linked to specific toxic mechanisms. Htt oligomers,12,14,18 fibrils,19,20 and even inclusions21 have
all been linked to a variety of toxic mechanisms.
The polyQ domain of htt is flanked on the N-terminal end by 17 amino acids (Nt17) that
act as a lipid binding domain and govern the interaction of htt with membranes.22–24 Nt17 is
intrinsically disordered in bulk solution, but undergoes a structural transition to an amphipathic
α-helix (AH) in the presence of binding partners like lipid membranes.23–25 The interaction
between htt and phospholipid membranes via Nt17 plays a role in a number of normal htt
functions26,27 and cytotoxic mechanisms.26,28 Nt17 functions in trafficking htt to mitochondria,
vesicles, the ER, and the nucleus;15-17 however, these membrane interactions can become
detrimental with mutant htt. Mutant htt damages and destabilizes membranes,29,30 and this
correlates with polyQ length.31 This may result from the aggregation process, as htt aggregates
incorporate membranous assemblies32,33 and brain lipids30,34 into their structures. These
interaction between htt aggregates and membranes are linked to cell death,35 synaptic
degeneration,36 disruption of htt trafficking,37 and deformation of membranous organelles.38–40
Nt17 not only facilitates htt’s interaction with phospholipids but also forms
intermolecular associations that promote htt aggregation.41–44 This interaction results in α-helical
oligomers that act as nucleation sites for fibrillization.44 Potentially due to the dual role of Nt17
in lipid binding and aggregation, membranes alter the kinetics and mechanism of htt
aggregation.30,41 POPC/PS vesicles catalyze htt aggregation through a unique Nt17-controlled
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membrane-mediated mechanism.41 On the other hand, brain lipid extracts inhibit htt
fibrillization45 and stabilize specific oligomer species.46 Increased cholesterol,47 sphingomyelin,
and GM146 content in membranes also influence the morphology of htt aggregates.
The conformational rearrangement of Nt17 from intrinsically disordered to AH is a
structural transition also found in other proteins that play a role in membrane-associated cellular
processes such as intracellular membrane targeting,48 curvature sensing,49 and membrane
remodeling.50 Many of these proteins function in the early secretory pathway and nuclear
envelope,49,51 while others function in the distinctly different lipid environment of the endosomal
or plasma membranes.52 The interaction between the AH and specific membranes are crucial for
proper function, but the properties contributing to their membrane affinity are not well
understood. Certain factors that influence the membrane selectivity of AH-containing proteins
like Golgi tethers or α-synuclein have been identified, but they rely on specific chemical
properties of the helix such as a lack of charged polar residues or a hydrophobic face consisting
entirely of small residues.52 These sequences result in an unbalanced helix, where either the
electrostatic or hydrophobic effects dictate the mechanism of AH binding. So far, few
mechanistic details have been identified for the association of AHs, such as Nt17, that contain a
well-defined hydrophobic face as well as charged polar residues.
Understanding the physicochemical properties of membranes that influence Nt17’s
interaction with lipids represents an intriguing target for the reduction of htt aggregation, lipid
binding, and membrane disturbance and can deepen the understanding of AH membrane binding
mechanisms. To determine how membrane physicochemical properties influence the behavior of
htt, the extent of htt aggregation and membrane association was investigated in the presence of
three pure lipid systems that have the same headgroup, but different tails (DMPC, POPC, and
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DOPC). First, the impact of the lipid vesicles on the kinetics of htt aggregate formation and the
morphology of aggregates was elucidated with Thioflavin-T aggregation (ThT) assays and
atomic force microscopy (AFM). In addition, the degree of htt membrane association and
complex formation with each lipid system was determined via polydiacetylene (PDA) lipid
binding assays and native mass spectrometry (MS). Finally, the initial interaction mechanism of
Nt17 with each lipid bilayer was determined via molecular dynamics (MD) simulations. Our
studies show that each lipid’s effect on the extent of htt aggregate formation does not correlate
with the degree of htt-lipid interaction, indicating that the mechanism of membrane-mediated
aggregation is altered uniquely by each lipid system. Also, the mechanism of Nt17 interaction
with the membranes is driven by a combination of peptide and membrane properties; the size of
both the peptide hydrophobic amino acids and the membrane defects determine the approach and
partitioning of Nt17 into the bilayers.
5.2 Methods
5.2.1 Purification of glutathione S-transferase (GST)-htt exon 1 fusion protein
Htt-exon1 with 46 repeat glutamine residues (htt-exon1(46Q)) was expressed in E. coli as
a glutathione S-transferase (GST) fusion protein and purified as previously described.53 Briefly,
the fusion proteins were purified via affinity liquid chromatography using a GST column
(BioRad LPLC). Relevant fractions were tested by SDS-PAGE to assess purity. Fusion protein
solutions were dialyzed for two days to remove glutathione that was used to elute fusion proteins
from the column. To remove pre-existing aggregates, fusion proteins were subjected to high
speed centrifugation (22000 ×g) prior to any experiment. Addition of Factor Xa (Promega,
Madison, WI) cleaved the GST tag and initiated aggregation.
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5.2.2 Lipid vesicle formation
1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1-palmitoyl-2-oleoyl-glycero-3phosphocholine (POPC), and 1-palmitoyl-2-oleoyl-glycero-3-phosphocholine (DOPC) were
obtained from Avanti Polar Lipids as dried films and rehydrated in tris buffer (pH = 7.4) for 1 h
at 1 mg/mL. Lipid solution were subjected to ten freeze-thaw cycles, proceeded by bath
sonicated for 1 h.
5.2.3 Thioflavin T assay
To monitor fibril formation as a function of time, a Thioflavin T (ThT, Sigma-Aldrich,
St. Louis, MO) aggregation assay was performed. Htt-exon1(46Q) (20 µM) was incubated with
ThT (125 µM) in the presence and absence of various lipid vesicles. In the lipid conditions, lipid
concentration was 100 µM, 200 µM, or 400 µM resulting in 5:1, 10:1, or 20:1 lipid:protein
ratios. Reactions were run in black Costar 96-well plates with clear flat bottoms, and ThT
fluorescence was monitored using a SpectraMax M2 microplate reader. Experiments were run at
37 °C with 440 nm excitation and 484 nm emission, with readings every 5 min for 18 h. Relative
maximum fluorescence for each condition was determined by finding the maximum fluorescence
intensity and normalizing to the maximum fluorescence of the huntingtin control (100%). The
relative rate for each condition was calculated over a period of 3 h, beginning at the point when
the fluorescence intensity reached 10% of the maximum for that condition. This setpoint was
determined to ensure that the data had made a significant increase from the baseline value and
that rate calculations did not begin in the noise of the lag phase. All rate values were normalized
to the rate of the huntingtin control (100%).
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5.2.4 Atomic force microscopy
Htt-exon1(46Q) (20 µM) was incubated with and without lipid vesicles (200 µM for a
10:1 lipid:protein ratio) at 37 °C and 1400 rpm using an orbital mixer. At various time points, 2
µL aliquots of each condition were deposited on freshly cleaved mica for 1 min followed by a
200 µL wash with 18 MΩ water and drying with a gentle stream of clean air. These samples
were imaged using a Nanoscope V Multi-Mode scanning probe microscope (VEECO) equipped
with a closed loop vertical engage J-scanner. Silicon-oxide cantilevers with a nominal spring
constant of 40 N/m and a resonance frequency of 300 kHz were used. Scan rates were set to 1.99
Hz with cantilever drive frequencies at 10% of resonance. All images were analyzed using the
Matlab image processing toolbox (MathWorks) as previously described.7,54
5.2.5 Polydiacetylene lipid binding assay
Polydiacetylene (PDA) assays were performed to measure the interaction between htt and
lipid vesicles over time using reported protocols. 55,56 In short, diacetylene monomers of 10,12tricosadiynoic acid and the pure lipid system of choice were mixed at a 2:3 molar ratio in a 4:1
chloforom/ethanol solution. The organic solvents were evaporated off with a gentle stream of
nitrogen. Films were reconstituted in tris buffer (70 °C), extensively sonicated to promote
mixing, and left at 4 °C overnight to allow for self-assembly into PDA/lipid vesicles. For each
experiment, the vesicle solutions were equilibrated to room temperature and irradiated at 254 nm
with constant stirring to polymerize the 10,12-tricosadiynoic acid, resulting in a royal blue
solution that would display a colorimetric shift to red upon applied mechanical stress to the
vesicles. PDA/lipid solutions were exposed to htt-exon1(46Q) (20 µM) for 18 h at 30 °C. For
each condition, the absorbance of the blue (650 nm) and red (500 nm) wavelengths were
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recorded by a SpectraMax M2 plate reader every 5 min for the duration of the experiment. A
negative control consisted of equal volumes of neat buffer and PDA/lipid solution, while a
positive control exposed vesicles to saturated NaOH (pH = 12) that stresses the system by
increasing repulsion among lipid head groups, invoking a colorimetric response.57,58 The NaOH
control can also be used to establish the sensitivity of the different lipid systems and used to
normalize the colorimetric response. The % CR was calculated for each condition using the
following equation:
% 𝐶𝐶𝐶𝐶 = �

𝑃𝑃𝑃𝑃0 −𝑃𝑃𝑃𝑃
𝑃𝑃𝑃𝑃0

� × 100

(1)

where the PB is defined as Ablue/(Ablue + Ared) for the negative control (PB0) and sample
condition (PB). Ablue and Ared refer to the measured absorbance at the blue and red wavelengths
respectively.
5.2.6 Electrospray ionization-mass spectrometry (ESI-MS)
For MS experiments, lipid vesicles were formed as previously described, but using
HPLC-grade water instead of tris buffer. Nt17 peptide (10 µM) was incubated with the lipid of
choice (100 µM) at 37 °C for 3 hours. All ESI-MS experiments were performed using a Q
Exactive Hybrid Quadruple Orbitrap mass spectrometer (Thermo Fischer, San Jose, CA).
Experiments were conducted using a HESITM as the degree of lipid adduction observed is not an
artifact of ionization method.59 MS spectra were recorded in positive ion mode over a mass-tocharge (m/z) range of 400 to 4,000. Samples were infused (10 uL/min) through a needle biased at
3,500 V above the instrument inlet. The parameters for the MS instrument were: 400 °C for the
capillary inlet temperature, 30 °C for the analyzer temperature, 80 V for the S-lens assembly, 400
ms for the maximum injection time, 1 × 106 for the AGC, and 70,000 for the MS resolution.
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Each spectrum was recorded (90 s) in triplicate; data were analyzed using Xcalibur 2.2 software
suite (Thermo Scientific).
5.2.7 Molecular dynamics system preparation1
The structure was generated based on a previous solid-state NMR study (PDB 2DL2) and
was modified in VMD.60 The standard N-terminal patch was applied, and the C-terminus was
amidated to mimic the absence of charge that would be present with the full huntingtin protein.
The peptide was solvated using the solvate plugin in VMD.60 Randomly-coiled conformations
were generated by heating from 300 K to 700 K with an NVT ensemble in NAMD 2.1361 over 20
ps followed by 1 ns at 700 K. A starting structure was randomly selected from among frames
with the proper omega dihedral angles. Separately, 3 pure lipid bilayers of DMPC, POPC, and
DOPC containing 150 lipids each were created, solvated, and ionized using the Optimal
Membrane Generator in LOOS.62,63 The systems were equilibrated using an in-house protocol
consisting of concurrent slow heating and release of restraints on the lipids. The randomly-coiled
peptide was merged with each of the respective membrane systems and ion concentrations were
adjusted to 150 mM using the ionize plugin in VMD.60 The merged systems were equilibrated in
the NPT ensemble for 1 ns at 310 K with the Langevin thermostat and 1 atm with the Langevin
barostat in NAMD 2.13.61 The systems’ sizes ranged from 49,000 to 53,000 atoms.
5.2.8 WESTPA
To facilitate sufficient sampling of binding and dissociation events of Nt17, the weighted
ensemble approach via Weighted Ensemble Simulation Toolkit with Parallelization and Analysis
(WESTPA) was utilized.64 WESTPA increases the sampling of rare events in MD while

1

All molecular dynamics simulations and analysis were performed by Nicolas Frazee and Dr. Blake Mertz.
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maintaining equilibrium conditions. This is accomplished via a user-defined progress coordinate
which describes the configurational space of the system. The progress coordinate is further subdivided into user-defined bins. WESTPA maintains a fixed number of simulations per bin
tracking the probability that the bin will be populated over time.
WESTPA spawns several short simulations of time, 𝜏𝜏, after which it will evaluate the

progress coordinate and add or remove simulations to maintain a constant number of simulations
per bin. This approach facilitates a significantly increased fraction of simulations sampling the
relevant space (i.e., bilayer proximal) and less time sampling the irrelevant space (i.e., diffusion
in bulk solution).
Each lipid system was run in triplicate with 100 iterations per replica, a dynamics period
(𝜏𝜏) of 20 ps, and five simulations per bin. NAMD 2.1361 was used for dynamics with the same
parameters as the final equilibration step. A one-dimensional progress coordinate was defined as
a function of the number of contacts between Nt17 and the bilayer. The progress coordinate, CAB,
was calculated as such
1

𝐶𝐶𝐴𝐴𝐴𝐴 = ∑i∈A ∑j∈B 𝑟𝑟𝑖𝑖𝑖𝑖 6
1+( )

(2)

𝑟𝑟0

where A is the set of atoms in the lipids, B is the set of atoms in the peptide, rij is the distance
between the ith lipid atom and jth peptide atom, and r0 is the cutoff distance of 3 Å. The binning
scheme was designed to evenly divide up the z-distance between the starting position of the
peptide and the center of the bilayer. The bin values are as follows: 0.0, 0.4, 0.8, 1, 1.5, 2, 3, 4, 5,
7, 10, 15, 25, 40, 70, 120, 200, 300, 500, 650, 800, 1000, 1250, 1500, 1750, 2000, 2250, 2500,
2750, 3000, 3250, 3500, 3750, 4000, 4250, 4500, 4750, 'inf'.
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5.2.9 Molecular dynamics analysis

Figure 5.1 Propensity of binding events in WE simulations. a) Count of frames from
each WESTPA trial by lipid system where Nt17 is considered to be in the “bound” state
(pcoord greater than 120). b) The percent time from each trial of WESTPA where Nt17 is
in the “bound” state. c) Average percent of time that Nt17 is in the bound state.
Analysis was performed on the subset of each weighted ensemble simulation that had a
progress coordinate of 120 or greater at either the beginning or end of the iteration. A progress
coordinate of 120 was chosen as a threshold based on visual inspection of the simulations where
Nt17 was near the bilayer surface. These snapshots are referred to as “bound” throughout the rest
of this paper. The distribution of bound frames can be seen in Fig. 5.1. Peptide-bilayer contacts:
The number of contacts per frame was determined using a custom python script and pyLOOS3,4
by iterating through every atom in the peptide paired with every atom in the bilayer; those that
were less than 4 Å apart were considered a contact. Distance plots: dz is defined as the projection
along the z-axis of the vector between the geometric average position of the atoms in each
respective residue and the surface of the bilayer. This involved two calculations: 1) calculation of
the length of the projection along the z-axis of the vector between the geometric average position
of the atoms in each respective residue and the P atoms of the bilayer, 2) calculation of the
average thickness of the bilayer by measuring the distance along the membrane normal between
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the P atoms in each respective leaflet of the bilayer. Half the bilayer thickness was subtracted
from the z-projection to obtain dz. Both measurements were made using the interdist tool in
LOOS.62,63 Orientation of Nt17: The first principal axis of the peptide was measured against the
bilayer normal using a custom python script and pyLOOS.62,63 Per residue distance dependent
orientation: Distance was calculated similarly to dz, however only the terminal heavy atom of the
sidechain was considered for each respective residue. To measure the angle of the sidechain with
respect to the bilayer normal, a vector was drawn from the Cα carbon to the terminal heavy atom
of each respective residue. Membrane maps: The membrane_map tool in LOOS62,63 was applied
to each trial calculating the windowed height of the P atoms in the upper leaflet of the bilayer.
Similar to dz, half the bilayer thickness was subtracted from each windowed height to determine
the displacement from the average. Membrane defects: Measurements of defects were based on
the approach used by Voth and coworkers.65 With the trajectory centered in the xy-plane on the
peptide, the measure sasa tool in VMD60 was used with a 3 Å separation, -samples 300, -restrict
to a selection of x/y < -13 and > 13 and z >10 (restricting the points to being on the surface of the
bilayer), and -points to create a point-based surface of the bilayer. Points were saved every 100
frames. Points were categorized based on their z-position with respect to the plane of the N
atoms in the upper leaflet (protrusions were above the plane; defects were below the plane).
Networks were constructed by grouping points within 0.6 Å of one another in the xy-plane.
Areas were determined by first finding the maxima and minima of all the points for the frame to
determine the rectangular area of the bilayer surface and then dividing the rectangular area into
2500 pixels of equal size. After this, the actual area was calculated by identifying how many
pixels each network (i.e., defect/protrusion) occupied. Helicity: The phi and psi angles of the
backbone were measured using the ramachandran tool in LOOS.62,63 A residue was considered
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helical if the previous and subsequent residues had a phi angle between -90 and -30 and a psi
angle between -77 and -17.66 Salt bridges: Salt bridges were measured using the salt bridge
plugin with default values in VMD60 with modifications to accommodate measuring the N and P
atoms of the lipid head groups.
5.3 Results
5.3.1 Lipid membranes impact htt aggregation
Figure 5.2 Lipid vesicles alone do
not induce ThT fluorescence. ThT
fluorescence assay controls of (a) neat
buffer, (b) DMPC vesicles, (c) POPC
vesicles, and (d) DOPC vesicles.

Experiments were performed with a glutathione S-transferase (GST)-htt-exon1(46Q)
fusion protein. Factor Xa cleaves GST, initiating aggregation. The impact of DMPC, POPC, or
DOPC lipid vesicles (5:1, 10:1, and 20:1 lipid:htt) on fibrillization was determined by ThT
assays. While vesicles alone don’t invoke a ThT signal (Fig. 5.2), each lipid system impacted
htt fibrillization (Fig. 5.3). Compared to aggregation in the absence of lipids, DMPC
accelerated fibrillization in a dose-dependent manner, as the rate of elongation increased by
29%, 88%, and 114% at DMPC:htt ratios of 5:1, 10:1, and 20:1 respectively. The final fibril
load, indicated by relative maximum fluorescence, increased in the presence of DMPC, with a
maximum increase of 70% at the 20:1 DMPC:htt ratio. POPC did not significantly alter
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fibrillization until the lipid:htt ratio increased to 20:1, which invoked a 26% increase in
aggregation rate and a 10% increase in maximum fluorescence. DOPC inhibited aggregation
in a dose dependent manner, with the highest lipid:htt ratio reducing the maximum
fluorescence 75%. The aggregation rate decreased with increasing DOPC:htt ratios (39%
decrease at 5:1, 75% decrease at 10:1, 82% decrease at 20:1).
Figure 5.3 Varying the lipid tail
alters how vesicles influence htt
fibrilization. ThT aggregation assays
for htt-exon1 (46Q) in the presence of
(a) DMPC, (b) POPC, or (c) DOPC
lipid vesicles. Htt-exon1 concentration
was 20 µM and the lipid to htt molar
ratio was 5:1, 10:1, or 20:1. (d) Direct
comparison of the 20:1 ratio for each
lipid system is shown. (e) The initial
rate of aggregation and (f) the relative
maximum fluorescence were
determined with respect to the htt
control. Error bars are provided for
every sixth data point (30 min) and
represent the standard error of the
mean. One asterisk represents a p value
of <0.05, and two asterisks represent a
p value of <0.01.

As ThT predominately probes fibrillization, AFM assays were performed to analyze
oligomer formation and aggregate morphology (Fig. 5.4). Htt-exon1(46Q) (20 µM) was
incubated alone or with DMPC, POPC, or DOPC vesicles at a molar ratio of 10:1 (lipid:htt).
Incubations were sampled after 1, 3, 5, and 8 h and imaged by ex situ AFM. Images were
analyzed to determine aggregate populations and morphologies. Oligomers were classified as
features at least 1.0 nm in height occupying a surface area less 4,000 nm2 with an aspect ratio
less than 3.0, indicating a globular structure. The 1 nm height threshold avoided counting
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artifacts associated with lipid backgrounds (as determined by control images, Fig. 5.5). Fibrils
were defined as features with aspect ratios larger than 3.0 and occupying at least 4,000 nm2. To
eliminate bias caused by varying fibril lengths and bundling, the percent surface covered by
fibrils was used as a measure of fibril load.

Figure 5.4 AFM images showing the effect of DMPC, POPC, and DOPC on htt-exon1(46Q)
aggregation. Representative AFM images of 20 μM htt-exon1(46Q) incubated alone, with
DMPC, with POPC, or with DOPC lipid vesicles as a function of time (10:1 lipid:htt ratio).
The color map is the same for all images.
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Figure 5.5 AFM images of backgrounds associated with different lipids. Representative
AFM images of the backgrounds associated with (a) neat buffer, (b) DMPC lipid, (c) POPC
lipid, (d) and DOPC lipid. The lines in each image correspond to the height profiles provided
below each image.
Htt-exon1(46Q) (no lipid) forms oligomers within 1 h with a peak population after 3 h
(Fig. 5.6a). A few fibrils were present at 1 h, but these became longer and more numerous with
time, occupying a larger surface area. The oligomer population decreased with increasing fibril
content. With DMPC, there was a slight increase in oligomers at 1 h compared with control.
After peaking at 3 h, the number of oligomers observed with DMPC was reduced at 5 and 8 h
compared to control (p < 0.05). DMPC enhanced fibrillization, with a clear increase in coverage
at 5 h compared with control (p < 0.05, Fig. 5.6b). The addition of POPC vesicles significantly
reduced the htt oligomer population at 3, 5, and 8 h (Fig. 5.6a). Despite this reduction in
oligomers, the extent of fibrillization was comparable to control (Fig. 5.6b). Aggregate
populations were altered by DOPC (Fig. 5.6a-b). DOPC promoted and stabilized oligomers as
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their population surpassed control at 1 h, remaining constant over 8 h. This oligomer stability
was accompanied by a significant decrease in fibril content. Fibril content observed with each
lipid system was consistent with ThT assays.
Figure 5.6 AFM analysis of the
impact of DMPC, POPC, or DOPC
lipid vesicles on htt-exon1(46Q)
aggregation (10:1 lipid:htt ratio). (a)
Analysis of the number of oligomers
per unit area as a function of time for
each condition. (b) Statistical analysis
of the percent of each image area
covered by fibrils as a condition of
time. (c-f) Comparison of the height
and diameter of oligomers formed at 1
h (red) and 8 h (blue) in the presence of
(c) no lipid, (d) DMPC, (e) POPC, and
(f) DOPC vesicles. One asterisk
represents a p value of <0.05, and two
asterisks represent a p value of <0.01.

Next, the morphologies of htt aggregates were compared. While varying rates of
fibrillization result in different fibril contour lengths, the average height along the fibril contour
was unchanged, suggesting that the underlying structure of fibrils was not altered by each lipid
(Fig. 5.7). However, lipids altered oligomer morphology (Fig. 5.6c-f). Without lipids, oligomers
increased in size with time (Fig. 5.6c). Specifically, oligomers had a mode height of ~4-5 nm
after 1 h, but this grew to 6-8.5 nm at 8 h with an increase in heterogeneity. A shift from smaller
to larger oligomers occurred in the presence of DMPC, but the 8 h population displayed less
heterogeneity and a smaller mode height (~4.5-6.5 nm, Fig. 5.6d). With both POPC and DOPC,
oligomers initially were larger (mode height of 4-5 nm for both conditions); however, oligomer
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morphology was stable, displaying extensive overlap in the correlation plots between 1 and 8
h (Fig. 5.6e-f).

Figure 5.7 Htt-exon1(46Q) fibrils formed in the presence of DMPC, POPC, and DOPC
vesicles are similar in morphology to those formed in the absence of lipid. AFM images
comparing the morphology of htt-exon1(46Q) fibrils formed in the absence of lipid, or when
incubated with DMPC, POPC, or DOPC lipid vesicles. The color lines in each image
correspond to the height profiles directly below each image. The color map is the same for
all images.
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5.3.2 Saturation in lipid tails influence htt/membrane interactions
Figure 5.8 Htt-exon1(46Q)
membrane interaction is altered by
properties associated with the lipid
tail. (a) Lipid binding assays for PDA/
DMPC, PDA/POPC, and PDA/DOPC
vesicles exposed to 20 µM httexon1(46Q). Error bars are provided
for every sixth data point and represent
the standard error of the mean. (b) The
average maximum relative % CR for
each PDA/lipid system.
The varying impact of the lipids systems on aggregation suggests differences in htt/lipid
interaction, so polydiacetylene (PDA)/lipid affinity assays were performed using DMPC, POPC,
or DOPC as a first assessment of htt/lipid interaction (Fig. 5.8). PDA/lipid vesicles undergo a
colorimetric shift (blue to red) as protein interaction with the vesicles results in a mechanical
strain on the PDA polymer backbone. By monitoring blue (640 nm) and red (500 nm)
absorbances of the vesicles upon exposure to htt-exon1(46Q), a percent colorimetric response (%
CR) can be calculated that directly correlates to the extent of htt/lipid interaction. To enable
direct comparison between the different lipid systems, the reported % CR are normalized against
a standard dose of NaOH. Based on this assay, the relative affinity of htt-exon1(46Q) for the
different lipid systems was POPC > DMPC > DOPC. Htt quickly bound POPC vesicles,
invoking a greater % CR within 3 h than was observed for the other lipid systems over 18 h.
After this initial jump, the % CR continued to increase. With DMPC/PDA vesicles, the % CR
steadily rose for ~9 h until a steady state interaction of ~20 % CR was observed. It took over 3 h
of htt exposure before DOPC/PDA vesicles elicited an observable % CR; however, once initiated
the % CR continued to gradually increase for the duration of the experiment. The overall trend
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did not correlate with degree of lipid tail unsaturation, and the differences between the % CR
curves suggests mechanistic differences in the interaction of htt with these lipid systems.
5.3.3 Nt17 forms a variety of complexes with lipids
As Nt17 facilitates htt-exon1 lipid interactions, ESI-MS was utilized to determine
complexes formed with Nt17 peptides and the lipid systems (Fig. 5.9, Table 5.1). Nt17 (10 µM)
was incubated alone or with DMPC, POPC, or DOPC vesicles (10:1 lipid:peptide ratio) for 3 h
before analysis. Relative abundance was determined in relation to the doubly-charged monomer
peptide ion ([M+2H]2+ ion at m/z 988). Without lipids, several Nt17 ions were present (Fig.
5.9a). The [M+2H]2+ ions at m/z 988 were the predominate species, followed by the [M+3H]3+
ions at m/z 988 and the [M+H]1+ ions at m/z 1974. Dimer, trimer, and tetramer ions for the Nt17
peptide (m/z 1317, 1482, and 1580, respectively) were observed at significantly lower
abundances. The lyophilized peptide contained sodium, resulting in sodium-containing ions.
A heterogeneous mixture of ions corresponding to Nt17-lipid complexes were observed
with all three lipid systems (Fig. 5.9b-d, Table 5.1). Complexes contained monomeric to trimeric
Nt17 and up to 6 lipids, with the makeup and abundance of complexes varying between lipid
systems (Fig. 5.9e-h). The relative intensity of ions for each lipid system decreased with
multimers of increasing size. However, lipid content in complexes with each system varied. The
number of distinct complexes identified was similar for each lipid system (Table 5.1), but the
total relative abundance paralleled the PDA assay (POPC > DMPC > DOPC, Fig. 5.9e). That
said, complexes of the same composition but different charge states were observed. POPC had
the lowest number of Nt17-lipid combinations despite having the highest relative abundance of
ions while DOPC had the most distinct combinations but the lowest relative abundance.
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Figure 5.9 Nt17 forms complexes with DMPC, POPC, or DOPC vesicles of different
makeup and abundance as a result of varying molecular contacts. The composition and
abundance of adducts formed with Nt17 and different lipids was analyzed via ESI-MS. Nt17
was incubated (a) alone or with (b) DMPC, (c) POPC, or (d) DOPC lipid vesicles. (e) The
total abundance of peptide-lipid complexes was compared across all systems, as well as the
abundance of complexes by lipid content with Nt17 (f) monomers, (g) dimers, and (h)
trimers. (i) The total molecular contacts made between Nt17 and DMPC, POPC, or DOPC
lipid bilayers in MD simulations.
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Table 5.1 Assigned ions for Nt17 incubated with DMPC, POPC, or DOPC lipid vesicles
along with their mass to charge ratios.
Iona

m/z

Charge
State

Iona

m/z

Charge
State

Iona

m/z

Charge
State

Nt17 + 1DMPC

2652.99

1

Nt17 + 1POPC

2734.63

1

Nt17 + 1 DOPC

2760.64

1

Nt17 + 1DMPC

1327.00

2

Nt17 + 1POPC

912.21

3

Nt17 + 1DOPC

1380.82

2

Nt17 + 1DMPC

885.00

3

Nt17 + 1POPC

1367.82

2

Nt17 + 2DOPC

1773.62

2

Nt17 + 2DMPC

1665.47

2

Nt17 + 2POPC

1747.11

2

Nt17 + 3DOPC

2166.42

2

Nt17 + 2DMPC

1110.98

3

Nt17 + 2POPC

1165.41

3

Nt17 + 3DOPC

1444.61

3

Nt17 + 3DMPC

2004.45

2

Nt17 + 3POPC

2126.91

2

Nt17 + 4DOPC

2559.22

2

Nt17 + 3DMPC

1336.96

3

Nt17 + 3POPC

1418.60

3

Nt17 + 5DOPC

2952.02

2

Nt17 + 4DMPC

2343.42

2

Nt17 + 4POPC

2506.70

2

Nt17 + 6DOPC

2230.21

3

Nt17 + 5DMPC

2682.40

2

Nt17 + 4POPC

1671.80

3

2Nt17 + 1DOPC

2367.84

2

Nt17 + 6DMPC

3021.37

2

Nt17 + 5POPC

2897.99

2

2Nt17 + 1DOPC

1578.89

3

Nt17 + 6DMPC

2014.91

3

Nt17 + 5POPC

1925.00

3

2Nt17 + 2DOPC

2760.64

2

2Nt17 + 1DMPC

2314.02

2

2Nt17 + 1POPC

2354.84

2

2Nt17 + 3DOPC

3153.44

2

2Nt17 + 1DMPC

1543.01

3

2Nt17 + 1POPC

1570.22

3

2Nt17 + 4DOPC

2364.49

3

2Nt17 + 2DMPC

2652.49

2

2Nt17 + 2POPC

2734.13

2

2Nt17 + 5DOPC

2626.36

3

2Nt17 + 3DMPC

2991.47

2

2Nt17 + 2POPC

1823.42

3

2Nt17 + 6DOPC

2888.22

3

2Nt17 + 3DMPC

1994.98

3

2Nt17 + 3POPC

3113.93

2

3Nt17 + 1DOPC

2236.90

3

2Nt17 + 4DMPC

3330.44

2

2Nt17 + 3POPC

2076.62

3

3Nt17 + 2DOPC

2498.77

3

2Nt17 + 4DMPC

2220.96

3

2Nt17 + 5POPC

2583.01

3

3Nt17 + 3DOPC

2760.64

3

3Nt17 + 2DMPC

2427.01

3

3Nt17 + 1POPC

2235.90

3

3Nt17 + 4DPOC

3022.51

3

3Nt17 + 3DMPC

2652.99

3

3Nt17 + 5POPC

3241.02

3

3Nt17 + 5DOPC

3284.37

3

3Nt17 + 4DMPC

2878.97

3

3Nt17 + 6POPC

3494.22

3

The following average masses have been used to assign the peaks: 1974.04 for Nt17 peptide, 677.95 for
DMPC lipid, 759.59 for POPC lipid, and 785.60 for DOPC lipid.
a

Monomeric Nt17 complexes were observed with up to 6 DMPC lipid monomers, with the
most abundant complexes containing 1 DMPC lipid (relative abundance of 4.44%), 3 DMPC
lipids (0.22%), and then 2 DMPC lipids (0.16%, Fig. 5.9f). Dimeric and trimeric Nt17-DMPC
complexes were significantly less abundant, containing only up to 4 DMPC lipids (Fig. 5.9g-h).
Complexes of trimeric Nt17 with 1 DMPC lipid were nonexistent. Instead, there was a high
abundance of trimeric Nt17 complexes with multiple DMPC lipids compared to other systems.
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The total relative intensities of Nt17-DMPC complex ions was 4.92%. In contrast, the total
relative intensity of Nt17- POPC complex ions was much higher (15.05%, Fig. 5.9e). This large
population was predominately comprised of monomeric Nt17-POPC complexes (relative
intensity of 14.21%, Fig. 5.9f). While eleven distinct monomeric Nt17-lipid ions were observed
with both DMPC and POPC, monomeric Nt17-POPC complexes only contained up to 5 POPC
lipids. Dimeric and trimeric Nt17-POPC complexes were less abundant (Fig. 5.9g-h). Nt17
dimers complexed with either 1, 2, 3, or 5 POPC lipids; Nt17 trimers complexed with 1, 5, or 6
POPC lipids. Nt17-DOPC complexes were the least abundant, reaching a total relative
abundance of only 2.38% (Fig. 5.9e). The most abundant complex consisted of monomeric Nt17
with 1 DOPC lipid (1.17%, Fig. 5.9f). Dimeric and trimeric Nt17-DOPC complexes were
observed with up to 6 DOPC lipids or 5 DOPC lipids respectively Fig. 5.9g-h).
To complement these native MS studies, the interaction of Nt17 with DMPC, POPC, or
DOPC was investigates using weighted ensemble molecular dynamic simulations. There appears
to be a rough correlation between the abundance of Nt17/lipid complexes observed by MS and
the total molecular contacts between Nt17 and the different lipid membranes (Fig. 5.9I). The
propensity of Nt17 to form 800 or fewer contacts with each lipid system was similar. Nt17 had
the highest propensity to form a large number (>1,400) of contacts with POPC, consistent with
the significantly larger abundance of observed complexes. While Nt17 had a higher propensity to
form an intermediate number of contacts (800 to 1,400) with DOPC compared with DMPC, Nt17
formed larger contacts (>1,400) with DMPC that were not observed with DOPC. The
observation of a slightly larger number of complexes comprised of Nt17/DMPC compared to
Nt17/DOPC suggests that these larger contacts lead to high stability. Based on this, the MD
simulations were further explored to better understand the binding of Nt17 to these lipid systems.
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5.3.4 Effect of lipid type on binding of Nt17 2
When examining overall binding, Nt17 possesses distinct orientations for each lipid type
(Fig. 5.10 and Fig. 5.11). Bound complexes to DMPC are dominated by partitioning of the Nterminus into the bilayer surface. This Nt17 segment is a mixture of nonpolar and polar residues
(MATL), which individually are not too bulky to access the bilayer interior sandwiched between
two relatively densely-packed headgroup regions (ADMPC = 60.6 Å2 / lipid)67 (Fig. 5.10). The
Nt17 C-terminus is mainly dissociated from the DMPC bilayer, with a small sub-population that
is less than 10 Å from the surface. In contrast, Nt17 strongly binds POPC via the C-terminus; F17
partitions almost 5 Å into the headgroup region, with an extensive segment (F11, E12, S13, L14,
K15, and S16) remaining less than 10 Å from the bilayer surface. This strong interaction
potentially stems from the opportunity for a bulkier, nonpolar sidechain with conformational
flexibility (i.e., F17) probing larger defects associated with a larger area per lipid (68.3 Å2 /
lipid).68 Although there is a small fraction of the middle segment of Nt17 within 15 Å of the
bilayer, in general, the N-terminal portion is dissociated from the membrane, beginning with A10
and getting progressively further from the bilayer as one proceeds towards M1. For both DMPC
and POPC, one of the Nt17 termini binds the membrane in a conformation that is orthogonal to
the bilayer surface (Fig. 5.10a, 5.10c). However, with DOPC, nearly all Nt17 residues interact
with the membrane (Fig. 5.10b), leading to a parallel orientation of the Nt17 principal axis with
respect to the bilayer. Additionally, not a single residue binds most strongly, likely stemming
from DOPC having the largest area per lipid of all the systems tested (72.2 Å2 / lipid)69 and
leading to a larger defect population that can be utilized by Nt17.

2

All molecular dynamics simulations and analysis were performed by Nicolas Frazee and Dr. Blake Mertz.
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Figure 5.10 Lipid tails affect the binding orientation of Nt17 to lipid bilayers. a)
Representative snapshots of the bound state for each lipid system from weighted ensemble
simulations. Yellow ribbon: Nt17, blue ribbon: first residue of Nt17, red/green: lipid
membrane. Water and ions omitted for clarity. b) Binned z-distance between the geometric
centers of the membrane and residues of Nt17 for frames in the bound state. Point size and
color correspond to percent occurrence. c) Binned angle between the principal axis of the
peptide and the bilayer surface. For b and c, green boxes represent data associated with the
most likely orientation of Nt17 on the bilayer, shown in panel a. Red boxes represent data
associated with a secondary population, shown in Figure 5.11.
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Figure 5.11 Secondary populations of Nt17 orientation on the lipid bilayers were
observed for all systems. Representative snapshots of less commonly observed bound
structures for each lipid system from weighted ensemble simulations. Two unique
conformations are shown for DOPC.
5.3.5 Relationship between sidechain orientation and binding of Nt17
Closer examination of residue-specific interactions of Nt17 with the bilayer surface
reveals that, in most instances, sidechain orientation lies either parallel or away from the bilayer.
For DMPC, T3 and K6 are notably parallel to the bilayer (~90 deg), likely ruling out the
potential for non-bonded interactions (hydrogen bonding for T3 and salt bridge formation for K6)
with PC headgroups to drive formation of stable binding conformations (Fig. 5.12 and Fig. 5.13).
Aromatic (F11 and F17) and charged (K15) residues in the C-terminal half of Nt17 occupy 2-3
areas of conformational space, indicating that the dissociated portion of Nt17 is restricted to
regions that allow it to bind via the N-terminus. Binding of Nt17 to POPC is much different: F17
partitions into the headgroup region nearly antiparallel to the membrane normal, most likely
between acyl chains near the triglyceride backbone. This serves to restrict F11 and K15
(proximal to F17) parallel to the membrane normal (90 deg), whereas other residues (T3, K6, and
K9) broadly sample orientations ranging from parallel (0 deg) to antiparallel (180 deg) (Fig.
5.12). For DOPC, there is a correlation between the distance of a given residue from the bilayer
surface and sidechain orientation for nonpolar or slightly polar residues. Specifically, L7, A10,
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S13, and L14 sample conformations partitioned into the bilayer (Fig. 5.13). Additionally, there
is a noticeable population for each lysine residue (K6, K9, and K15) oriented towards the bilayer
and close enough to potentially form a salt bridge with the negatively-charged phosphate moiety
in the PC headgroup. This, in conjunction with the overall closer positioning, suggests binding
of Nt17 to DOPC is driven by a combination of charge-charge interactions and greater
accessibility for peptide partitioning. With DOPC, a threshold has been reached with respect to
area per lipid and Nt17 binding, in that there is a sufficient population and size of defects to
allow the entire peptide to partition into the bilayer.

Figure 5.12 Nt17 binding is facilitated via partitioning of amino acid sidechains into
bilayer systems with higher areas per lipid. Correlation plot between the binned
distribution of sidechain angles of select residues in Nt17 and the binned distribution of the
z-distance between each respective residue’s terminal atom and the plane of the P atoms in
the lipid headgroups. (0 deg: parallel to bilayer normal, 90 deg: parallel to bilayer surface;
180 deg: antiparallel to bilayer normal (i.e., pointing into the bilayer)). Top row: DMPC;
middle row: POPC; bottom row: DOPC.
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Figure 5.13 Lipid tails influence the partitioning of Nt17 amino acid sidechains into the
bilayer. Correlation plot between the binned distribution of sidechain angles of select
residues in Nt17 and the binned distribution of the z-distance between each respective
residue’s terminal atom and the plane of the P atoms in the lipid headgroups. (0 deg: parallel
to bilayer normal, 90 deg: parallel to bilayer surface; 180 deg: antiparallel to bilayer normal
(i.e., pointing into the bilayer)). Top row: DMPC; middle row: POPC; bottom row: DOPC.
5.3.6 The role of protrusions and defects in binding and stabilization of Nt17
When examining the behavior of the bilayer surface in the upper leaflet, each lipid
system possesses areas of protrusions and defects. In general, areas of protrusions or of defects
tend to group together (Fig. 5.14a). POPC has more well-defined and broader areas of defects
compared to DMPC, which correlates with the more effective binding of Nt17. DOPC had the
fewest areas of protrusions and defects, likely contributing to the global but weaker interactions
of Nt17. Quantification of the total number of protrusions and defects in the bilayer surface
provides a more well-defined description of what occurs when Nt17 binds to a membrane. In the
absence of Nt17, the three lipid systems have similar distributions of protrusions (“above”, Fig.
5.14b) but slightly different distribution of defects (“below”, Fig. 5.14b). Upon Nt17 binding,
two changes take place in the bilayer surface: 1) the population of protrusions and defects
decreases due to partitioning of the peptide, and 2) the distribution of protrusions and of defects
between lipid systems becomes separable. With protrusions, the distributions remain consistent
across all lipid systems; with defects, the distributions arrange according to the corresponding
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areas per lipid. The difference in the shifts in the distribution of protrusions indicates that the
initial interactions of Nt17 with the bilayer surface (i.e., with protrusions) is entirely non-specific
with respect to lipid type. In contrast, the number and distribution of defects is most greatly
affected by the ability of the bilayer to accommodate partitioning of Nt17 into the headgroup
region. Since DMPC is the most tightly-packed bilayer in the lateral plane of the membrane, both
by area per lipid and by the number of defects, it is incapable of easily changing its lateral
compressibility, a necessary prerequisite for surface binding and partitioning of a peptide. This
underscores why POPC and DOPC have progressively larger distributions of defects.

Figure 5.14 Formation of stable proteolipid complexes occurs via contributions from
both redistribution of bilayer deformations and stable intermediates of Nt17. a) Heat
map of the average displacement of headgroups in the upper leaflet for all three trajectories
of DMPC (left), POPC (middle), and DOPC (right) as measured with membrane_map in
LOOS. b) Logarithmic distribution of protrusions (“above”, left) and defects (“below”, right)
as calculated with the measure SASA tool in VMD. c) Percent helicity for Nt17 in DMPC,
POPC, and DOPC. (Residues that were not helical were omitted for clarity.) d) Percent of
total simulation time a charged residue in Nt17 was involved in formation of a salt bridge for
DMPC, POPC, and DOPC.
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Non-bonded interactions also play a role in stable binding of Nt17 to the membrane.
Although we did not observe the extensive formation of an α-helix that was reported by
Bechinger and coworkers,24 Nt17 undergoes partial helical folding in POPC and DOPC (Fig.
5.14c). Folding is centered around L14 and K15, with about 20-25% helicity. Additionally, an
intramolecular salt bridge frequently exists between E12 and K15. i + 3 salt bridges can
contribute to α-helix formation in short peptides;70 in this case, the salt bridge formation appears
to work cooperatively with headgroup accessibility in facilitating Nt17 partitioning into the
bilayer.
5.4 Discussion
A number of cytotoxic features of HD are associated with the localization of htt to lipid
membranes.38–40 In this study, the impact of lipid tail saturation on htt-exon1(46Q) interaction
with lipid membranes and subsequent consequences on aggregation were determined. The
different lipids influenced htt aggregation to varying extents, with DMPC accelerating
fibrillization, POPC having a minimal impact, and DOPC decreasing fibrillization. However, the
extent of htt association with each lipid system did not correlate with the extent of fibrillization,
indicating that the membrane environment provided by different lipid systems influences the
membrane activity and aggregation of htt. In addition, the interaction of the htt-exon1 lipid
binding domain, i.e. Nt17, with the lipid systems demonstrated that the match between defect
and hydrophobic amino acid size determined the orientation of the peptide on the bilayer. These
early interactions between Nt17 and each lipid system manifest in down-stream impacts on httexon1(46Q) aggregation.
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Components within the cellular environment, particularly lipid membranes, modify
amyloid formation, promoting or stabilizing specific aggregate species.71 Htt undergoes unique
aggregation mechanisms on lipid membranes compared to bulk solution,41 and this appears
dependent on membrane composition.46,47,72 Beyond the three simple lipid systems investigated
here, more complicated lipid systems also modify htt aggregation to various extents.45,47,73,74
Total brain lipid extract (TBLE) stabilizes oligomers of truncated polyQ peptides that contain
Nt1722 and impedes fibrillization of htt-exon1,45 and this impact is further modified by the
exogenous addition of cholesterol,47 sphingomyelin, and GM1.46 In contrast, htt fibrillization is
accelerated in the presence of POPC/POPS through a unique Nt17-mediated mechanism
involving membrane anchoring and two-dimensional diffusion.41 Based on 3D HNCO NMR
studies using a small peptide with Nt17 and a polyQ domain of 17 residues, the interaction of
Nt17 with lipid membranes is dynamic; however, there were clear differences in the interaction
of Nt17 with DOPE/DOPS/DOPC compared to brain extracts.72 In this regard, the varied
orientations of Nt17 observed here by MD on different lipid systems impact htt anchoring and
diffusion along the membrane. These initial changes in Nt17-lipid binding manifested in altered
abundances of Nt17/lipid complexes and lead to altered aggregation. Collectively, these
observations indicate that the initial htt/lipid interactions profoundly impact subsequent
aggregation.
While the extent of htt fibrillization correlated with lipid tail saturation (DMPC > POPC
> DOPC; determined by ThT and AFM assays), the htt-membrane association (POPC > DMPC
> DOPC; measured by PDA and MS) did not, suggesting a more complex relationship between
htt-lipid interaction and subsequent aggregation. Through MD simulations, clear differences
occur in the initial Nt17-lipid interactions that likely influence downstream aggregation. While a
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significant gap in timescale persists, Nt17/lipid contact density measured in MD simulations are
consistent with the populations of Nt17/lipid complexes observed by MS with all three lipids. As
Nt17 peptides did not contain polyQ tracts, the MD and MS studies cannot provide insight into
fibrillization; however, oligomerization is driven by Nt17.25,43,44,75 Therefore, changes in Nt17lipid interaction should impact downstream htt oligomerization, and all three lipid systems
reduced the heterogeneity of oligomer populations compared to aggregation in the absence of
lipids. This impact of lipids on htt aggregation is significant as cellular dysfunction and toxicity
are linked to both htt oligomers12,14 and fibrils.19,20 Furthermore, the formation or stabilization of
specific aggregate species by lipid membranes could promote the toxic disruption of membranes
and organelles observed in HD.30,76,77 This suggests that targeting the initial htt/lipid interaction
may represent an upstream therapeutic target.
The properties determining selectivity of AHs (like Nt17) for specific membranes are
often related to curvature-induced membrane defects.49,78,79 As curvature enhances the membrane
binding of Nt17,80,81 defect sensing represents a plausible mechanism associated with htt
membrane affinity. Here, the population of available membrane defects correlates well with the
affinity of Nt17 for each lipid system, and the orientation of Nt17 on membranes appears to be
predicated by matching residue and defect sizes. Such a scenario has been observed with other
AH lipid binding motifs. For example, the amphipathic lipid-packing sensor (ALPS) inserts large
hydrophobic residues preferentially into membranes with larger membrane defects.82 Nt17
exhibits many similarities with ALPS motifs, including a structural transition from intrinsically
disordered to an AH in the presence of lipids,23,24,83 increased association with membranes of
lower cholesterol content47,52 or increased curvature78,80 and, as shown here, a preference for
insertion into bilayers comprised of monounsaturated phospholipids.52,84 Despite sharing
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functional similarities, Nt17 and ALPS motifs vary in sequence; while ALPS motifs contain a
hydrophobic side comprised primarily of large amino acids (F, L, W), 49,82 the hydrophobic face
of Nt17 contains several smaller amino acids (A, T) near the N-terminus. The lack of variety in
ALPS motifs hydrophobic residue sizes leads to the initial insertion of hydrophobic residues into
the bilayer in a random manner.48 The mechanism of Nt17 membrane binding appears more
complex, with both hydrophobic residues size and defect size determining the initial orientation
and selective binding of the motif. This defect mechanism gains further importance for selective
binding of AHs taken lipid composition and curvature synergistically determine defect size and
distribution.85
Upon exposure to tightly packed DMPC (saturated tails) bilayers with a relatively small
area per lipid, the smaller, N-terminal residues (MATL) partitioned into the bilayer. POPC
(monounsaturated) bilayers display an increased area per lipid and occurrence of defects. The
interaction between Nt17 and the POPC bilayer was driven by the partitioning of the larger, Cterminal residues (LKSF). While the smaller N-terminal residues could insert into the larger
defects present on POPC bilayers, Nt17 preferred a C-terminus approach, indicating a
thermodynamic advantage to sequestering larger hydrophobic residues. DOPC (polyunsaturated)
bilayers had a higher propensity to form defects with a broader distribution of sizes. Due to this,
residues along the entire length of Nt17 exhibited more frequent, but weaker binding and Nt17
sampled a broader variety of orientations on the bilayer surface. The interaction between Nt17
and DOPC is nonspecific and weak, explaining why complexes observed with MS had larger
DOPC content but were significantly less abundant overall than complexes formed with DMPC
or POPC.
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Beyond the impact of lipids on htt aggregation, htt and its aggregate forms can induce
physical changes in membranes. Many amyloid-forming proteins have deleterious impact on
membrane integrity that leads to dysfunction, organelle disruption, and cell death by specifically
targeting bilayers.30,71,77 For example, Aβ, IAPP, and htt all distort membrane morphology and
rigidity of model lipid bilayers.86 Specifically, mutant htt is associated with membrane
degradation of the ER, nuclear envelope, and mitochondria.38–40 With the complex nature of
amyloid formation, assigning specific aggregate species to a particular toxic mechanism is
challenging. This is further complicated by the dynamic nature of aggregation with the process
of aggregation potentially playing a role rather than a specific aggregate. That is, understanding
the link between the initial protein/lipid interaction, subsequent aggregation, and impact on
membrane integrity would provide a clearer, complete picture of these phenomena.
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6. Conclusion and Future Directions
6.1 Introduction
Huntington’s Disease (HD) is a fatal neurodegenerative disorder that is caused by an
expanded glutamine repeat (polyQ) domain of htt. As a result of the expanded polyQ domain,
mutant htt misfolds into a variety of toxic aggregate species including oligomers, annular
aggregates, and fibrils. The interaction of pathogenic htt monomers and aggregates with the
membranes of subcellular organelles results in a variety of toxic mechanisms that encourage the
progression of HD.1–4 Currently, the details of the toxic mechanisms associated with the
interaction of htt aggregates with lipid membranes are not well understood. Understanding the
mechanism of htt association with lipid membranes increases the understanding of membraneassociated toxic mechanisms of htt and presents targets for HD therapeutic strategies.
In order to understand the factors influencing the interactions between htt and lipid
membranes, it is critical to develop techniques that can be used to efficiently measure membrane
association. Polydiacetylene (PDA) lipid binding assays have emerged as a simple, cost-effective
method of measuring membrane affinity with the potential for high-throughput application,5,6 but
the effect of lipid composition on membrane fluidity and assay response makes the quantitative
comparison of different PDA/lipid systems challenging. In Chapter 2, we aimed to develop a
PDA-based assay to directly compare the interactions between molecules and vesicles of varying
lipid composition (Fig. 6.1). This study demonstrated that exposing PDA/lipid vesicles with
DOPC, POPC, POPE, or POPG as the lipid component to increasing concentrations of NaOH
resulted in a linear increase in % CR until the 45 mM dose, at which point increasing the NaOH
concentration no longer resulted in further colorimetric shift. Despite the linear response of %
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CR to NaOH exposure within the working range for all systems, the magnitude of the response
from system to system varied greatly. To account for this, the maximum CR for each system was
determined by incubation of the PDA/lipid vesicles with a concentration of NaOH that was well
above the working range. By normalizing the assays to the maximum CR for each lipid system,
batch-to-batch and between-lipid RSD values were lowered significantly, allowing for
meaningful comparisons of results obtained with different lipid systems.

Figure 6.1 A schematic presenting a method for PDA lipid binding assay
normalization. PDA/lipid vesicles are formed by mixing the PDA monomers with hydrated
lipid and allowing it to self-assemble into vesicles. Once formed, the PDA is polymerized
with UV light to result in blue vesicles that undergo a colorimetric shift to red when
mechanical stress is applied. The normalization of the PDA assay decreases batch-to-batch
variation and variation between lipid systems.

The interaction of htt with lipid membranes alters the mechanism of aggregation and can
stabilize specific aggregate species and morphologies.7–9 With the formation of aggregate species
being a hallmark of HD,2,10 studies have attempted to identify small molecules that inhibit
amyloid formation. However, with the influence of membranes on htt aggregate mechanisms, the
efficiency of these small molecules in inhibiting aggregation may be altered by the presence of
lipid membranes. In Chapter 3, we sought to determine if aggregation inhibitors epigallocatechin
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3-gallate (EGCG) and curcumin maintain their efficiency in the presence of a pure lipid system
(POPC) and physiologically relevant system (TBLE) (Fig. 6.2). EGCG reduced the interaction of
htt with both POPC and TBLE vesicles, and it remained effective in inhibiting fibrillization in
both cases. On the other hand, curcumin reduced htt association with both lipid systems but
became ineffective in inhibiting fibrillization the presence of POPC vesicles and actually
increased fibrillization in the presence of TBLE vesicles. The difference could lie in how the two
small molecules act to inhibit fibrillization; EGCG acts to target early events in htt aggregation,11
explaining why it remains effective in the presence of lipid vesicles, while curcumin may target
later stages of aggregation that are altered by the presence of lipid membranes and thus decrease
the ability of curcumin to inhibit aggregation. Collectively, the results of Chapter 3 highlight that
htt aggregation and the effectiveness of small molecule aggregation inhibitors are largely
influenced by components of the cellular environment like lipid membranes.

Figure 6.2 Lipid membranes influence the efficiency of small molecules in inhibiting htt
aggregation. EGCG is still an efficient htt aggregation inhibitor in the presence of POPC and
TBLE lipid vesicles. On the other hand, curcumin is no longer an effective aggregation
inhibitor in the presence of POPC vesicles, and cur actually increases aggregation in the
presence of TBLE vesicles.
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Figure 6.3 The mechanism of htt lipid binding and aggregation are altered by
membrane charge. Htt multimers exhibit a higher affinity for zwitterionic lipids, while
monomers exhibit a higher affinity for anionic lipids. Also, htt does not appreciably insert
into anionic membranes, resulting in a localization of htt at the surface of the membranes
that encourages htt aggregation.
Results from Chapter 3 revealed that htt associated with POPC and TBLE vesicles to
different extents, indicating that htt affinity for membranes is influenced by the membrane
composition. Determining the lipid properties that influence the interaction of htt with specific
membranes is important for the understanding of a number of htt normal functions1,12 and
cytotoxic mechanisms.3,13,14 Therefore, in Chapters 4 and 5, we set out to determine how
membrane physicochemical properties alter htt-lipid affinity and htt aggregation. Chapter 4
specifically focused on membrane properties associated with the size and charge of the lipid
headgroup (Fig. 6.3). PDA assays revealed that htt associated less with negatively charged
membranes, and MS analysis on htt-lipid complexes revealed a localization of monomers at the
surface of the vesicle. The combined PDA and MS results indicate a barrier between the
anchoring and insertion step of Nt17 when interacting with negatively charged vesicles. As a
result, htt localizes at the bilayer surface and increases htt fibrillization as observed by ThT and
AFM in the presence of negatively charged lipids. In addition, htt exhibited a higher affinity for
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the most fluid system when comparing membranes of similar charge. In Chapter 5, the focus was
on the influence of membrane properties associated with the saturation of the lipid tail on htt
aggregation and lipid binding. In this case, the trend of the lipid effect on htt aggregation as
observed by ThT and AFM (DMPC > POPC > DOPC) did not match the trend of membrane
affinity observed by both PDA and MS (POPC > DMPC > DOPC), indicating a complex
combination of mechanisms occurring in the presence of these membranes. Despite the similar
charge of the bilayers, MD studies revealed that Nt17 approached each bilayer differently, and
residue insertion seemed to be dependent on both residue size and the size of available bilayer
defects. Together, the results from Chapters 4 and 5 reveal that membrane fluidity, charge
density, and defect size play a role in determining the selectivity of htt affinity for membranes.
The work presented in this dissertation has increased our understanding of the factors
contributing to the selective interaction of htt with lipid membranes, but further work must be
done to fully understand the mechanisms of interaction and induced toxicity that contribute to the
progression of HD. Here, future directions based on the results obtained during these studies will
be presented that could further advance the understanding of htt mechanisms with respect to
membrane association: 1) the effect of cholesterol on the interaction of htt with membranes of
different physicochemical properties; 2) the properties of membranes that determine the
selectivity of specific htt aggregate species; and 3) the role of hydrophobic amino acid size in the
selective membrane affinity of amphipathic α-helices.
6.2 Research in progress: Elucidating the effect of membrane cholesterol content on htt
aggregation and membrane affinity
Lipid membranes heavily influence the aggregation of htt, but the role that specific lipid
components play is not yet fully understood. For example, cholesterol is an important component
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of biological membranes, with 23% of mammal’s total body cholesterol existing in the brain.15
Cholesterol is a significant structural component of neuronal membranes16 and maintains the
integrity of synapses by defining membrane functional properties.17,18 By altering bilayer
properties such as fluidity, bilayer thickness, and surface hydrophobicity, cholesterol influences
crucial functions such as signal transduction, synaptogenesis, and neurotransmitter release.19–24
Patients with HD show abnormalities in cholesterol metabolism and homeostasis, but it is
debated whether their cholesterol levels decrease25–28 or increase.29–31 Alterations to cholesterol
homeostasis has been linked to altered neuronal32 and neurotransmitter receptor function33 and
leas ads to neurological symptoms in both mice and humans.34 Due to the potential importance of
cholesterol in HD, a series of preliminary experiments were performed that complement the
studies in Chapters 4 and 5. Results from Chapters 4 and 5 indicate that bilayer physicochemical
properties play a role in determining htt affinity for membranes, so altered physicochemical
properties as a result of altered cholesterol content in membranes likely influences htt-lipid
interaction. Pure lipid systems POPC, DOPC, and POPG were spiked with 0, 10, or 20%
cholesterol to determine the effect of increased cholesterol content on htt aggregation and lipid
binding relative to the physicochemical properties of the pure lipid system. ThT assays and AFM
were used to gather information on aggregation kinetics and morphologies in the presence of
each lipid system, and PDA assays were be used to monitor the binding of htt to the lipid
vesicles.
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Figure 6.4 Representative AFM images showing htt aggregation after 3 and 8 h in
the presence of no lipid, POPC, DOPC, or POPG vesicles with 0, 10, or 20%
cholesterol. Height histograms of fibrils observed in AFM images after 8 h are included.
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The effect of lipid vesicles with increased cholesterol content on htt aggregation was
different than the effect of the pure lipids for all three systems. Increased cholesterol levels were
associated with decreased aggregation when compared to aggregation in the presence of the pure
lipid system for POPC and POPG, while the opposite effect was observed with DOPC (Fig. 6.4,
Fig. 6.5a and c). While the extent of fibrillization was influenced by membrane cholesterol
content in all cases, the fibril morphology was similar across all POPC and DOPC conditions,
indicating that the structure of the htt flanking regions in the structure did not change.35
However, with POPG, the decrease in the height of fibrils formed compared to htt alone is
consistent with the results of Chapter 4, and the fibrils also seem to get shorter with increased
cholesterol content (Fig. 6.4). Further AFM analysis will need to be performed to analyze
morphological changes, such as changes in the height and diameter of oligomeric aggregates.
Preliminary results also indicate that the physicochemical properties of the lipid system
being spiked with cholesterol influence the effect on htt lipid binding (Fig. 6.4b-c). However,
the lipid binding trends do not correlate to the aggregation trends across all lipid systems,
highlighting the complexity of htt aggregation and indicating multiple mechanisms at play. Our
PDA assays reveal that htt exhibits a lower affinity for POPC vesicles with up to 20% added
cholesterol. Amphipathic α-helices like the Nt17 domain of htt preferentially bind membranes
with increased defects36–38 and the addition of cholesterol to POPC results in decreased fluidity
and increased order,39 thus decreasing the occurrence of membrane defects. On the other hand,
while the acyl chains of DOPC are compressed with the addition of cholesterol, the area per
DOPC lipid headgroup increases,40 resulting in more defects at the bilayer surface and allowing
for the observed increase in htt-DOPC interaction with increasing cholesterol content. Increasing
cholesterol content also increased the interaction of htt with POPG lipid vesicles. Despite the
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electrostatic repulsion between POPG lipid headgroups, interlipid bridges and hydrogen bonding
overcome the repulsion to result in a tightly packed bilayer.41 Cholesterol insertion into the
membrane may spread out the POPG headgroups, limiting that strong interaction and allowing
for increased interaction with htt. In addition, the cholesterol would decrease the charge density
in the bilayer, which Chapter 4 results indicate could help facilitate htt insertion. As a future
direction, MS studies should be performed to analyze the complexes formed between htt and the
lipid systems as a result of increased cholesterol content, similar to the MS studies performed in
Chapters 4 and 5.

Figure 6.5 The impact of cholesterol on a membrane’s effect on htt aggregation and
lipid binding is dependent on the physicochemical properties of the pure lipid system.
(a) ThT aggregation assays for htt-exon1(46Q) (20 µM) in the presence of POPC, DOPC, or
POPG with 0, 10, or 20% cholesterol. Error bars are provided for every sixth data point (30
min) and represent the standard error of the mean (SEM). (b) PDA lipid binding assays of
POPC, DOPC, or POPG with 0, 10, or 20% cholesterol exposed to htt-exon1(46Q). (c) The
maximum ThT and PDA signal for each condition relative to the condition of the pure lipid
system (set to 100). Error bars represent SEM.
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In previous studies, increasing cholesterol content of total brain lipid extract (TBLE)
systems decreased the ability of htt to permeabilize the vesicles and altered the morphology of
aggregates.8 Membrane disruption by amyloid proteins is theorized to be a mechanism associated
with many neurodegenerative diseases like Alzheimer’s Disease and Huntington’s Disease, so
understanding factors that decrease membrane damage and permeabilization could lead to
potential therapeutic approaches that focus on preventing toxic interactions. Previous studies of
htt aggregation in the presence of TBLE enriched with cholesterol used cholesterol levels that
exceeded what is observed in a typical cellular membrane. 8 Determining the effect of
physiological concentrations of cholesterol in different pure lipid systems would lead to a better
understanding of how cholesterol homeostasis influences htt binding to and aggregation on
different lipid membranes.
6.3 Identifying the interaction of specific aggregate species with lipid membranes
The interaction of htt with lipid membranes is associated with a number of cytotoxic
effects such as disrupted trafficking,13 organelle dysfunction,4,42,43 and neuronal death.44
However, due to the complex and heterogeneous nature of htt aggregation, it is difficult to
pinpoint which specific aggregate species are responsible for the detrimental effects on
membranes. In addition, aggregate species may exhibit a higher affinity for membranes with
specific physicochemical properties, potentially determining the affinity and specificity of htt
toxic mechanisms. In Chapter 4, PDA/lipid binding assays revealed that the affinity of mutant htt
for lipid membranes changes with lipid composition. Interestingly, the membrane affinity was
also influenced by htt concentration. At low htt concentrations, htt exhibited a higher affinity for
the negatively charged membranes (POPG and POPS), while a higher affinity for zwitterionic
lipids (POPC and POPE) was observed at higher htt concentrations. The change in membrane
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affinity with htt concentration may be due to the population of aggregate species formed at each
condition. As our PDA assays are kinetic assays that run for 12+ hours, extensive htt aggregation
occurs throughout the experiment. Htt aggregation is dependent on concentration, with increased
concentration resulting in shortened lag phase, increased aggregation rate, and an overall
increase in aggregate formation.45 With enhanced aggregate formation altering overall httmembrane association, this indicates that membrane affinity may vary between the various
aggregate species. For example, increased affinity of htt for POPC with increased concentration,
and thus increased aggregation, may indicate that higher-order aggregate species interact directly
with the vesicles. Understanding the lipid properties that determine htt aggregate membrane
affinity could help explain the targeted toxic effects of mutant htt on organelles with different
membrane compositions.

Addition of lipid

Figure 6.6 A proposed experimental protocol for studying the association of specific
htt aggregates with lipids of varying physicochemical properties. Htt-exon1(46Q) will
be purified and incubated with lipid vesicles, and the mixture will then undergo extensive
separation procedures to result in separate monomer, oligomer, fibril, and lipid vesicle
samples. Htt species will be separated from associated lipids with hydrophobic interaction
chromatography, and lipid populations will be analyzed with LC-MS/MS.
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In order to determine the association of specific aggregate species with different lipid
systems, a protocol must be developed to separate and analyze the complex mixture of species
formed during htt aggregation in the presence of the lipids (Fig. 6.6). This can be accomplished
through a combination of separation techniques. First, ultracentrifugation could be used to pellet
the fibrils and free-lipid species, leaving the monomers and oligomers in solution. The
monomers and oligomers could then be separated via gel filtration chromatography on Sephacryl
S1000 resin, which has been used to successfully separated htt-exon1(46Q) monomers and
oligomers with a resolving range of 20-300 nm.46 To separate the fibrils from the free lipid
species pelleted during ultracentrifugation, amyloid fibril isolation could be performed as
previously described.47 The combination of applied separation techniques will result in four
samples of fully separated monomers, oligomers, fibrils, and lipid vesicles (Fig. 6.7). One
problem when performing separation techniques on amyloid samples is that each of the samples
will continue to aggregate after the separation is complete, potentially changing the population
of aggregate species. However, in this case, further aggregation of each sample is not
problematic as the lipid content of the entire sample represents only lipids that were associated
with the originally separated aggregate species. Therefore, samples would undergo delipidation
via hydrophobic interaction chromatography48 and the lipid content associated with each
aggregate species could be analyzed using an MS lipidomic protocol.49
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Figure 6.7 A schematic for the separation protocol of htt aggregates and lipid vesicles.

While this proposed separation protocol would work well for samples of htt alone, the
separation becomes more complex due to the presence of the lipid vesicles. Htt aggregates
accumulate and incorporate lipids into their structures,4,50–52 which could result in the additional
mass causing protein aggregates to pellet with the lipid vesicles during the ultracentrifugation
step. In this situation, the current proposed separation protocol would not account for the
aggregate species associated or incorporated into the lipid vesicles, bringing about misleading
results about relative aggregate affinity for membranes. This can be accounted for by separating
the vesicles from the fibrils in the pellet formed during ultracentrifugation, then performing
native gel electrophoresis, Western Blots, and densitometry on the aggregates incorporated into
the lipid vesicles. The Western Blots can be stained with antibodies for htt monomers (MW1)53
and oligomers (A11).54 Densitometry can be utilized to determine the concentration of each
aggregate species associated with the lipid vesicles, allowing for a relative comparison of
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aggregate affinity for specific lipid systems. Another complexity added by the presence of lipid
membranes is the potential for aggregation in the bilayer and in solution. Htt can aggregate on
the bilayer via lateral diffusion,7 so it is difficult to know if oligomers associated with lipid
vesicles formed in solution and then bound the vesicle, or if they formed as a result of
aggregation on the bilayer. To account for this, single-molecule microscopy can be used to
monitor aggregation and diffusion of individual species in a lipid bilayer as has been done with
Aβ.55 Total internal reflection fluorescence (TIRF) allows for the monitoring of aggregation on a
bilayer, as well as the mobility of membrane-bound aggregate species to determine relative
binding affinities. Using this technique, the extent of htt aggregation in the bilayer – as opposed
to in solution – can be observed with membranes of different physicochemical properties.
Due to the complexity of htt aggregation, it is challenging to identify the specific
aggregate species responsible for toxic effects on lipid membranes. In addition to the aggregate
species most responsible, the mechanism of htt-induced membrane damage is largely unknown.
Membrane damage could occur via the interaction of toxic aggregate species with the membrane,
or via the aggregation of htt in the bilayer. It is possible that there are several toxic mechanisms
at work. The contribution from this work is significant because it will provide insight into htt’s
interaction with lipid membranes that results in membrane damage and organelle dysfunction,
with an additional focus on the membrane affinity of specific aggregate species. Knowledge
gained from this study would broaden the understanding of organelle dysfunction in HD
progression and potentially reveal specific interactions as a target for therapeutics.
6.4 A systematic approach to understand amphipathic α-helix membrane selectivity
Much like htt, numerous proteins have domains that undergo a conformational transition
from intrinsically disordered to an amphipathic α-helix in the presence of binding partners.56
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Many of these proteins are associated with critical functions that depend on the selective
interaction of the α-helical domain with specific membranes.38,57,58 Mechanisms have been
proposed for the selective binding of AHs to particular membranes, however many of these
mechanisms rely on an unbalanced helix with one poorly developed face, whether it be the
hydrophobic or hydrophilic face.37,59,60 A poorly developed hydrophobic face is characterized by
an abundance of small, weakly hydrophobic residues, while a poorly developed hydrophilic face
lacks charged residues.60 One well-studied motif, the amphipathic lipid packing sensor (ALPS),
has only large residues on its hydrophobic face and lacks charged residues.38,61 Nt17, the AH
utilized in our MD studies in Chapter 5, has two well-developed faces, as the hydrophobic face
includes large and small residues and the hydrophilic face includes numerous charged, polar
residues. Our simulations showed that Nt17’s approach and initial interactions with the three
bilayer systems indicated a correlation between the size of bilayer defects available and the size
of the amino acid residue that initiated the interaction. The results obtained in Chapter 5 may
have a broader impact on the field of protein-lipid interactions, as they reveal a potential
mechanism for the selective membrane binding of AH-containing proteins that do not fall into
the specific classification of containing a poorly developed face.
In order to thoroughly investigate the properties of AH sequences that influence
membrane affinity, a large screen of the interactions between short de novo peptides and lipid
vesicles with varying physicochemical properties could be performed. In a study like this, the
peptides could be based on the AH sequence of three well-studied proteins: GMAPN, αsynuclein, and htt. The AH of GMAPN has a poorly developed polar face, forcing it to rely on
hydrophobic forces for interaction with membranes, while α-synuclein largely depends on
electrostatic interactions due to numerous charged residues and a poorly developed hydrophobic
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face.60 Nt17, on the other hand, will present a system that balances the two forces. To determine
the effect of certain sequence properties on the membrane affinity of these peptides, systematic
amino acid substitutions will be performed. For example, to determine if amino acid size is a
determinant in membrane affinity, large hydrophobic amino acids at the N-terminus of GMAPN
could be replaced with smaller amino acids to determine if that increases the affinity of the
peptide for lipid systems will smaller defects. In addition, the small amino acids on the
hydrophobic face of α-synuclein could also be replaced for similar studies. To study the effect of
the polar face, amino acid substitutions could be performed that systematically add or remove
charge to peptides.
In order to fully study the effects of amino acid size and charge on AH membrane
affinity, many sequence combinations must be examined. For this screen, New England
Peptide’s custom peptide arrays62 can be utilized to perform high-throughput PDA assay to
compare the affinity of AH-forming peptides for different lipid systems as developed in Chapter
2. This proprietary peptide array platform includes 96 unique, individually synthesized shortsequence peptides in a 96-well format that reduces the chances of cross-contamination.62 For the
lipid components, three lipids with the same headgroup but different fluidity and size/propensity
of bilayer defects could be utilized like in Chapter 5 (DMPC, POPC, DOPC). The PDA assay
would reveal the impact of certain sequence changes to the peptide’s affinity for different lipid
vesicles, which could then be linked back to the physicochemical properties of the lipids. Based
on results obtained from the PDA screen, WESTPA MD simulations could be performed as in
Chapter 5 to study the modified peptides’ method of approach to each bilayer system and see if it
changes with amino acid size.
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6.5 Conclusion
Huntington’s Disease is a fatal neurodegenerative order that is caused by an expanded
glutamine repeat domain of htt, resulting in the formation of toxic aggregate species. Recent
therapeutic strategies have focused on inhibiting the aggregation and fibrillization of htt,63–65 but
so far these efforts have remained unsuccessful in identifying a cure or treatment for HD. The
results presented in this dissertation reveal that the physicochemical properties of lipid
membranes influence htt aggregation, lipid binding, and the efficiency of aggregation inhibiting
molecules that could influence future directions of HD therapeutic approaches.
In Chapter 3, the efficiency of two proven htt aggregation inhibitors was examined in the
presence of lipid membranes. While EGCG remained effective, the effectiveness of curcumin in
inhibiting htt aggregation was eliminated in the presence of lipids. In addition, the effect of the
lipids on curcumin effectiveness was dependent on composition, as curcumin actually increased
aggregation in the presence of one lipid system. These results highlight the complexity of htt
aggregation in the presence of different membranes and indicated a different mechanism of
membrane association and aggregation with the two membranes tested. This led to Chapters 4
and 5, where we aimed to determine the properties of lipid membranes that influence the
mechanisms of htt aggregation and lipid binding. Fluidity was identified as a contributing
property, with htt preferentially associating with more fluid membranes. In addition, an overall
negative charge of membranes disrupts the insertion of htt into lipid vesicles, resulting in
localization of htt at the bilayer surface that encourages rapid fibrillization. Finally, the size and
propensity of membrane defects influences the mechanism of Nt17’s approach and initial
interaction with membranes of different composition. Combined, these results reveal details of
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the complex mechanisms of htt that are influenced by membrane properties with implications for
normal htt function, toxic membrane interactions, and htt aggregate formation.
In addition to the advancement of knowledge about htt mechanisms, techniques
developed and results obtained during this series of studies has the potential to advance the
broader field of protein-lipid interactions. In Chapter 2, the developed normalized PDA lipid
binding assay can be applied to measure and quantitatively compare the membrane affinity of
pharmaceuticals, proteins, small molecules, and much more. While neither is a new technique,
the combination of AFM and native MS complex analysis presents a novel approach to linking
initial protein-lipid interactions to downstream aggregation that can be utilized with amyloid
forming proteins such as Aβ (Alzheimer’s Disease) and α-synuclein (Parkinson’s Disease).
Finally, the results presented in Chapter 5 indicate that both residue size and membrane defect
size play a role in determining amphipathic α-helix (AH) membrane affinity, a mechanism that is
likely in play with other biologically relevant membrane-binding AHs.
Overall, the results presented here provide details about the mechanisms of mutant htt in
HD progression and reveal the challenges of inhibiting aggregation in a physiologically relevant
environment. Together, these studies highlight the important factors of htt lipid binding
mechanisms. Despite the new knowledge gained about the factors influencing htt membrane
affinity, further studies are required to link the association of specific aggregate species and
complex membrane systems with toxicity. The identification of the toxic species and
mechanisms involved in the interaction of htt with subcellular membranes will present novel
targets for HD therapeutic development.
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